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Epigenetics is defined as the study of heritable changes in gene expression resulting 
from changes in a chromosome without alterations in its DNA sequence [1-3]. These 
epigenetic changes or chemical modifications occur either to the DNA, DNA binding 
histones or histone binding nucleosomes, and are referred to as DNA methylation, 
histone modifications and nucleosome positioning, respectively  [4]. In normal 
processes, epigenetic modifications are important in regulating gene and non-coding 
RNA expression in response to changing conditions and maintaining normal 
development. DNA methylation is currently the most widely studied epigenetic 
mechanism. 
DNA methylation is the addition of a methyl group to DNA and typically 
occurs at the 5’ carbon position of the cytosine base in DNA to form 5-methylcytosine 
[Figure 1]. This process is catalyzed by DNA methyltransferase enzymes (DNMTs) [5] 
and frequently occurs at a Cytosine-phosphate-Guanine (CpG) dinucleotide where the 
cytosine base is followed by a guanine base separated by a phosphodiester bond. 
There are three major types of DNMTs: DNMT1, DNMT3a and DNMT3b. In mammalian 
cells, DNMT1 is most abundant of the three DNMTs [6]. It is referred to as maintenance 
methyltransferase because it prefers to bind to CpG sites of the hemi-methylated DNA 
(when only one of two complementary strands are methylated) in order to copy the 
existing methylation pattern of the DNA [7]. DNMT3a and DNMT3b are referred to as 
de novo methyltransferases because they are necessary for early development. They 
can bind to both hemi-methylated and non-methylated DNA [7]. 
 
Figure 1. Methylation of cytosine to 5-methylcytosine, catalyzed by DNMT enzymes. The 
methyl transfer s-adenosylmethionine (SAM) donates its methyl group to cytosine to 
produce s-adenosylhomocysteine (SAH). 
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DNA methylation can influence gene function and gene expression by two 
mechanisms. One, CpG methylation can interfere with the binding of the transcription 
factors to the DNA, which can in turn suppress gene transcription. Two, there are 
certain proteins that act as transcriptional repressors by binding to specific sequences 
of the methylated DNA and are called methylated DNA-binding proteins (MDBP) [8-10]. 
DNA methylation is dynamic across the life course [11] and age-associated changes 
have been seen both during early childhood [12] and adulthood [13, 14]. Sex-
associated DNA methylation differences have also been found [15]. DNA methylation is 
an essential epigenetic process involved in regulation of genes in all biological 
processes and has an essential role in embryonic development, genomic imprinting, 
genomic integrity, transcriptional regulation and adult homeostasis [16, 17]. DNA 
methylation is influenced by several metabolic, environmental, nutritional, lifestyle and 
genetic factors [Figure 2]. 
 
Figure 2. Factors that can affect DNA methylation. Nucleotides in blue are the Adenine (A) 
and Thymidine (T) bases and nucleotides in purple are the Guanine (G) and Cytosine (C) 
bases, respectively. Methyl groups in red typically attach to the 5’ carbon position of the 
cytosine base of DNA to form 5-methylcytosine. Cis-meQTLs (methylation Quantitative Trait 
Loci) are the SNPs that correlate with a CpG that is <1 Mb away. Trans-meQTLs are SNPs 
that correlate with CpGs that are >1 Mb away. 
METHYL-GROUP METABOLISM AND ROLE OF B-VITAMINS 
Methyl-group metabolism, also known as one-carbon metabolism, is a network of 
biochemical reactions that is involved in the transfer of one-carbon units, typically as 
methyl (-CH3) groups, from one metabolite to the other, and subsequently to the DNA 
[18]. Several enzymes participate in the catalysis of these reactions along with dietary 
micronutrients that act as cofactors, such as B-vitamins (folate, vitamin B2, B6 and 
B12), choline and betaine [19] [Figure 3]. For this reason, nutrition status, particularly 
micronutrient intake, has been a focal point when investigating epigenetic mechanisms 
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[18]. The important metabolites of this pathway include s-adenosylmethionine (SAM), 
s-adenosylhomocysteine (SAH) and homocysteine (Hcy). In the transmethylation 
pathway, the methyl donor, SAM is biosynthesized from methionine and donates its 
methyl group to the DNA, itself being converted to SAH. SAH is a potent inhibitor of 
this same methyltransferase reaction and is hydrolyzed to Hcy. Due to the reversible 
reaction of Hcy with SAH, Hcy needs to be transported out of the cell or be 
metabolized to prevent accumulation of SAH. Hcy metabolism takes place either 
through the remethylation pathway by converting back to methionine, or the 
transsulfuration pathway by converting to cystathionine [20]. Impairments in the 
metabolism of Hcy can lead to elevated Hcy and consequently elevated SAH and 
reduced SAM:SAH ratio [21, 22]. Elevated Hcy has been associated with reduced global 
methylation [22] and is a marker of several disorders such as cardiovascular diseases, 
neural tube defects, cognitive decline and different types of cancers [23]. Elevated Hcy 
can be a consequence of either genetic variants in one or more of the key enzymes 
and/or nutritional deficiencies [24]. 
The most widely studied Hcy-associated genetic polymorphism includes the 
methylene tetrahydrofolate reductase (MTHFR) 677C>T variant. This variant can lead 
to reduced MTHFR enzyme activity of up to 45% and impairs the conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-methyl-THF) in the 
remethylation pathway, where 5-MTHF acts as a cosubstrate by converting Hcy to 
methionine [24, 25]. Another commonly studied polymorphism for MTHFR includes 
MTHFR 1298A>C, which is associated with 68% of reduced MTHFR activity [25, 26]. In 
the remethylation pathway, methionine synthase (MTR) catalyzes the remethylation of 
Hcy to methionine. The common polymorphism within the MTR gene is MTR A66G, 
which results in reduced activity of the MTR enzyme and Hcy accumulation [27]. In the 
transsulfuration pathway, cystathionine-beta-synthase (CBS) enzyme catalyses the 
conversion of Hcy to cystathionine. Two mutations in the CBS enzyme include the rare 
CBS 1330G>A [28] and CBS 833T>C [29]. Both these mutations are associated with 
reduced activity of CBS enzyme and Hcy accumulation and occur in CBS deficiency. 
Apart from the ones mentioned, other Hcy-associated polymorphisms were also 
previously found in candidate gene studies and genome-wide association studies 
(GWAS) [25, 30-32]. In a previous large GWAS of 44,147 individuals, van Meurs JB et al 
found 18 variants associated with Hcy, of which 13 were common polymorphisms that 
explained 5.9% of variation in Hcy [32]. 
Folate and vitamin B12 are widely studied co-factors, deficiencies of which 
could impair the methyl-group metabolism and lead to elevated Hcy [24]. Therefore, 
impaired methyl-group metabolism due to shortage of B-vitamins or genetic variants 
could play a vital role in DNA methylation. A few studies until now have investigated 
the association of Hcy, Hcy-associated variants particularly the MTHFR 677C>T and B-
vitamins with global DNA methylation, but showed inconsistent findings. 
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Figure 3. A simplified figure of methyl-group metabolism, which includes the main enzymes 
(purple) and dietary factors (blue). DHFR: Dihydrofolate reductase; SHMT: Serine 
hydroxymethyltransferase; MTHFR: 5,10-Methylenetetrahydrofolate reductase; MSR: 
Methionine synthase reductase; MS: Methionine synthase; BHMT: Betaine-homocysteine 
methyltransferase; MAT: Methionine adenosyltransferase; DNMT: DNA methyltransferase; 
SAHH: S-adenyl-l-homocysteine hydrolase; CBS: Cystathionine β-synthase; CSE: 
Cystathionine γ-lyase. Ser: Serine; Gly: Glycine. R: Remethylation pathway; T: 
Transsulfuration pathway; F: Folate cycle. 
LIFESTYLE FACTORS 
In addition to the one carbon metabolism and nutritional factors, other lifestyle factors 
such as cigarette smoking, alcohol intake and physical activity can also affect DNA 
methylation [33]. Cigarette smoking is a crucial risk factor for disorders such as 
respiratory diseases, cardiovascular diseases, cancer and reproductive outcomes [34]. 
There are a few mechanisms known by which cigarette smoking can alter DNA 
methylation [35]. One, cigarette smoke contains carcinogens such as arsenic, 
chromium, polycyclic aromatic hydrocarbons, formaldehyde, and nitrosamines that 
causes double-stranded breaks to the DNA causing DNA damage [36]. The enzyme 
DNMT1 is recruited to repair the damage in survival cells which causes methylation of 
CpGs adjacent to the repaired nucleotides [36-38]. Two, cigarette smoke can alter DNA 
methylation through the effect of nicotine on DNMT1 expression. Nicotine binds to and 
activates the nicotinic acetylcholine receptors that increases intracellular calcium and 
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activates the key transcription factor (cAMP response element-binding protein) of 
many genes with possible downregulation of DNMT1 [39-41]. Three, cigarette smoking 
increases expression of the DNA-binding protein, Sp1, which protects CpG sites from 
being methylated [42-44]. Four, cigarette smoke contains carbon monoxide that 
competes with oxygen to bind to hemoglobin. This causes inadequate oxygenation of 
tissues in a condition called hypoxia [45]. Hypoxia further leads to the HIF-1α-
dependent upregulation of methionine adenosyltransferase 2A, which is an enzyme 
that synthesizes the methyl donor, SAM [46]. Previous EWAS studies have investigated 
the association between cigarette or tobacco smoking and epigenome-wide DNA 
methylation [47-56], but large-scale meta-analysis studies have not been conducted 
yet. Sufficiently large sample size is necessary for detecting small effects, reliability of 
results and internal and external validation [57, 58]. Such studies may further help in 
identifying new smoking-related CpGs that can serve as biomarkers in smoking-related 
pathologies. 
METHODS TO MEASURE DNA METHYLATION 
Different methods that are used to profile global and site-specific genome-wide DNA 
methylation are available [59-64]. These methods vary in terms of their genomic region 
coverage, DNA input and resolution. For global methylation, the high performance 
liquid chromatography (HPLC) and HPLC tandem mass spectrometry (LC-MS/MS) are 
regarded as the golden standards to measure the total methylated cytosine content in 
the DNA [60, 61]. These methods are highly quantitative and reproducible. Since the 
protocol for their assay optimization is demanding and requires relatively large 
amounts of DNA (1-5 µg), other methods have been developed that use more readily 
available equipment, require less DNA and are less expensive. These include PCR-based 
methods which measure methylation status of genomic repeat elements such as LINE-1 
and Alu, and other method includes the Luminometric methylation assay (LUMA) 
which is based on polymerase extension assay using the pyrosequencing platform [60, 
61]. The repeat elements are representative of the human genome since they 
constitute about 45% of it [60]. However, the information on methylation levels 
derived from these surrogate methods is limited to analyzed sequences and their 
comparison to total methyl cytosine content in DNA is uncertain. LINE-1 assay showed 
an acceptable surrogate to golden standard methods as compared to Alu assay or 
LUMA [60, 61]. Considering the highest sensitivity and specificity, minimal assay-to-
assay variability and also the amount of starting material required by each assay, these 
methods are recommended in order of their preference: (1) LINE-1/pyrosequencing; 
(2) LC-MS/MS; and (3) LUMA [61]. For gene-specific methods, PCR-based methods 
were developed wherein primers are used to amplify the gene of interest from the 
bisulfite converted DNA [62]. 
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For genome-wide site-specific DNA methylation profiling, various microarray- 
and sequencing-based technologies have been developed [59, 61, 62, 64]. They are 
grouped into 3 categories, namely; (1) restriction enzyme based methods, (2) affinity 
enrichment-based methods, and (3) bisulfite conversion-based methods. Restriction 
enzyme based methods cleave DNA at specific positions to distinguish between 
methylated and unmethylated DNA. Affinity enrichment-based methods use either 
anti-methylcytosine antibodies (as in methylated DNA immunoprecipitation (MeDIP)) 
or methyl-CpG-binding domain (MDB) proteins specific for 5-methyl cytosines to enrich 
methylated DNA regions. Bisulphite conversion-based methods can distinguish cytosine 
base from methylated cytosine by converting cytosines to uracil and keeping 
methylated cytosines as cytosines. These three types of methods are either coupled 
with microarray or sequencing technologies. Each of these techniques have their own 
pros and cons, and the preference for a particular technique highly depends on the 
research questions, the amount of required starting material, sensitivity, specificity, 
resolution, coverage and cost. Comparing with other techniques, bisulphite conversion-
based Illumina HumanMethylation450K BeadChip arrays (Illumina, Inc., San Diego, CA, 
USA) provide a high coverage with high sensitivity and specificity at a single base 
resolution, along with lower cost and low starting material. This makes it as the 
preferred technique for our study. 
EPIGENOME-WIDE ASSOCIATION STUDIES 
In order to investigate associations between site-specific DNA methylation variations 
and a phenotype of interest, EWASs assess a genome-wide collection of epigenetic 
marks that exist in a cell at any given point in time [65]. Illumina 450K array measures 
up to 485,764 CpGs per DNA sample distributed across the whole genome [66]. These 
CpGs represent 99% of RefSeq genes and 96% of CpG island regions that include high 
density islands and low density shores and shelves. This array also includes non-CpG 
methylated sites identified in human stem cells (CHH sites), differentially methylated 
CpG positions (DMPs) identified in tumor versus normal, FANTOM 4 promoters, DNase 
hypersensitive sites and miRNA promoter regions. Validation and evaluation of this 
technique using cell lines and tissue samples indicated that it is highly robust and 
reliable and showed high concordance with the widely used pyrosequencing method 
[66-68]. 
The human genome contains more than 28 million CpGs [69], 70-80% of 
which are methylated [70, 71]. The Illumina 450K arrays measures 1.7% of the CpGs in 
the genome. Among the gene regions for CpGs included on this array, most (41%) of 
them are present at gene promoters, 31% at gene bodies, 3% at 3’UTR regions and 25% 
at intergenic regions. Among the genome regions, most (31%) of them are present in 
high density at regions known as “CpG islands” that are usually associated with 
promoters. CpGs with low density (23%) are present at “CpG island shores” that are 
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about 2 Kb away from CpG islands. CpGs with much lower density (31%) than CpG 
island shores are present at “CpG island shelves” also known as CpG poor regions, that 
are in turn about 2 Kb away from CpG island shores. The rest (36%) of them are the 
isolated CpGs known as “Open Sea” regions [66] [Figure 4]. This gives an advantage 
over other techniques that measure global methylation as the total methylated 
cytosine content of the DNA, which does not indicate the specific CpGs, genes and 
pathways involved. Illumina 450k arrays give opportunities to uncover novel epigenetic 
markers and help explore mechanisms that could be associated with disease risks in a 
hypothesis-free manner. When the knowledge of associations about a particular 
phenotype and DNA methylation is limited, the hypothesis free approach gives the 
benefit to eliminate the preexisting bias of traditional biology, meaning that it is 
unbiased by prior pathophysiological assumptions [72]. Therefore, hypothesis-free 
approach gives us the opportunity to unravel novel epigenetic markers associated with 
methyl-group metabolism factors. 
The design of the Illumina 450k arrays is such that it contains two different 
probes; type I (28% CpGs) and type II (72% CpGs) [73]. Type I probes use two different 
bead types corresponding to methylated and unmethylated probe alleles, both of 
whose signals are generated in same red colour channel. Type II assay uses one bead 
type corresponding to both methylated and unmethylated probe alleles whose signals 
are generated in green and red colour channels, respectively. 
 
Figure 4. Distribution of CpGs in the Illumina 450k array based on gene regions, genomic 
regions and associated RNA transcripts. Figure adapted from Sandoval J et al. 
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DIFFERENTIALLY METHYLATED REGIONS 
It is known that CpGs that are closely located to each other often show similar 
methylation patterns [74] and that DNA methylation is regulated in longer regions [75]. 
Therefore, in linear models, treating a region as a unit with two or more CpG sites 
might help identify regions with consistent methylation changes. Different methods 
have been developed that use different approaches to identify differentially 
methylated regions (DMRs) such as IMA [76], Bumphunter [77], DMRcate [78], Comb-p 
[79, 80], Probe Lasso [81], Aclust [82] and seqlm [83]. Authors of the DMRcate and 
seqlm compared their method with other methods and showed that their method 
performed better than the other methods [78, 83]. However, despite so many 
developed methods and their approaches, they all have their pros and cons, and there 
is no standard method until now. IMA package in R calculates methylation mean or 
median of β-values for gene-based predefined regions such as promoter, 5’-UTR, first 
exon, gene body and 3’-UTR and also other regions that are not necessarily gene-
based, such as CpG islands, shores and shelves [76]. On the other hand, methods such 
as Bumphunter and DMRcate identify DMRs using region finding algorithms that are 
based on sliding window and effect size cutoffs [77, 78]. These methods however might 
not be well suited for the uneven distribution of the Illumina 450k CpGs. In the analysis 
from this thesis, we used the method Comb-p [79, 80] that was developed considering 
this uneven distribution. It uses nominal p-values as input in a sliding window and also 
takes into account the correlation between CpGs associated with these p-values. 
MENDELIAN RANDOMIZATION STUDIES 
Classical epidemiological association studies do not indicate the cause and effect of a 
particular association. They just detect association. To determine causal direction, 
genetic instrumental variables of phenotypes or methylation can be used, in a concept 
called Mendelian Randomization (MR) [84, 85]. The relationship of Hcy, vitamin B12 
and folate with DNA methylation can be subject to substantial bias, given the strong 
relationship between several lifestyle factors, diseases and methyl-group metabolism 
factors. To circumvent this bias, genetic factors determining the methyl-group 
metabolism factors as an instrument can be used to study the relationship between 
these factors and methylation by MR. This would eliminate the effects that are possibly 
caused by measurement errors, confounding and reverse causality. 
STUDY POPULATION 
1. Rotterdam Study (RS) 
All studies described in this thesis were performed within a large population-based 
cohort study of the Netherlands, the RS, also known as “Erasmus Rotterdam 
Gezondheid Onderzoek (ERGO)”. The RS is a prospective study aimed at assessing the 
occurrence of risk factors for chronic (cardiovascular, endocrine, locomotor, hepatic, 
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neurological, ophthalmic, psychiatric, dermatological, oncological, and respiratory) 
diseases in the elderly [86]. The study comprises 14,926 subjects in total, living in the 
well-deﬁned Ommoord district in the city of Rotterdam in the Netherlands. Genome-
wide DNA-methylation levels were determined in a random subset of 1,613 individuals 
using the Illumina HumanMethylation450K BeadChip arrays [Figure 5]. 
Several EWASs of phenotype measures such as Hcy, the common Hcy 
associated variant MTHFR 677C>T, folate intake, vitamin B12 intake, cigarette smoking, 
age, gender, lipids, and anthropometry were conducted in RS. Inorder to improve the 
estimates of found associations and find new loci [57, 58], the power of the study was 
increased by including multiple studies in a meta-analysis approach. Several studies 
participated in the following consortium efforts to achieve the goal. 
2. Biobank-based Integrative Omics Studies Consortium (BIOS) consortium 
Within the BIOS consortium, Biobanking and BioMolecular resources Research 
Infrastructure (BBMRI)-Omics (http://www.bbmri.nl/) is the joint collection of omics 
data that has collaboratively been generated and is made available for BBMRI 
researchers focusing on integrative omics studies in Dutch Biobanks in the 
Netherlands. RNA-sequencing (>15 M paired end reads) and genome-wide DNA 
methylation data has been generated using Illumina 450k arrays and Illumina RNA 
sequencing, for over 4000 samples. In addition, phenotype measures such as age, 
smoking, gender, lipids, metabolomics (>200 metabolites) and anthropometry are 
available within the same samples. The Netherlands-based cohorts that are a part of 
this consortium are the Rotterdam Study, the Leiden Longevity Study, the Groningen 
LifeLines study, the Netherlands Twins Register, the Cohort on Diabetes and 
Atherosclerosis Maastricht and the Prospective ALS Study Netherlands [Figure 6]. 
3. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
consortium 
The CHARGE consortium (http://www.chargeconsortium.com/) was formed to 
facilitate genome-wide association study meta-analyses and replication opportunities 
among multiple large and well-phenotyped longitudinal cohort studies [87]. This 
consortium is a collaboration between many cohorts studies, both from Europe and 
the United States. The five founding member cohorts of this effort include the Age, 
Gene/Environment Susceptibility-Reykjavik Study, the Atherosclerosis Risk in 
Communities Study, the Cardiovascular Health Study, the Framingham Heart Study  
and the Rotterdam Study. The additional core cohorts include the Coronary Artery Risk 
Development in Young Adults, the Family Heart Study, the Health, Aging, and Body 
Composition Study, the Jackson Heart Study and the Multi-Ethnic Study of 
Atherosclerosis. Within this thesis, cohorts within this consortium who had both DNA 
methylation data measured from the Illumina 450k arrays as well as the phenotypes of 
interest, were used for the EWAS analyses [Figure 6]. 
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OUTLINE OF THIS THESIS 
The aim of this thesis is to study the association of methyl-group metabolism, 
nutritional and lifestyle factors with genome-wide DNA methylation. The first section 
of this thesis includes two literature reviews. Chapter 2 is a literature review of Hcy and 
its role in DNA methylation. Chapter 3 is a systematic literature review of the relation 
between micro- and macro- nutrients and DNA methylation in humans across the life 
course. 
The second section of this thesis focuses on a key metabolite of the methyl-
group metabolism, Hcy. Chapter 4 is a meta-analysis of EWASs to investigate the 
association between plasma Hcy and DNA methylation in leukocytes of 2,035 
individuals from six cohorts. In Chapter 5, we used genetically defined elevated Hcy as 
an instrument, i.e. the MTHFR 677C>T variant and the combined weighted genetic risk 
score of 18 previously studied Hcy-associated variants, to test whether genetically 
defined elevated Hcy levels are associated with DNA methylation changes in leukocytes 
of 9,894 individuals from 12 cohorts. In Chapter 6, we conducted an interaction study 
to investigate the effect of elevated Hcy in individuals by MTHFR 677C>T genotype on 
genome-wide DNA methylation in leukocytes of 1280 individuals from 2 cohorts. 
The third section of this thesis focuses on nutrition and lifestyle factors. 
Chapter 7 is a meta-analysis of EWASs to investigate the association of folate intake 
and vitamin B12 intake with DNA methylation in leukocytes of 5,841 participants from 
10 cohorts. Chapter 8 focuses on association between cigarette smoking as a lifestyle 
factor and DNA methylation in leukocyte assessed in 15,907 individuals (2,433 current, 
6,518 former, and 6,956 never smokers) from 16 cohorts. 
 
Figure 5. Overview of the long-term population survey of the Rotterdam Study (RS), also 
known as “Erasmus Rotterdam Gezondheid Onderzoek” (ERGO) in the Netherlands. In 1989, 
the first cohort, RS-I (also known as ERGO) comprised of 7,983 subjects with age 55 years or 
above. In 2000, the second cohort, RS-II (also known as ERGOPLUS) was included with 3,011 
subjects who had reached an age of 55 or over. In 2006, the third cohort, RS-III (also known 
as EROGJONG) was further included with 3,932 subjects with age 45 years and above. In 
2016, the forth cohort, RS-IV (also known as ERGOXTRA) was included with expected 
recruitment of 4,000 subjects with age 40 years and above. At the Genetic Laboratory 
(Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the 
Netherlands), genome-wide DNA-methylation levels in 1,613 individuals mainly belonging to 
ERGOJONG and ERGO-5 were determined using the Illumina HumanMethylation450K 
BeadChip arrays (Illumina, Inc., San Diego, CA, USA). After quality control, 1,544 of the 1,613 
individuals were used for the downstream analysis. Phenotypes of interest such as 
homocysteine, MTHFR 677C>T, B-vitamin intake and cigarette smoking with overlapping 
DNA methylation data were used to run EWASs in this thesis. 
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ABSTRACT 
Homocysteine (Hcy) is a sulfur-containing non-protein forming amino acid, which is 
synthesized from methionine as an important intermediate in the one-carbon pathway. 
High concentrations of Hcy in a condition called hyperhomocysteinemia (HHcy) are an 
independent risk factor for several disorders including cardiovascular diseases and 
osteoporotic fractures. Since Hcy is produced as a byproduct of the methyltransferase 
reaction, alteration in DNA methylation is studied as one of the underlying mechanisms 
of HHcy-associated disorders. In animal models, elevated Hcy concentrations are 
induced either by diet (high methionine, low B-vitamins, or both), gene knockouts 
(Mthfr, Cbs, Mtrr or Mtr) or combination of both to investigate their effects on DNA 
methylation or its markers. In humans, most of the literature involves case–control 
studies concerning patients. The focus of this review is to study existing literature on 
HHcy and its role in relation to DNA methylation. Apart from this, a few studies 
investigated the effect of Hcy-lowering trials on restoring DNA methylation patterns, by 
giving a folic acid or B-vitamin supplemented diet. These studies which were conducted 
in animal models as well as humans were included in this review. 
HIGHLIGHTS 
o Hyperhomocysteinemia in animals is associated with high SAH and low 
SAM/SAH ratio, but changes in SAM were not consistent. 
o SAM:SAH ratio is not a good proxy for DNA methylation levels in 
hyperhomocysteinemic animal models. 
o Both diet- and genetically induced hyperhomocysteinemic animal models 
have altered methylation indicating homocysteine as a keyplayer. 
o Global DNA methylation was not consistently altered in humans with 
hyperhomocysteinemia. 
o Homocysteine-lowering trials did not result in a clear improvement of DNA 
methylation patterns in most studies. 
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1. INTRODUCTION 
Homocysteine (Hcy) is a sulfur-containing non-protein forming amino acid, which 
occurs naturally in the blood plasma. It is biosynthesized as an intermediate in the one-
carbon pathway from methionine, via two main cofactors: S-adenosylmethionine 
(SAM) and S-adenosylhomocysteine (SAH). SAM acts as an important cosubstrate and 
is used by the DNA methyltransferase enzymes in transferring methyl groups to the 
DNA. The product of this reaction, SAH, is then synthesized to Hcy in a reversible 
manner. The concentrations of Hcy are maintained by two routes; namely: the 
remethylation pathway, where Hcy is converted back to methionine, and the 
transsulfuration pathway, where Hcy is converted to cystathionine to form cysteine [1]. 
A basic illustration of the Hcy pathway is given in Fig. 1. 
 
Figure 1. A simplified figure of homocysteine pathway as present in the liver, which includes 
the main enzymes and dietary factors described in this review. DHFR: Dihydrofolate 
reductase; SHMT: Serine hydroxymethyltransferase; MTHFR: 5,10-
Methylenetetrahydrofolate reductase; MSR: Methionine synthase reductase; MS: 
Methionine synthase; BHMT: Betaine-homocysteine methyltransferase; MAT: Methionine 
adenosyltransferase; DNMT: DNA methyltransferase; SAHH: S-adenyl-l-homocysteine 
hydrolase; CBS: Cystathionine β-synthase; CSE: Cystathionine γ-lyase. Light  gray boxes: B-
vitamins; Dark gray boxes: enzymes; Black boxes: Homocysteine and DNA methylation; the 
dashed line divides the remethylation from the transsulfuration pathway. 
  
34 PART A: Introduction 
 
Almost 20 years ago, high concentrations of Hcy in a condition called 
hyperhomocysteinemia (HHcy), were shown to be an independent risk factor for 
several disorders including cardiovascular diseases [2] and osteoporotic fractures [3]. 
Since the reaction from SAH to Hcy is reversible, high concentrations of Hcy increase 
the concentrations of SAH, which acts as a competitive inhibitor of the 
methyltransferase reaction [4]. Elevated SAH leads to lower SAM:SAH ratio, which 
could result in less donation of methyl groups to the DNA by SAM. Elevated SAH is 
shown to be associated with global DNA hypomethylation, but this phenomenon is 
tissue-specific and the mechanisms are unknown [5]. Since Hcy is produced as a 
byproduct of the methyltransferase reaction, alterations in DNA methylation levels are 
studied as one of the underlying mechanisms of HHcy-associated disorders. 
The primary causes of HHcy are dietary and/or deficiencies of the key 
enzymes of the Hcy metabolism pathway [Fig. 1]. These dietary factors and enzymes 
that play a role in the remethylation and transsulfuration pathway, balance the 
concentrations of Hcy by converting it to methionine or cystathionine. The essential 
dietary factors include methionine and B vitamins (folate, vitamin B6 and vitamin B12). 
Low vitamin B12 and/or folate are associated with high Hcy [6] and associated risks like 
cardiovascular disease [7], pregnancy complications [8] and neural tube defects [9]. 
Besides methionine and B-vitamins, dietary choline and betaine are also important co-
factors of the one-carbon pathway. Low dietary choline or with its association with 
dietary betaine is associated with elevated Hcy in both mice and humans [10–12]. 
Dietary choline undergoes oxidation to produce betaine and helps in the synthesis of 
SAM, thus being an indirect methyl donor contributing to the SAM:SAH ratio. Due to 
limited literature on choline deficient diets, we have focused this review only on high 
methionine (HM) and B-vitamin deficient diets. 
Polymorphisms in genes encoding for enzymes like 
methylenetetrahydrofolate reductase (MTHFR), cystathionine β-synthase (CBS), and 
methionine synthase (MS) are important determinants of Hcy concentrations [13]. 
MTHFR converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-
MTHF). 5-MTHF acts as a cosubstrate in the remethylation pathway by converting Hcy 
to methionine. The enzyme MS encoded by the MTR gene, is reductively activated by 
methionine synthase reductase (MSR) enzyme, which is encoded by MTRR. MS 
catalyzes the remethylation of methionine from Hcy. The enzyme CBS plays a role in 
the transsulfuration pathway by catalyzing the conversion of Hcy to cystathionine. 
Depending on the severity of one or more dietary and/or enzyme deficiencies, HHcy 
may occur at different levels. Hcy concentrations < 15 μmol/L are referred to as mild, 
between 15 and 30 μmol/L are referred to as moderate, between 30 and 100 μmol/L 
as intermediate, and >100 μmol/L as severe HHcy [14]. 
The focus of this review is to study existing literature on HHcy and its role in 
relation to DNA methylation. We included studies with effects of diet and/or genotype 
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on plasma or serum Hcy and its consequent role in the alteration of global, gene-
specific or genome-wide DNA methylation. Scientific papers based on both animal and 
human experiments were reviewed in PubMed. A literature search with varied terms of 
Hcy and DNA methylation was done, in order to filter out relevant articles which were 
published from 2001 until 2014. In the animal literature, we focused on mice and rat 
studies. We included all papers which measured plasma or serum Hcy and either or all 
of the methylation markers like SAM and SAH or global or gene-specific DNA 
methylation. We divided the animal literature in three subtopics, namely 1) diet-
induced HHcy, 2) genetically-induced HHcy, and 3) genetically- and diet-induced HHcy. 
A hyperhomocysteinemic (HH) diet mainly involves either HM, low folate (LF) or 
vitamin B12 or their combination. In addition, low concentrations of choline, riboflavin 
and pyridoxine might be present. From the human literature, studies which measured 
plasma or serum Hcy and DNA methylation levels were included, and only if the main 
aim of the study was to test the association between the two. We focused at vascular 
diseases, cancer, renal disease and brain disorders. 
Methylation can be measured at 3 levels: global, genome-wide and gene-
specific. We used the term “global” in this review for studies that report DNA 
methylation as the total 5-methyl cytosine content, using techniques like cytosine 
extension assay and LC–MS/MS. Some groups measured methylation of LINE-1, B1 and 
Alu repetitive elements, which are suggested to be surrogate markers of global 
methylation levels. We used the term “genome-wide” for methylation measures from 
DNA-methylation arrays. “Gene-specific” methylation measures methylation levels of 
cytosines located at specific genes or within their promoters. 
2. ANIMAL STUDIES 
2.1. Diet-induced HHcy 
Diet with an excess of methionine and/or deficient in one or more of the B vitamins like 
folate, vitamin B6 or vitamin B12, play a role in elevating the concentrations of Hcy. 
The resulting deregulation of global or gene-specific DNA methylation and the 
methylation markers SAM and SAH is demonstrated with experiments involving 
different rat and mouse models [Table 1]. The apolipoprotein E (ApoE)- deficient 
mouse, a model that develops spontaneous atherosclerosis, have often been used in 
experiments to study the dietary impact of Hcy-induced DNA methylation alteration in 
vascular pathologies. A few other experiments are done in mice and rats without gene 
knock- outs to investigate similar effects. 
2.1.1. High methionine diet 
Among the many diseases linked to HHcy, vascular pathologies are mostly explored in 
the literature of Hcy and DNA methylation. In 2001, Dayal and associates showed in 
both Cbs (+/+) mice and Cbs (+/−) mice models from C57BL/6J background that, even in 
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the absence of folate deficiency, HHcy and endothelial dysfunction occur in mice fed 
with a HM diet for 15 weeks. SAM was lower in brain at 7 weeks and SAH was higher in 
liver at 15 weeks. Both in the brain and liver, SAM:SAH ratio was markedly reduced at 
15 weeks, which had a strong correlation with high plasma Hcy [15]. 
In 2007, Jiang et al. investigated the effects of HHcy on DNA methylation of 
the B1 repetitive elements, in relation to atherosclerosis. They gave a HM diet with 
different concentrations of 1%, 1.5% and 2% to healthy Sprague–Dawley rats for 4 
weeks to achieve HHcy. B1 elements, as quantified by real-time PCR, were 
hypomethylated to 26.2%, 20.1% and 22.2%, respectively for the three diet 
concentrations. Aortic SAM decreased and SAH increased, leading to a 3- to 4-fold 
decrease in SAM:SAH ratio [16]. In order to further examine these effects of HHcy on 
the pathogenesis of atherosclerosis more thoroughly, the same group also studied an 
ApoE-deficient mouse model. For 15 weeks, the mice were given a HM diet to induce 
HHcy. Methylation of both global DNA and B1 elements was measured in the aorta, by 
both methylation-dependent restriction analysis and nested methylation- specific PCR 
(MSP). The HM group showed a lower methylation of global DNA and B1 elements, 
compared to controls. Aortic SAM and SAH were 1.35- and 1.86-fold higher, 
respectively. SAM:SAH ratio showed an opposite trend of being 1.46-fold higher unlike 
previous study, and the atherosclerotic lesions were also larger [17]. In a similar study, 
ApoE-deficient mice when given a HM or HM-B-vitamin deficient diet showed an 
increase in plasma Hcy in the HM diet group, with a more remarkable increase in HM-
B-vitamin deficient group. Plasma SAH was higher in both groups, compared to the 
ApoE-deficient mice with control diet. The atherosclerotic lesion areas were 53% and 
95% larger in the HM and HM-B-vitamin deficient groups, respectively. Aortic global 
methylation identified by detection antibodies and quantified by an ELISA, was lower in 
both groups [18]. Another similar study examined HHcy effects on cardiac injury by 
gene-specific DNA methylation alteration in ApoE-deficient mice induced by a HM diet. 
Lower cardiac SAM and 5.2% lower methylation of the key cardiac apoptotic gene, 
Trp53, was observed compared to the ApoE-deficient mice with regular diet, as 
measured by nested MSP. It remains unclear what the effect of these small changes in 
methylation is on cardiovascular phenotypes of these mice [19]. 
In addition to vascular pathologies, methionine-induced HHcy is explored in 
relation to other disorders like bone loss and neurodegeneration. A HM diet given for 
20 weeks to female Wistar rats, induced HHcy and accumulated Hcy in bone tissue by 
13 times leading to a reduced bone strength and cancellous bone loss. SAM and SAH 
concentrations were increased and the SAM:SAH ratio was decreased in the plasma 
and bone [20]. The same authors in a later study gave a HM diet to female Wistar rats 
for 5 months to study the effects of HHcy in relation to neurodegeneration. As a result, 
SAH was higher and SAM:SAH ratio was lower in plasma, brainstem and frontal cortex 
of rats on HM diet, compared to the rats on control diet. SAM concentrations were 
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higher in the plasma and brainstem [21]. 
2.1.2. B vitamin deficient (folate, B6, B12) diets 
Similar to HM diet, a B-vitamin deficient diet to induce HHcy in animal models has been 
studied too. Caudill et al. administered a diet low in methionine and deficient in folate 
and choline to C57BL/6J mice. After 24 weeks, Hcy was higher, compared to the control 
diet mice. SAM concentrations and SAM:SAH ratio were lowered in all the analyzed 
tissues; liver, kidney, brain and testes. SAH was higher in the liver, but not in other 
tissues. However, global DNA methylation measured by cytosine extension assay did 
not change in any of the tissues [22]. 
In the context of vascular pathologies, effects of HHcy induced by a B-vitamin 
deficient diet were not as clear as compared to the effects by the HM diet. In a study 
by Liu et al., B-vitamin deficient diet with or without HM was given to a group of ApoE-
deficient mice. The aortic sinus plaque areas were shown to be larger as a result of HM 
diets, but not with B-vitamin deficient diet alone. Plasma Hcy was elevated, but there 
was no change in the plasma SAH or aortic global methylation levels [18]. Another 
study investigated the effects of folate and/or vitamin B12 deficiency on endothelium-
dependent relaxation in rats. Serum Hcy was higher in the folate deficient (FD) and 
folate-vitamin B12 deficient diet groups, compared to controls. Liver SAM and SAM: 
SAH ratio were lower, and SAH showed no difference. However no association of 
folate, vitamin B12, Hcy, SAM, SAH or SAM:SAH ratio was found with vascular reactivity 
[23]. In yet another study, moderate HHcy resulted when ApoE-deficient mice were 
treated with either a FD or folate, vitamin B6 and B12 deficient diet for 16 weeks. The 
hepatic SAM:SAH ratio for both the diets were reduced up to 80 and 90% respectively. 
However, they showed no association with atherosclerosis and global DNA methylation 
of the vascular or liver tissue, even after an increased atherosclerotic lesion formation 
in the aortic arch [24,25]. 
In relation to pregnancy outcomes, maternal folate status affects the 
homeostasis of Hcy pathway in their offsprings. In a study by Blaise et al., female 
Wistar rats were fed a diet deficient in vitamin B12, B2, folate and choline from one 
month before pregnancy until weaning at day 21. Hcy concentrations were moderately 
elevated in mothers. The pups, who were fed on dams with such a deficient diet, also 
developed HHcy and had a decline in hepatic SAM:SAH ratio due to the decrease in 
SAM. Cbs, Mthfr and Ms activities in the liver were extremely lower in deficient pups in 
comparison to normal fed pups [26]. In another similar study of a FD diet given to 
female pregnant rats starting 2 weeks before mating until gestation at day 21, 4.5-fold 
increased maternal plasma Hcy concentrations were seen. However in this case, no 
change in the global DNA methylation levels was observed in the maternal or fetal rat 
livers [27]. Similarly, Mejos et al. randomly administered a FD or a folate supplemented 
(FS) diet to male and female rats for 4 weeks until mating. Hcy concentrations were 
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elevated in the postnatal rats of either or both of the deficient parents, in comparison 
to the postnatal rats of both FS parents. There was a marked reduction of hepatic 
folate and global DNA methylation levels as identified by detection antibodies and 
quantified using an ELISA [28]. In another study, pregnant Mthfr (+/+) mice were fed a 
FD diet to induce HHcy. Hepatic SAM concentrations were decreased and SAH 
concentrations were increased, which was accompanied by a reduction of SAM:SAH 
ratio. Placental SAH also increased with decrease in SAM:SAH ratio [29]. 
Two other studies measured the levels of DNA methylation and its 
metabolites in the brain of FD diet induced HH rats. The treatment periods for the 
studies were 30 days and 36 weeks. SAM, SAH and SAM: SAH ratio remained unaltered 
in both cases. In the first case, global DNA methylation measured by in vitro methyl 
acceptance capacity assay, was lowered in the deficient group compared to controls 
[30]. Interestingly, in the second case, at 18 and 36 weeks, the global DNA methylation 
levels quantified by high-performance liquid chromatography–(electrospray)-mass 
spectrometry, were higher in the FD diet group, as compared to controls, although the 
same mice group had also shown global hypomethylation in the liver, when quantified 
by the cytosine extension assay [31,32]. The trend in the alteration of DNA methylation 
differed between studies, or might suggest a different mechanism with prolonged 
treatment period. Furthermore in an additional study, such a similar HH model of Cbs 
(+/+) mice showed elevated SAH with lower SAM:SAH ratio in the brain [33]. 
Folate deficiency, which is also implicated in relation to colon cancer, was 
experimented in the colon of HH rats by two groups. In the first study, SAM 
concentrations of the colonic mucosa and methylation of Trp53 promoter region 
remained unchanged in the FD diet group. A 3–3.5 fold higher SAH and 64–71% lower 
SAM:SAH ratio was observed at 5 weeks, in comparison to controls. A 30% higher 
colonic global DNA methylation, measured by an in vitro methyl acceptance capacity 
assay was observed only at 3 weeks, which directly correlated with plasma Hcy [34]. 
The second study group conducted a FD treatment of 24 weeks. An ~11% lower hepatic 
SAM:SAH ratio was observed, in comparison to controls. But no change was found in 
colonic SAM and SAH concentrations or their ratio. Global DNA methylation in the liver 
and colon did not lower significantly, even after this longer treatment period of 24 
weeks [35]. 
In general, different diets may have variable effects on Hcy, DNA methylation 
and its markers. Devlin and associates conducted a study, where they assigned one of 
the 3 diets for 7–15 weeks to random groups of both Mthfr (+/+) and Mthfr (+/−) mice; 
1) HM 2) LF 3) HM-LF. Plasma Hcy showed no difference between control and the HM 
diet group. But higher Hcy was observed in the LF and HM-LF group, as compared to 
controls. Hepatic and brain SAM:SAH ratio were lower in all experimental diet groups, 
being the most in the LF and HM-LF groups. In the liver, the lower SAM:SAH ratio in LF 
and HM-LF groups was due to higher SAM, whereas, in the HM group, it was due to 
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higher SAH. No effect on global hepatic or brain DNA methylation was observed in any 
of the three cases [36]. 
2.2. Genetically-induced Hhcy 
Genetic variants in the key enzymes of the one-carbon pathway like MTHFR, MTRR, MS 
or CBS are associated with disease risks. These enzymes help balance Hcy 
concentrations within the pathway. In order to study Hcy-induced change in DNA 
methylation or its markers by such enzyme deficiencies, a few study groups used gene 
knockout mice models [Table 2]. 
2.2.1. MTHFR deficiency 
MTHFR is one of the common enzymes that could be deficient leading to alterations in 
Hcy metabolism. In relation to vascular pathology, Chen et al. generated two groups of 
Mthfr (+/−) and Mthfr (−/−) mice, which showed 1.6 and 10-fold higher plasma Hcy, 
respectively, compared to Mthfr (+/+) mice. SAM and SAH concentrations in the brain, 
ovaries, testes and liver were altered, and global DNA methylation, measured by 
cytosine extension assay, was lowered in the brain and ovaries. This was accompanied 
by an abnormal lipid deposition in the aorta for both knockout groups, and a 76.4% 
reduced survival of Mthfr (−/−) mice [37]. In 2004, Devlin et al. used the Mthfr (+/−) 
mice that were generated by Chen et al. They observed lower SAM: SAH ratio in the 
liver and brain tissue compared to Mthfr (+/+) mice. Disrupted Mthfr gene also 
sensitized the mice to diet-induced HHcy and endothelial dysfunction [36]. In yet 
another study, Mthfr (−/−) mice showed lower global DNA methylation which was 
quantified by thin layer chromatography in the cerebellum, as compared to the control 
mice. They also found lower methylation of CpG dinucleotide 4 within first exon 17 of 
the Nr3c1 gene encoding the glucocorticoid receptor in the hippocampus, which was 
measured by pyrosequencing. This was accompanied by more mRNA and protein of the 
Nr3c1 gene, behavioral anomalies, disrupted cognitive function, increased apoptosis 
and other neurobiological changes [38]. 
2.2.2. CBS deficiency 
In 2001, Caudill and coworkers studied the effects of HHcy on Cbs (+/−) mice. As a 
result, SAM and SAM:SAH ratio were lower in all the analyzed tissues; liver, kidney, 
brain and testes, as compared to the Cbs (+/+) mice. SAH showed an increase in the 
liver and testes, but not in the kidney and brain. DNA methylation was measured by 
cytosine extension assay and did not show to be hypomethylated in any of the tissues, 
but the testes [22]. In the same year, Dayal et al. set up a similar Cbs (+/−) mouse 
model to induce HHcy. In the liver and brain, SAH were 2-fold higher and SAM:SAH 
ratios were lowered. In addition, an approximately 20% lower thrombomodulin activity 
was observed in the aortic arch of the Cbs (+/−) mice, which correlated with SAH [15]. 
Sontag et al. in their defined HH model also showed an ~27% lower methylation of 
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protein phosphatase 2, regulatory subunit A, alpha (Ppp2r1a) gene in the brain. The 
methylation was identified by detection antibodies and quantified by ELISA [33]. In 
three studies that followed, severe HHcy showed in Cbs (−/−) mice. In the first study, 
SAH concentrations were 8 times higher in the liver and kidney and 190 times higher in 
the brain, as compared to Cbs (+/+) mice. The SAM:SAH ratio was observed to be 80% 
in the liver, 87% in the kidney and 100% in the brain. Only in the liver tissue, SAM 
concentrations were higher and global DNA methylation measured by the in vitro 
methyl acceptance capacity assay was lower [39]. In the second study, 20-fold higher 
liver Hcy in 4- to 6-month old Cbs (−/−) mice were seen, as compared to Cbs (+/+). 
Hepatic SAM and SAH concentrations were also higher [40]. In the third study, Cbs 
(−/−) mice developed fatty livers at 2 weeks, which became less apparent at 8 weeks. 
The fatty livers at 2 weeks also showed a decline in global protein arginine methylation. 
The liver SAM and SAH concentrations increased at both weeks, showing a 2-fold 
decrease of the SAM:SAH ratio at 8 weeks [41]. 
2.2.3. MSR deficiency 
The enzyme MSR is required for the normal functioning of the MS enzyme, which helps 
in Hcy remethylation. In 2005, Dayal et al. com- pared Mtr (+/−) mice with Mtr (+/+) 
mice, and demonstrated that higher plasma Hcy was observed in the Mtr (+/−) mice, 
compared to the Mtr (+/+) mice. However, no effect was seen on methylation markers 
of the liver or brain tissue [42]. In 2007, Elmore et al. generated HH mice with either a 
heterozygous or a homozygous knockout for the Mtrr gene, encoding MSR. No 
difference in SAM and SAH was observed in the kidney and brain. Heart tissue showed 
higher SAH and lower SAM:SAH ratio, as compared to the Mtrr (+/+) mice. But 
unexpected opposite trends were observed in the liver, which showed higher SAM and 
lower SAH with higher SAM:SAH ratio [43] study demonstrated that maternal Mtrr 
(−/−) mice influences the placental methylation levels of their Mtrr (+/+) grandprogeny, 
both globally and in about 45–70% of the studied imprinted genes. In this case, global 
DNA methylation was identified using detection antibodies and methylation of the 
imprinted genes was quantified by bisulfite pyrosequencing [44]. 
2.3. Genetically- and diet-induced Hhcy 
Dietary deficiencies affect Hcy concentrations and consequently DNA methylation. 
However if dietary deficiencies are accompanied by enzyme deficiencies, then a more 
sensitive effect on Hcy and DNA methylation can be expected [Table 3]. A few studies 
in rat and mouse models have shown a combined effect of diet and gene knockout to 
investigate the same. 
2.3.1. Diet and CBS deficiency 
Caudill et al. studied the HHcy effects from a diet deficient in methionine, choline and 
folate, in a Cbs (+/−) mice. SAM and SAM:SAH ratio were lowered in all analyzed 
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tissues; liver, kidney, brain and testes, compared to Cbs (+/+) mice with regular diet. 
SAH concentrations were higher in the liver, brain and testes, but not in the kidney. 
Using the cytosine extension assay, global DNA was found to be hypomethylated only 
in the brain and testes [22]. 
In relation to vascular pathologies, several studies administered a HM-LF diet 
to Cbs (+/−) mice to induce HHcy. Using such a mouse model, tissue-specific alterations 
of methylation in the maternal differentially methylated domain of the H19 gene were 
observed. This domain was hypomethylated in the liver, and hypermethylated in the 
brain and aorta, as compared to the Cbs (+/+) mice with control diet. SAH 
concentrations increased and SAM:SAH ratio decreased in the liver and brain. The 
expression of H19 transcripts in the aorta increased by 2.5-fold [45]. In a similar study, 
when giving a HM-LF diet to Cbs (+/−) mice, Glier et al. reported mildly higher Hcy. SAH 
concentrations were higher and SAM:SAH ratio was lower in the liver, but not in the 
brain, as compared to Cbs (+/+) mice with control diet. Lower SAM:SAH ratio in the 
liver was accompanied by lower methylation in the maternal H19 DMD allele which 
was measured by bisulfite sequencing. Interestingly, higher methylation in this domain 
was observed in the brain, despite no effect in brain SAM:SAH ratio. This also suggests 
tissue-specific differences [46]. Previously, the authors observed alteration of the SAM 
and SAH in the liver and brain at 7 and 15 weeks of diet treatment, with a lower 
SAM:SAH ratio at 15 weeks [15]. In another recent study, 12 weeks of HM-LF diet given 
to a Cbs (+/−) mice showed hypermethylation of the promoter transcripts of the Nr3c1 
gene, measured using bisulfite pyrosequencing. This epigenetic silencing of Nr3c1 gene 
in the aorta was associated with HHcy [47]. 
With a combination of Cbs knockout and HM-LF diet in mice, studies have 
also been conducted in relation to HHcy associated liver pathologies. In the first study, 
a fatty acid desaturase enzyme of the liver, which is encoded by Fads2 gene and 
involved in fatty acid synthesis, was epigenetically silenced with hypermethylation in its 
promoter in Cbs (+/−) mice with HM-LF diet, compared to Cbs (+/+) mice with control 
diet. This was accompanied by lower SAM:SAH ratio, which associated with 
phospholipid and fatty acid metabolism in the liver [48]. In a similar study, the liver acyl 
CoA:cholesterol acyl transferase 2 (Acat2) enzyme responsible for the production of 
cholesteryl esters, had lower expression levels in Cbs (+/−) mice with HM-LF diet, 
compared to Cbs (+/+) mice with regular diet. Soat2 which encodes Acat2, had an 
altered methylation which was quantified by bisulfite pyrosequencing at the CpG rich 
region of its 5′ portion, compared to Cbs (+/+) mice with control diet. This was also 
accompanied by higher methylation of the B1 repetitive elements that were quantified 
by the same technique [49]. 
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3. HUMAN STUDIES 
Besides in animals, effects of Hcy on DNA methylation are also investigated in humans. 
Most of these concerned patients and a few healthy volunteers [Table 4]. In a study, 71 
vegetarians, 58% of whom were vitamin B12 deficient, were evaluated for their 
methylation markers and their relationship with peripheral blood DNA methylation. 
Serum Hcy was higher than 12 μmol/L in 45% of the vegetarians, which was higher 
than in omnivores. It showed no association with SAM, SAH or SAM:SAH ratio. 
Methylation levels of 3 CpG sites in Alu-repetitive elements correlated with SAH and 
SAM:SAH ratio, but not with Hcy or SAM. In addition, the methylation status of the 
SHC1 promoter was investigated, however this was not correlated with Hcy, SAM, SAH 
or SAM:SAH ratio [50]. 
In another study, healthy adult women with elevated Hcy had a 2.6-fold lower 
lymphocyte global DNA methylation, which was measured by cytosine extension assay. 
Plasma SAH concentrations were 2-fold elevated, which decreased SAM:SAH ratio by 
one-half. This SAM:SAH ratio showed a direct relation with intracellular lymphocyte 
SAM:SAH ratio [51,52]. In a study by Perng et al. plasma Hcy positively correlated to 
LINE-1 methylation, which was quantified by pyrosequencing in healthy middle-aged 
adults. However, Alu methylation did not significantly correlate with plasma Hcy [53]. 
A study by Farkas and group divided Hcy concentrations of 56 blood leukocyte 
samples into low (5–10 μmol/L) and high (20–113 μmol/L) Hcy and considered them as 
well-nourished and poorly nourished subjects, respectively. Site-specific methylation 
differences quantified by pyrosequencing were observed in 17 CpG sites of the RFC1 
gene between the groups. [54]. 
In relation to pregnancy, LINE-1 methylation in blood and folate- related 
parameters from 24 pregnant women, all of whom were under folate diet, were 
determined using pyrosequencing. Cord plasma Hcy showed inverse correlation with 
LINE-1 methylation in cord blood [55]. This study was later extended by using DNA 
methylation arrays in 12 pregnant women in order to assess correlation of genome-
wide methylation patterns with plasma Hcy and LINE-1 methylation. Univariate 
regression analysis identified 298 autosomal and 8× chromosome CpG sites associated 
with Hcy. In addition, methylation of 146 autosomal CpGs mostly located within CpG 
islands, was associated with LINE-1 methylation [56]. 
A few more studies were performed in individuals having specific diseases, 
which have known to be associated with high Hcy. We focused this review at vascular 
disease, cancer, renal diseases and brain disorders. 
3.1. Vascular disease 
Two case-control studies were performed to evaluate Hcy effects on global DNA 
methylation in vascular diseases, measured using cytosine extension assays. The first 
study measured global DNA methylation in leukocytes, which was lower in 
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atherosclerotic patients (N = 17), as compared to controls (N = 15) and had an inverse 
correlation with plasma Hcy. In addition, plasma SAH concentrations were higher and 
SAM:SAH ratio was lower, which also correlated with Hcy [57]. The second study 
measured global DNA methylation in peripheral blood lymphocytes. In this case, Hcy 
and global DNA methylation were higher in 137 coronary artery disease cases 
compared to 150 controls, with a positive association between the two [58]. In another 
study, LINE-1 methylation was measured at baseline in 712 elderly men either at low 
risk or with high risk for ischemic heart disease or stroke. Plasma Hcy was higher and 
LINE-1 methylation was lower in the case of individuals at risk. However, the two were 
not correlated [59]. 
DNA methylation was further studied in a few candidate gene studies. Two 
case–control studies with atherosclerotic patients were performed. In the first study 
(54 cases, 28 controls), elevated Hcy concentrations positively correlated with DNA 
methylation of CpG islands at the estrogen receptor alpha (ESR1) promoter, which 
were quantified using nested MSP [60]. In the second study (197 cases, 165 controls), 
elevated Hcy was correlated with MSP measured DNA hypomethylation of human 
telomerase reverse transcriptase (hTERT) and its downregulation, which was 
accompanied by shortened leukocyte telomere length. This was also confirmed in 
methionine fed HH mouse model [61]. High Hcy was also inversely correlated with site-
specific methylation of the SHC1 promoter which was quantified using Sequenom 
EpiTyper in peripheral blood leukocytes of coronary artery disease patients. [62] . In a 
group of 192 patients that underwent coronary artery bypass grafting, there was no 
correlation between Hcy and DDAH2 methylation of the internal mammary artery, but 
with NOS2 methylation of the internal mammary artery and punch aortic fragments 
[63]. 
In a study by Heil and group, heparin blood samples were used to isolate 
genomic DNA from 9 CBS deficient patients treated with Hcy lowering therapy and 8 
healthy controls. Hcy, SAM and SAH were higher in patients than in controls. However, 
no difference in SAM:SAH ratio was found. In addition, global DNA methylation and 
gene- specific methylation of H19 DMR were measured, which showed no difference 
compared to controls [64]. 
3.2. Cancer 
In 2003, Pufulete et al. observed 26% lower colonic global DNA methylation in patients 
with colorectal adenoma (N = 35) and 30% lower methylation in 28 patients with 
colorectal cancer, as compared to 76 controls. DNA methylation was quantified using in 
vitro methyl acceptance capacity assay. Plasma Hcy, even though not significantly 
higher in patients, showed an association with colonic DNA methylation [65]. The same 
group also generated methylation indexes of the ESR1 and mutL homologue 1 (MLH1) 
genes by PCR and pyrosequencing in the same subjects, which were higher in patients 
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compared to controls. The methylation indexes of the ESR1 promoter correlated 
positively with Hcy, while those at MLH1 did not show any correlation [66]. Similarly, a 
colorectal cancer case–control study investigated the relation between variables of 
one-carbon metabolism and promoter methylation of an eight-gene panel (CDKN2A, 
MLH1, CACNA1G, NEUROG1, RUNX3, SOCS1, IGF2, and CRABP1) of archival colorectal 
tumor tissue in colorectal cancer cases (N = 190). The methylation of these genes did 
not associate with Hcy [67]. 
In summary, these studies demonstrate that MLH1 gene methylation was not 
correlated with Hcy in colorectal cancer patients. However, in patients with esophageal 
diseases (N = 124), promoter MLH1 hyper- methylation as quantified by restriction 
enzyme-based methylation analysis, was observed in 63.5% of cancer cases and in 
53.8% of precancer cases, which showed association with elevated plasma Hcy [68]. 
Two further studies were conducted in breast cancer patients, where in 
promoter methylation of the targeted genes was quantified by MSP. In the first study, 
the RARB promoter and exon 1 regions of ESR1 in breast tumor tissue of 137 primary 
breast cancer cases were hypermethylated and showed elevated Hcy [69]. In the 
second study (179 cases), elevated Hcy correlated with BRCA1 promoter 
hypermethylation in the breast cancer tissue and corresponding peripheral blood of all 
breast cancer types. In addition, RASSF1 promoter hypermethylation was studied in 
breast cancer tissue of estrogen receptor (ER)-negative and progesterone receptor 
(PR)-negative breast cancer cases and was also shown to correlate with Hcy [70]. 
3.3. Renal disease 
Ingrosso et al. investigated the effects of HHcy on global DNA methylation in 32 
patients with uremia who had elevated Hcy, and compared them with 11 healthy 
controls. DNA methylation of peripheral blood mononuclear cells (PBMCs) measured 
by cytosine extension assay and southern blotting was lower in patients, which 
associated with HHcy. This change in global DNA methylation was associated with loss 
of imprinting of the H19 DMR [71]. In two other studies, global DNA methylation was 
measured in leukocytes of 78 stages 2–4 chronic kidney disease or 20 chronic 
hemodialysis patients. However, in these studies, global DNA methylation was not 
associated with plasma or serum Hcy [72,73]. 
3.4. Brain disorders 
Patients with Alzheimer's disease showed a negative association of plasma SAM:SAH 
ratio with plasma Hcy. In addition, SAM and SAH concentrations were higher in 
patients [74]. Case–control studies were per- formed with euthymic bipolar or 
schizophrenia patients by Bromberg et al. Hcy was elevated in schizophrenia patients, 
but not in euthymic bipolar patients compared to controls. Global methylation levels in 
peripheral blood leukocytes did not differ between either of the cases and controls, 
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and was not associated with Hcy [75,76]. A similar study performed in schizophrenia 
patients (N = 42), examined the effect of plasma Hcy on genome-wide DNA 
methylation of peripheral leukocytes measured by arrays. Patients had moderate 
concentrations of Hcy, as compared to controls. Out of the analyzed CpGs, 1338 of 
them, annotated at different gene regions, showed to be differentially methylated with 
elevated Hcy. 56.6% of these sites were located in the CpG islands and their flanking 
regions. Two of them included the methylated sites from the SLC18A2 and GNAL genes, 
which had previously shown to associate with schizophrenia. However no correction 
for multiple testing was used [77]. 
3.5. MTHFR 677C>T 
Multiple studies looked at differences in Hcy and DNA methylation comparing MTHFR 
677CNT (rs1801133) CC and TT genotypes. Two studies investigated levels of global 
DNA methylation, one in PBMCs using LC Ion Trap LC/MS and the other in leukocytes 
using cytosine extension assay. In both studies, the MTHFR TT genotype had lower 
levels of methylation, in comparison to subjects carrying the CC genotype, which 
positively correlated with folate status and negatively correlated with plasma Hcy 
[78,79]. Two other studies were conducted in young women who participated in a 
regime of folate depletion and repletion diet for 2 consecutive periods of 7 weeks. 
Global DNA methylation in leukocytes was measured at baseline, weeks 7 and 14. In 
the first study, methylation levels did not decrease significantly after 7 weeks of folate 
depletion. But at 14 weeks, the methylation increased only in women with the TT 
genotype. Folate concentrations were reduced and plasma Hcy were elevated in 
women with TT genotype, both post-depletion and post-repletion. Hcy directly 
correlated with DNA methylation only during depletion [80]. In the second study, there 
was no difference in methylation levels post-depletion, but they were lower after post-
repletion. A delay in methylation response to folate in- take was suggested here, and 
no correlation was observed with Hcy [81]. 
Three other studies assessed methylation in controls of colorectal cancer 
subjects according to their genotypes. However, no difference in global DNA 
methylation of lymphocytes, colon or colonic mucosa was observed when stratifying 
between MTHFR CC and TT genotypes. Also, no association was found between Hcy 
and methylation [82,83], except in colonic mucosa, where plasma Hcy showed a 110% 
increase in individuals of TT genotypes [84]. 
4. EFFECT OF HCY-LOWERING THERAPY IN RELATION TO METHYLATION 
4.1. Animal studies 
Few studies investigated the effect of Hcy-lowering therapy on DNA methylation by 
giving a B-vitamin supplemented diet to either rat or mouse models [Table 5]. Three 
studies investigated the effect on liver DNA methylation. A study using male Wistar rats 
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given a 40 mg/kg high folate diet for 4 weeks, showed lower plasma Hcy, compared to 
controls. But no change was observed in hepatic SAM, SAH, SAM:SAH ratio or global 
DNA methylation [85]. Another study fed Sprague–Dawley rats a vitamin B12 deficient 
diet for 6 weeks to induce high Hcy. In addition, these rats were simultaneously given a 
high folate diet of 100 mg/kg. Similar to the previous study, Hcy concentrations were 
normalized by this treatment, but there was no change in hepatic and brain SAM, SAH, 
SAM:SAH ratio or hepatic global DNA methylation [86]. Later, when Sie et al. 
investigated the effect of high maternal and post-weaning folate diet on the offspring 
of female Sprague–Dawley rats, contrasting results were observed. At weaning, hepatic 
global DNA methylation which was quantified by in vitro methyl acceptance capacity, 
was decreased by 25% due to maternal folate diet of 5 mg/kg. Hcy and site-specific 
methylation of Pparg, Esr1, Trp53 and Apc genes measured by methylation-sensitive 
restriction enzyme, were also decreased. At 14 weeks of post-weaning, Hcy decreased 
due to both maternal and post-weaning folate diet, and methylation levels of Pparg, 
Trp53 and P16 genes were increased. A decrease in global DNA methylation and 
increase in methylation of Esr1 and Apc genes were also observed, but only due to 
post-weaning supplementation [87]. 
In the case of colon tissue, male Sprague–Dawley rats on a 8 mg/kg high 
folate diet for 5 weeks, showed no modulation of SAM, SAH, SAM:SAH ratio or DNA 
methylation at any measured time-point, as compared to controls [34]. Yet again, 
contrasting results were seen when Sie et al. in 2011 investigated maternal and post-
weaning folate diet effects on colonic global DNA methylation quantified by liquid 
chromatography–electrospray ionization mass spectrometry. Hcy at weaning 
decreased due to maternal high folate diet of 5 mg/kg, and colonic global DNA 
methylation increased by 3%. At 14 weeks of post-weaning, Hcy similarly decreased 
due to both maternal and post-weaning supplementation, but colonic global DNA 
methylation decreased only due to post-weaning supplementation [88]. 
For brain tissue, 30 days of 8 or 40 mg/kg high folate diet did not modulate 
brain methylation markers [30]. Another recent study used a Cbs (+/−) mouse model 
on a HM diet for 4 weeks to induce HHcy, which increased brain DNA methylation. To 
investigate the effects of high folate diet, they supplemented 0.0057 μg/g bodyweight 
per day dose of folic acid in drinking water to these mice. As a result, Hcy 
concentrations were lowered in the HHcy mice, and brain methylation was lower, 
although not significant. Global DNA methylation was detected using antibodies and 
quantified by ELISA [89]. 
4.2. Human studies 
In humans, Hcy-lowering therapy studies did not lead to promising results for restoring 
DNA methylation patterns [Table 6]. In case of colorectal adenoma patients, Pufulete 
and coworkers performed a placebo-control trial with a short-term folate diet given 
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400 μg/day to patients with colorectal adenoma for 10 weeks. As a result, 12% lower 
plasma Hcy was observed. Successively, global DNA methylation measured by in vitro 
methyl acceptance capacity in leukocytes and colonic mucosa were higher by 31% and 
25%, respectively, suggesting that DNA methylation can be reversed by this therapy 
[90]. The same authors also investigated whether 400 μg/day folate diet re- stores 
methylation in CpGs of the ESR1 and MLH1 genes of colonic mucosa, since they were 
previously shown to be hypermethylated in case of colorectal tumors. After 
supplementation, Hcy decreased in folate diet group, but no effect was found on ESR1 
and MLH1 methylation [91]. Another placebo-control study was conducted with a 6 
months daily supplementation of 5 mg/day folate diet and 1.25 mg/day vitamin-B12 to 
patients with previous colorectal adenomas. Again, Hcy concentrations were lower. 
However no methylation change was determined in the promoter of 6 tumor 
suppressor and DNA repair genes in rectal biopsies [92]. 
Ingrosso et al. gave a folate treatment of 15 mg/day oral 
methyltetrahydrofolate to patients with HHcy and uremia for 2 months, as a result, 
plasma Hcy was decreased. Global DNA of PBMCs which was hypomethylated before 
treatment, restored methylation levels showing an increase. This was measured by 
cytosine extension assay and southern blotting. In addition, folate was able to restore 
loss of imprinting of the H19 gene [71]. When giving 5 mg/day folate diet to patients 
with intermediate HHcy for 8 weeks, Hcy concentrations were restored with an 
increase in plasma SAM and SAM:SAH ratio. However, no change in plasma SAH or 
global methylation levels of PBMCs was observed [93]. 
End stage renal failure patients have increased global DNA methylation in 
peripheral lymphocytes. In order to investigate whether Hcy-lowering therapy could 
reduce lymphocytic methylation, long- term stable dialysis patients were given a short 
term folate diet (15 mg thrice weekly) with or without an additional supplementation 
of vitamin B12 (1000 μg once a week). At 12 weeks, plasma Hcy was lower in folate diet 
group, compared to controls. However, lymphocyte global DNA methylation measured 
at 20 weeks, did not change [94]. Also a 1 year Hcy-lowering treatment with B-vitamins 
(folate diet: 5 mg/day, pyridoxine: 100 mg/day and vitamin B12: 1 mg/day) in stage 2–4 
chronic kidney disease patients, showed no change in global DNA methylation in 
leukocytes [72]. 
Three other long-term studies were conducted for either 1, 2 or 3 years. In 
the first study, the effect on whole blood LINE-1 methylation was studied by 
supplementing adult subjects with B (folate diet: 500 μg/day, vitamin B12: 500 μg and 
vitamin B6: 50 mg) and D vitamins (1200 IU) for 1 year. As a result, no change in LINE-1 
methylation levels was observed, but the plasma Hcy decreased [95]. In the second 
study, a Hcy-lowering therapy of 1 mg/day folate and B vitamins (vitamin B12: 500 
μg/day and vitamin B6: 10 mg) given to an older healthy group with elevated Hcy of 
N13 μmol/L showed a reduction in plasma Hcy after 2 years, while no difference was 
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found in the plasma SAM, SAH and the SAM:SAH ratio [96]. On the third study, a 
placebo-control trial of participants with moderately elevated Hcy between 13 μmol/L 
and 26 μmol/L was investigated with a daily supplementation of 0.8 mg/ day folate diet 
for 3 years. After supplementation, plasma Hcy decreased by 21.6%. However, no 
difference in global DNA methylation in peripheral blood leukocytes was observed 
between the treatment groups [97]. 
In addition to therapies, a recent study investigated the impact of folic acid 
fortification of the US food supply on leukocyte global DNA methylation in 408 
postmenopausal women. After nearly 2 years of fortification, they observed a 
reduction in plasma Hcy and increase in RBC folate. There was no change in leukocyte 
global DNA methylation. However, when these women were grouped into highest and 
lowest tertiles of RBC folate distribution, they observed that the group with the highest 
tertile had elevated mean DNA methylation in the pre-fortification period and lower 
mean DNA methylation in the post-fortification period, in comparison to the lowest 
tertile group. Global DNA methylation was negatively correlated with plasma Hcy in the 
pre-fortification period and positively in the post-fortification period. Thus RBC folate 
and plasma Hcy were proved to be important predictors of leukocyte global DNA 
methylation [98]. 
5. DISCUSSION AND CONCLUSION 
We reviewed the current literature on Hcy and DNA methylation. Although in most 
studies, a clear association between Hcy and DNA hypomethylation was observed, 
results were not always consistent. In animals, the association between Hcy and DNA 
hypomethylation was clear whereas in humans, several contradictory findings were 
published. This might be caused by the pathophysiological effects of the underlying 
disease or might be explained by genetic differences between humans. 
HH animal models in general have higher SAH, lower SAM:SAH ratio and 
lower global DNA methylation compared to normohomocysteinemic animals. However, 
a few studies showed higher SAM [15,20,21]. In addition, Cbs (−/−) mice with severe 
HHcy also showed higher SAM concentrations in the liver with lower SAM:SAH ratio 
[39,41]. Despite higher SAM concentrations, lower SAM:SAH ratio might be the result 
of severely elevated SAH, which is due to severely higher concentrations of Hcy in Cbs 
(−/−) mice. Hence, severely elevated SAH concentrations act as a strong inhibitor of 
methyltransferase reaction, despite of the higher SAM. On the contrary, two other 
studies in Mtrr (+/−) and Mtrr (−/−) mice found higher SAM, lower SAH and higher 
SAM:SAH ratio in the liver [17,43,44]. This suggests that different genetic backgrounds 
influence the outcomes differently. 
SAM:SAH ratio, also called the methylation potential, did not seem to be a 
proxy for DNA methylation levels in HH animal models. Some studies showed a similar 
trend between the two, but in other cases, a clear opposite trend was observed. Jiang Y 
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et al. observed higher aortic SAM:SAH ratio with lower global DNA methylation [17], 
while Devlin AM et al. observed a lower brain and hepatic SAM:SAH ratio with higher 
global DNA methylation [45,48]. 
Hcy concentrations did not seem to be dependent on the type of treatment 
i.e. by diet, gene knockout or both. However, three studies which investigated both 
independent and combined effects of diet and genotype, observed higher Hcy 
concentrations in HH genetic model, a similar or a higher effect in HH diet model, and a 
markedly higher effect in the combined model, as compared to the control model 
[15,22,36]. Despite these difference in Hcy, SAM:SAH ratios did not always show a clear 
difference between the three models. Hence, the association between Hcy and 
methylation markers seems independent of the underlying cause; i.e. effects were 
consistently shown in diet-induced animal models, genetic animal models and in the 
combination of both. 
DNA methylation was not consistently altered in humans with HHcy. Global 
DNA was not always hypomethylated, but was also found to be hypermethylated in 
participants with high Hcy [52,58]. Studies were not similar considering tissue types, 
participants and the region measured. For example, global DNA methylation was 
measured in leukocytes and peripheral lymphocytes of vascular disease patients. 
Global DNA in leukocytes was hypomethylated [57], whereas in peripheral lymphocytes 
it was hypermethylated [58]. Disease-specific studies are limited and tissues are not 
always similar. Despite the clear association observed between Hcy and global or gene-
specific methylation in vascular disease patients, we could not derive strong 
conclusions. In case of other diseases, a few studies showed association, while others 
did not. Hence, there is a need for more disease-specific studies which can evaluate 
and compare similar regions and tissues. 
Furthermore, not many large scale genome-wide studies have been published 
until now, except for two [56,77]. In patients with schizophrenia and HHcy, no change 
in leukocytic global DNA methylation was observed [75], but genome-wide changes in 
DNA methylation were found [77]. Hence, more genome-wide studies should also be 
done to evaluate more site-specific genome regions and genes involved in Hcy-induced 
DNA methylation alteration. 
Moreover, variable tissue types must be measured for DNA methylation and 
its markers to explore Hcy effects tissue-specifically. Two studies conducted in a 
heterozygous Cbs knockout mice observed tissue-specific effects in the H19 DMD of 
the liver, brain and aorta when given a HM-LF diet to induce HHcy [45,46]. Looking at 
all the studies, we did not notice any strongest effects of homocysteine metabolism on 
methylation in the liver tissue, as compared to other tissues. Although this might be 
expected, since plasma Hcy reflects liver stores primarily. In human studies, there is 
limited availability of the variable tissue data, which is clearly a major obstacle and may 
contribute to the lack of association between plasma Hcy and accessible tissues such as 
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blood. In most studies, leukocytes are used as proxies for other tissues as they are 
easily accessible. However, it remains questionable whether DNA methylation in 
leukocytes is representative of what is occurring in tissues. A few recent studies have 
investigated this possible correlation between DNA methylation in blood and other 
tissues. For example, leukocytic DNA methylation of selected imprinted genes like 
insulin-like growth factor 2 (IGF2) may serve as a proxy for mammary tissue DNA 
methylation in women with or without breast cancer [99]. In addition, leukocytic DNA 
methylation of LINE-1 repetitive elements may also serve as a proxy showing its 
correlation with that of colon tissue [100]. Similar studies comparing leukocytic DNA 
with tissue DNA, but in relation to Hcy metabolism should be performed to account for 
tissue-specificity. 
In both animal and human studies, SAM:SAH ratio was usually observed to be 
lowered in HH mice or participants, in comparison to controls. In animals, not many 
studies were able to show strong tissue-specificity, except for one [43], where 
SAM:SAH ratio was increased in the liver and lowered in the heart of HH Mtrr (+/−) and 
Mtrr (−/−) mice as compared to Mtrr (+/+) mice. Tissue-specificity on the relationship 
of Hcy concentrations and SAM:SAH ratio was also observed in few studies showing 
lowered SAM:SAH ratio in the liver, but no change in the brain and colon of HH mice 
and rats, as compared to their controls [15,31,32,35,46]. As mentioned before, since 
plasma Hcy reflects liver stores primarily, it might suggest that this relationship could 
be the strongest in the liver, as compared to other tissues. 
In Hcy-lowering trials, animal studies showed contrasting results in the liver, 
colon or brain tissues. Some studies restored methylation patterns, while others did 
not. But as mentioned before, this might be due to different pathophysiology between 
models. In humans, Hcy-lowering trials did not result in a clear improvement of DNA 
methylation patterns in most studies. All the reviewed trials were able to restore Hcy 
concentrations, but this only restored DNA methylation levels in 2 out of 10 studies 
[71,84]. In few studies, despite the longer trials of 1, 2 or 3 years, the methylation 
patterns did not change. 
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ABSTRACT 
Background and objectives: DNA methylation can be modified by environmental 
factors, including nutrition. In order to gain more insight in effects of nutrients on DNA 
methylation, we conducted a systematic review on the relation between nutrients and 
DNA methylation in humans across the life course.  
Methods: The literature search was designed by an experienced biomedical 
information specialist. Six bibliographic databases (Embase.com, Medline (Ovid), Web-
of-Science, PubMed, Cochrane Central and Google Scholar) were searched. We 
selected studies that examined the association between nutrients (blood levels; dietary 
intake; or dietary supplements) and DNA methylation (global, site specific, or genome-
wide) in humans of any age, with no restrictions on year of publication, language, or 
study design. Abstract screening, full text selection, and data extraction was performed 
by two independent reviewers, with a third reviewer available to solve any 
disagreements. 
Results: We identified 3774 references, of which 98 studies met all inclusion criteria. 
The majority was performed in adult study populations, and folate was the main 
nutrient of interest. Several candidate gene and epigenome-wide association studies 
reported differential DNA methylation of CpG sites in response to folate (e.g. IGF2, 
H19, HOX), fatty acids (e.g. PPRAGC1A, TNFα), and vitamin D (CYP24A1). Some of these 
observed associations were specific to life course stage (e.g. IGF2 in early life) and 
tissue (e.g. opposite directions for PPRAGC1A in muscle versus fat tissue). 
Conclusions: To date, promising results have been reported in the field of nutrition and 
DNA methylation in humans at different stages across the life-course; especially for 
nutrients known to be involved in one-carbon metabolism, including folate, but also 
others, such as fatty acids and vitamin D. Studies on other nutrients, such as other 
macronutrients and several minerals are still scare. Further large-scale studies of high 
quality are needed to expand our understanding on the role of nutrition in DNA 
methylation and its effects on health and disease.  
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1. INTRODUCTION 
DNA methylation is prone to modification by environmental factors, including 
nutrition. The susceptibility of change in DNA methylation in response to nutrition is 
particularly high during early life (1). Nevertheless, nutrition has also been reported to 
be associated with DNA methylation in other stages of the life course, for instance, 
during adolescence and adulthood (2). 
Nutrients that are known to be involved in DNA methylation through their 
role in one-carbon metabolism are B-vitamins and methionine. However, also other 
nutrients such as fatty acids, protein, and vitamin D, are suggested to have an effect on 
DNA methylation (3). To date, many studies have been carried out investigating the 
role of nutrition on DNA methylation, in animal studies as well as human studies. 
Although evidence from animal studies demonstrates that nutrition has effects on DNA 
methylation, findings from studies in humans are inconsistent (4).  
In order to gain more insight in effects of several nutrients on DNA 
methylation across the life-course, a clear overview of the current knowledge is of 
importance. Identifying which nutrients affect DNA methylation, either globally or at 
specific CpG sites, will provide insight in the mechanisms that are responsible for the 
effect of nutrition on several health outcomes. Therefore, we conducted a 
comprehensive systematic review on the relationship between status and intake of 
nutrients with DNA methylation in humans across the life course. 
2. METHODS  
This systematic review was performed and reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (5). 
Literature search  
A literature search was designed for six electronic databases by an experienced 
biomedical information specialist. The search engines Embase.com (Medline and 
Embase), Medline (Ovid), Cochrane Central, Web-of-Science, PubMed, and Google 
Scholar were searched from inception until May 10th 2016 (date last searched) to 
identify published studies that examined the association between nutrients and DNA 
methylation. The full search strategies of all databases are provided in Supplement 1.   
Study selection and inclusion criteria 
We selected studies that examined the association between nutrients (blood levels; 
dietary intake; and/or dietary supplements) and DNA methylation (global, site specific, 
and/or genome-wide) in humans. We excluded studies that were performed among 
only patients with chronic diseases (e.g. Alzheimer’s disease, diabetes, anorexia 
nervosa, cardiovascular diseases, etc.) and case reports (n<5). No restrictions were set 
on year of publication, language, or study design. We excluded studies on caloric 
intake, alcohol intake, glucose levels, triglyceride levels, and cholesterol levels as these 
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were outside the scope of our review. Two reviewers screened the retrieved titles and 
abstracts and selected eligible studies according to predefined selection criteria 
independently of each other (Supplement 2). Discrepancies between the two 
reviewers were resolved through discussion, with an arbitrator available if no 
consensus was reached. We retrieved full texts for studies that satisfied all selection 
criteria. These full-text articles were evaluated in detail once more by two investigators 
against the selection criteria. 
Data extraction 
A structured database was developed prior to the data extraction. Detailed 
characteristics of individual studies were extracted including study design, study size, 
country, characteristics of the study population, and details on exposure and outcome 
assessment. In addition, we extracted information on covariate adjustments, and 
conclusions. The association of each nutrient with each methylation measure, either 
global or genome-wide site-specific or gene-specific, was extracted separately to report 
each specific analysis. Gene-specific studies were considered per gene separately.  
Quality analysis 
The quality of included studies was evaluated by two reviewers using a predefined 
scoring system. This quality score (QS) was previously developed for its use in 
systematic reviews and meta-analyses including studies with various study designs (6). 
A score of 0, 1 or 2 points was allocated to each of the following five items: 1) study 
design; 2) size of the population for analysis; 3) quality of the methods used for 
exposure assessment or appropriate blinding of an intervention; 4) quality of the 
methods used for outcome assessment; and 5) adjustment for potential confounders 
or adequate randomization of an intervention. The combined scores resulted in a total 
QS between 0 and 10 points, with 10 representing the highest quality. Details on the 
QS are presented in Supplement 3. 
3. RESULTS  
Characteristics of the included studies 
From the literature search we identified 3,774 unique references, of which 3,523 were 
excluded after screening of title and abstract based on the selection criteria. Of the 251 
remaining references, full-texts were retrieved and reviewed, of which 98 studies met 
all criteria and were included in this systematic review (Figure 1). Of the included 
studies, 25 studies investigated the association between maternal nutrition and 
offspring DNA methylation, nine studies were carried out during infancy, childhood, or 
adolescence, and 70 studies were performed in adults (Table 1, Figure 2). Most studies 
examined associations between nutrients and gene-specific DNA methylation, of which 
the majority focused on folate as nutrient of interest (Tables 2-18). Summaries of the 
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findings of all included studies are presented below per nutrient or nutrient groups and 
per life stage. Detailed information of population characteristics, DNA methylation 
assessment, confounder adjustment, and description of results is included in the online 
supplementary material. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow chart of included studies 
Unique records identified 
through database searching 
n = 3,774 
Studies included 
n = 98 
Records excluded based 
on title and abstract 
n = 3,523 
Full-text articles excluded 
n = 153 
Records screened 
n = 3,774 
Records given full text 
detailed assessment 
n = 251 
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Table 1. Number of studies per category of life course stage, nutrient group, and DNA 
methylation type 
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MICRONUTRIENTS 
             
Vitamin A, α-
carotene & 
β-carotene 
0 0 0 0 1 1 0 0 3 1 2 0 4 
Folate 16 6 7 4 3 3 1 0 43 34 12 1 59 
Vitamin B1 0 0 0 0 0 0 0 0 1 1 0 0 1 
Vitamin B2 1 0 1 0 0 0 0 0 5 5 0 0 6 
Vitamin B3 1 0 1 0 0 0 0 0 1 1 0 0 2 
Vitamin B6 1 0 1 0 0 0 0 0 11 11 1 0 12 
Vitamin B12 4 2 2 0 2 1 1 0 22 18 7 0 26 
Vitamin C 0 0 0 0 0 0 0 0 5 1 4 0 5 
Vitamin D 3 0 2 1 3 1 2 1 5 3 3 0 10 
Vitamin E 0 0 0 0 0 0 0 0 4 1 3 0 4 
Choline & betaine 2 2 1 0 0 0 0 0 3 3 1 0 3 
Minerals & trace 
elements 
0 0 0 0 1 1 0 0 7 6 2 0 8 
Combined 
nutrients 
1 0 0 1 0 0 0 0 6 3 2 1 7 
Bioactive 
compounds 
0 0 0 0 0 0 0 0 6 1 5 0 6 
MACRONUTRIENTS 
            
Fat & fatty acids 5 2 3 1 2 0 0 2 18 4 10 5 25 
Carbohydrates & 
fiber 
2 1 1 0 0 0 0 0 6 4 3 0 8 
Protein & 
amino acids 
2 1 1 0 0 0 0 0 7 5 3 0 9 
TOTAL 25 9 13 6 9 4 4 3 70 42 26 7 98 
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MICRONUTRIENTS 
Vitamin A, α-carotene, and β-carotene 
Vitamin A in infancy, childhood, and adolescence and DNA methylation 
Perng et al (QS: 6) showed that higher plasma vitamin A levels in children aged 5 to 12 
years were associated with global DNA hypomethylation in blood (7).  
Vitamin A in adulthood and DNA methylation 
Piyathilake et al. (QS: 6) observed no association between plasma vitamin A levels and 
global DNA methylation in either PBMCs or cervical cells (8). Bollati et al (QS: 6) 
investigated the association of intake of α-carotene, β-carotene, and retinol with 
methylation of CD14, Et-1, HERV-w, iNOS and TNFα in blood. They observed an 
association of higher intake of β-carotene with hypermethylation of HERV-w and 
higher intake of β-carotene and retinol was associated with hypomethylation of TNFα. 
However, no significant association was observed for the other genes (9). Stidley et al 
(QS: 6) did not find an association of α-carotene, β-carotene, and retinol intake with 
methylation index of genes (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and 
GATA5) in sputum (10). 
Folate 
Maternal folate and offspring DNA methylation 
Sixteen unique studies investigated the association between maternal folate and 
offspring DNA methylation, six at a global level, seven gene-specific, and four at a 
genome-wide level. Of the four studies investigating global DNA methylation in cord 
blood (QS: 2-6), one found that an increased dietary folate as well as RBC folate were 
associated with global hypomethylation (11), whereas the other three studies reported 
no significant association with folate (12-14). In contrast, studies investigating DNA 
methylation in other fetal tissues, including placenta, brain and heart, showed that 
higher maternal folate levels were associated with global hypermethylation (15, 16). 
Four studies investigated the association between levels or intake of maternal folate 
and IGF2 methylation in offspring (QS: 5-7). Three of these studies measured 
methylation in cord blood. In these studies, higher folate intake was shown to be 
associated with IGF2 hypermethylation (11) and no association was observed between 
serum folate and DNA methylation (17). Higher RBC folate showed association with 
IGF2 hypermethylation in one study (18) and no association in another study (11). One 
observational study found IGF2 hypermethylation in offspring at 12-18 months in 
mothers who used folate supplements during pregnancy compared to those of 
mothers who did not (19). Furthermore, Hoyo et al. (QS: 5 and 7) found an association 
of maternal folate supplements and erythrocytes with H19 hypomethylation in cord 
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blood (18, 20). Maternal intake and erythrocyte folate were found to be associated 
with PEG3 hypomethylation in cord blood (11, 18), whereas no association was found 
with maternal RBC folate (QS: 5-7) (11). Furthermore, higher maternal erythrocyte 
folate was also associated with hypermethylation of PEG1/MEST and hypomethylation 
of PEG10/SGCE in cord blood (QS: 7) (18). Higher maternal erythrocyte folate was 
associated with hypomethylation of MEG3, MEG3-IG (intergenic), NNAT and PLAGL1 
promoters in cord blood (QS:7) (18). Van Mil et al. showed that supplement use and 
venous blood levels of folate were associated with NR3C1 hypermethylation, and 
higher folate supplement use was associated with 5-HTT hypomethylation in cord 
blood (QS: 6 and 7) (21). Furthermore, no associations were observed between 
maternal folate intake or RBC and SNRPN or ZAC1 methylation in cord blood (QS: 5 and 
6) (11, 22).  
Of the four studies investigating maternal folate levels and epigenome-wide 
DNA methylation in cord blood, three used Illumina 450K arrays and identified several 
CpG sites. Amarasekera et al. (QS: 4, N=23) found seven differentially methylated 
regions, of which ZFP57 was validated using Sequenom EpiTyper platform (23). Joubert 
et al. (QS: 8, N=1988) identified 443 CpG sites annotated to 320 genes, of which some 
novel genes included APC2, GRM8, SLC16A12, OPCML, PRPH, LHX1, KLK4 and PRSS21 
(24). Gonseth et al. (QS: 6, N=347) found that maternal folate intake was associated 
with three CpG sites annotated to genes TFAP2A, STX11 and CYS1 (25). The fourth 
EWAS (QS: 6, N=200) did not find associations between maternal folate levels and 
genome-wide DNA methylation (26).  
Folate in infancy, childhood, and adolescence and DNA methylation 
Three unique studies investigated the association between folate levels and global DNA 
methylation during infancy or childhood, of which one also examined gene-specific 
DNA methylation. Two studies (QS:4 and 5) examined the association between folate 
levels and global DNA methylation in cord blood: Haggerty et al. showed that RBC 
folate was associated with global hypomethylation whereas Fryer et al. observed no 
association (11, 13). Perng et al. (QS: 4) studied the association between erythrocyte 
folate and global methylation in children aged 5-12 years, but found no association (7). 
Haggerty et al. (QS: 6) also examined the association between RBC folate and DNA 
methylation of IGF2, PEG3 and SNRPN in cord blood. In line with their findings for 
maternal folate and offspring DNA methylation, they found that RBC folate at birth was 
also associated with IGF2 hypermethylation, PEG3 hypomethylation and no difference 
in SNRPN methylation (11).    
Folate in adulthood and DNA methylation 
There were 41 unique studies that investigated the association between folate and 
adult DNA methylation. Thirty-three studies examined DNA methylation at a global 
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level, 12 gene-specific, and one at a genome-wide level. In observational studies that 
measured DNA methylation in blood, folate intake was associated with DNA 
hypomethylation in one study (QS: 5) (27), DNA hypermethylation in three studies (QS: 
3-5) (28-30), but no difference in methylation was observed in majority of the studies 
(QS: 1-6) (12, 31-35). Higher blood levels of folate were associated with DNA 
hypomethylation in one study (QS: 6) (36), whereas DNA hypermethylation in six 
studies (QS: 4-6) (37-42). A few studies showed no difference in methylation (QS: 3-6) 
(34, 43-45). Overall, dietary intake and levels of folate in these observational studies 
tend to be more often associated with global DNA hypermethylation than 
hypomethylation. In contrast, intervention studies with folate supplements showed an 
effect of folate on DNA hypomethylation in three studies (QS: 2-8) (46-48), DNA 
hypermethylation in two studies (QS: 3) (49, 50) and no effect on methylation in three 
studies (QS: 3-8) (51-53). The direction of effect in these intervention studies were 
contradictory to those shown in the observational studies. In studies that measured 
DNA methylation in colonic tissue, higher folate intake was associated with global DNA 
hypomethylation on one side of the colon (QS: 3) (54), whereas folate in blood levels 
(54-57) and colonic tissue (55) showed no association with DNA methylation (QS: 4-6). 
Furthermore, Llanos et al. measured DNA methylation in breast tissue and observed no 
association with folate levels from plasma and breast tissue (QS: 6) (58). In an 
intervention study, Aarabi et al. found a significant association between higher folate 
supplements and DNA hypomethylation (QS: 4) (59).  
Two studies investigated the association between levels or intake of folate 
and methylation in IGF2 and H19. In contrast to the studies that examined the same 
genes in maternal-offspring (11, 18-20), Hanks et al. (QS: 7) did not find an association 
between folate in serum, RBC and colonic tissue with IGF2 methylation in adults (55). 
In addition, in an intervention study by Aarabi et al. (QS: 5), no effect was observed 
between folate supplements and methylation in H19 (59).  
Higher folate intake was associated with promotor hypomethylation of TNFα 
and methylation index of genes (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, 
and GATA5) in blood and sputum, respectively. However, no association was observed 
with promoter TLR2, CD14, Et-1, HERV-w, iNOS and IL-6 methylation in blood (QS: 5-6) 
(9, 30, 60). Dhillon et al. (QS: 5) showed no significant association between folate 
intake and GSTM1 methylation in serum. However, when analysis was stratified for 
MTHFR genotype, low folate intake was associated with lower methylation of GSTM1 
methylation for CT and TT group only (61). Two studies investigated the association of 
levels of folate in serum, RBC, plasma, and colonic tissue with gene-specific 
methylation in colonic tissue or rectal mucosa (QS: 6-7). Hypermethylation of MYOD, 
SFRP1, SFRP2 and methylation index of genes (HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, 
ESR1, MYOD, N33) was observed with higher folate levels. However, no significant 
associations were observed for methylation of individual genes: APC, MYOD1, MLH1, 
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N33, SOX17 and/or ESR1 (55, 57). Ottini et al. (QS: 5) reported that higher folate levels 
in plasma were associated with hypomethylation of methylation index of genes (p16, 
FHIT, RAR, CDH1, DAPK1, hTERT, RASSF1A, MGMT, BRCA1 and PALB2) (62).  
Some studies observed associations for nutrient levels in a tissue specific 
manner. Tapp et al. (QS: 6) investigated the association of folate levels with HPP1 and 
WIF1 methylation in rectal mucosa. They observed hypermethylation of HPP1 and 
WIF1 in association with higher plasma folate levels, but not with higher RBC folate 
levels (57). Hanks et al. (QS: 7) examined the association between folate levels and 
MGMT methylation in colonic tissue. They observed hypomethylation of MGMT in 
association with higher serum folate levels, but not with higher folate levels in RBC and 
colonic tissue (55). In women with HPV, higher plasma folate levels were associated 
with HPV 16 hypermethylation (promoter) in blood (QS: 5) (63). In healthy women, 
higher plasma and breast folate levels were associated with hypomethylation of 
p16INK4a (QS: 7) (64). In intervention studies, folate supplementation had no effect on 
ESR1 and MLH1 methylation in colonic mucosa, and DLK1/GTL2, MEST, SNRPN, PLAGL1 
and KCNQ1OT1 methylation in sperm (QS: 5 and 7) (59, 65). Song et al. (QS: 4) 
performed an EWAS of folate levels in breast tissue in women, and found two 
differentially methylated CpG sites. One CpG site near JAG2 was hypomethylated and 
another CpG site near DNAJC2 was hypermethylated (66).  
Vitamin B1 
Vitamin B1 in adulthood and DNA methylation 
Marques-Rocha et al. (QS: 5) showed that higher vitamin B1 intake was associated with 
global DNA hypomethylation in blood (67).  
Vitamin B2 
Maternal vitamin B2 and offspring DNA methylation 
Azzi et al. (QS: 6) showed that higher vitamin B2 intake during pregnancy was 
associated with hypermethylation of ZAC1 in cord blood (22).  
Vitamin B2 in adulthood and DNA methylation 
Five studies (QS: 3-5) investigated the association between vitamin B2 intake and 
global DNA methylation in blood or colonic tissue (27, 30, 35, 54, 67), and only one 
study found an association: that higher vitamin B2 intake was associated with DNA 
hypermethylation in blood (67). In addition, Figueiredo et al. (QS: 4) found no 
association between vitamin B2 levels in plasma with global methylation in colonic 
tissue (54). Zhang et al. (QS: 5) showed that vitamin B2 intake was not associated with 
methylation of IL-6 in blood (30). 
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Vitamin B3 
Maternal vitamin B3 and offspring DNA methylation 
Azzi et al. (QS: 6) showed that vitamin B3 intake during pregnancy was not associated 
with methylation of ZAC1 in cord blood (22). 
Vitamin B3 in adulthood and DNA methylation 
Marques-Rocha et al. (QS: 5) showed that higher vitamin B3 intake was associated with 
global DNA hypomethylation in blood (67).  
Vitamin B6 
Maternal vitamin B6 and offspring DNA methylation 
Azzi et al. (QS: 6) reported that vitamin B6 intake during pregnancy was not associated 
with methylation of ZAC1 in cord blood (22). 
Vitamin B6 in adulthood and DNA methylation 
Eight studies (QS: 3-5) investigated the association between vitamin B6 intake with 
global DNA methylation in blood or colonic tissue (7, 27, 29-31, 34, 35, 54), and only 
one study found an association and reported that higher vitamin B6 intake was 
associated with global hypomethylation in blood (31). Two other studies (QS: 4 and 6) 
investigated the association of vitamin B6 levels in plasma and venous blood with 
global DNA methylation in blood or colonic tissue, but did not find any association (38, 
54). An intervention study by Hübner et al. (QS: 3), showed that vitamin B6 
supplementation had no effect on global DNA methylation in blood (51). Zhang et al. 
(QS: 5) showed that vitamin B6 intake was not associated with methylation of IL-6 in 
blood (30). 
Vitamin B12 
Maternal vitamin B12 and offspring DNA methylation 
Two studies investigated the association of intake and serum levels of vitamin B12 with 
global DNA methylation in cord blood (QS: 5 and 6). Higher serum levels of vitamin B12 
were associated with hypermethylation (14), whereas no difference in methylation was 
observed with higher vitamin B12 intake (12). For the gene-specific studies, Ba et al. 
(QS: 6) showed that higher vitamin B12 levels in serum were associated with IGF2 
promoter hypomethylation in cord blood (17). Azzi et al. (QS: 6) showed that higher 
vitamin B12 intake during pregnancy was associated with hypermethylation of ZAC1 in 
cord blood (22).  
CHAPTER 3: Nutrients and DNA methylation: a systematic review  79 
 
 
 
Vitamin B12 in infancy, childhood, and adolescence and DNA methylation 
In children aged 5 to 12 years, no association was observed between plasma vitamin 
B12 levels and global DNA methylation in blood (QS: 4) (7). In cord blood, McKay et al. 
(QS: 7) showed that higher serum vitamin B12 levels were associated with 
hypomethylation of IGFBP3 (14).  
Vitamin B12 in adulthood and DNA methylation 
Eight studies (QS: 3-6) found no association between vitamin B12 intake and global 
DNA methylation (12, 27, 29-32, 34, 35). Also for vitamin B12 levels in plasma or serum, 
no associations were found with global DNA methylation in blood, colonic tissue or 
rectal mucosa in eight studies (QS: 3-6) (34, 38, 43-45, 54, 56, 57). However, in one 
study (QS: 6), higher plasma vitamin B12 levels were associated with global 
hypermethylation in blood clots (68). An intervention study (QS: 3) showed that 
vitamin B12 supplements had no effect on global DNA methylation in blood (69). For 
gene-specific studies, vitamin B12 intake was not associated with methylation of CD14, 
Et-1, HERV-w, iNOS, TNFα, IL-6, and TLR2 in blood (QS: 5-6) (9, 30, 60). In addition, 
Tapp et al (QS: 6) found no association between vitamin B12 levels in plasma and 
methylation of HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, ESR1, MYOD, N33 and 
methylation index of these genes (57). Al-Ghnaniem et al. (QS: 6) observed that higher 
vitamin B12 levels in venous blood were associated with hypomethylation of ERα in 
colonic mucosa (70). Furthermore, plasma vitamin B12 levels were associated with 
hypermethylation of HPV 16 (QS: 5) and no difference in methylation index of genes 
(p16, FHIT, RAR, CDH1, DAPK1, hTERT, RASSF1A, MGMT, BRCA1 and PALB2) (QS: 3) (62, 
63).  
Vitamin C 
Vitamin C in adulthood and DNA methylation 
Piyathilake et al. (QS: 6) investigated the association between plasma vitamin C levels 
and global DNA methylation in PBMCs and cervical cells, but did not find a significant 
association (8). Two studies (QS: 6) investigated the association between vitamin C 
intake and gene-specific promoter DNA methylation. One study found that higher 
intake of vitamin C was associated with hypomethylation of PON1 in venous blood (71), 
whereas the other study did not find an association of vitamin C intake with 
methylation index of genes (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and 
GATA5) in sputum (10). Furthermore, Bollati et al (QS: 6) investigated the association of 
intake of ascorbic acid with methylation of CD14, Et-1, HERV-w, iNOS and TNFα in 
blood, but no significant association was observed (9). Piyathilake et al. (QS: 5) found 
no association between vitamin C levels in plasma and HPV 16 methylation in blood 
(63). 
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Vitamin D 
Vitamin D and offspring DNA methylation 
One study (QS: 5) found that higher maternal vitamin D levels in plasma were 
associated with hypomethylation of RXRA in umbilical cord tissue (72), whereas 
another study (QS: 4) did not find an association between maternal vitamin D levels in 
serum and CYP24A1 methylation in placenta (73). Mozhui et al (QS: 6) conducted an 
EWAS of vitamin D levels, but found no significant CpG site associations in cord blood 
(26). 
Vitamin D in infancy, childhood, and adolescence and DNA methylation 
For vitamin D, Zhu et al. (QS: 7) found that higher plasma vitamin D levels as well as an 
intervention with vitamin D supplementation were associated with global 
hypermethylation in blood (74). In neonates, Novakovic et al (QS: 4) found no 
association between serum vitamin D levels and CYP24A1 methylation in placenta (73). 
Zhu et al. (QS: 4) investigated the associated between plasma vitamin D levels and 
gene-specific methylation in blood among children around 16 years of age. Higher 
vitamin D levels were found to be associated with hypomethylation of CYP2R1, 
hypermethylation of CYP24A1, and differential methylation in opposite directions of 
two CpG sites annotated to DHCR7 (75). In an EWAS of vitamin D levels, Zhu et al. (QS: 
5) identified two differentially methylated CpG sites: higher vitamin D levels were 
associated with hypomethylation of DOI3 and hypermethylation of MAPRE2 (75). 
Vitamin D in adulthood and DNA methylation 
Three studies, of which two were cross-sectional (QS: 5) and one intervention (QS: 3) 
found no effect of vitamin D supplementation or vitamin D levels in plasma or serum 
on global DNA methylation in blood or rectal mucosa (51, 57, 76). In gene-specific 
studies, Bollati et al (QS: 6) found no association between vitamin D intake and 
promoter methylation of CD14, Et-1, HERV-w, iNOS and TNFα (9). Tapp et al. (QS: 6) 
investigated the association between plasma vitamin D levels and gene-specific 
methylation of HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, ESR1, MYOD and N33 in rectal 
mucosa. They found that higher vitamin D levels were associated with 
hypomethylation of index of these genes and also individual genes such as APC, WIF1 
and MYOD. No association was found for the other individual genes (57). Furthermore, 
Ashktorab et al. (QS: 7) found no significant association between serum vitamin D 
levels and DKK1 methylation in blood (77). 
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Vitamin E 
Vitamin E in adulthood and DNA methylation 
Piyathilake et al. (QS: 6) observed that higher levels of plasma vitamin E were 
associated with global hypomethylation in PBMCs, but not with global methylation in 
cervical cells (8). In a gene-specific study, Stidley et al (QS: 6) did not find an association 
of vitamin E intake with methylation index of any of the studied genes (p16, MGMT, 
DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and GATA5) in sputum (10). 
Choline and Betaine 
Maternal choline and betaine and offspring DNA methylation 
Boeke et al. (QS: 6) showed that higher choline or betaine intake during pregnancy 
were associated with global DNA hypomethylation in cord blood (12). In contrast, Jiang 
et al. (QS: 6), in an intervention study, reported that higher supplemental choline 
intake during pregnancy was associated with global DNA hypermethylation in placenta, 
but not in cord blood (78). For gene-specific studies, an intervention study by Jiang et 
al. (QS: 5) showed that higher supplemental choline intake during pregnancy was 
associated with hypermethylation of promoter CRH and NR3C1 in placenta. In contrast 
to placental tissue, in cord blood promoter CRH and NR3C1 were hypomethylation in 
response to a higher supplemental choline intake. No effect of choline 
supplementation was observed in methylation of GNAS-AS1, IGF2, IL-10, or LEP in 
placenta or cord blood (78).  
Choline and betaine in adulthood and DNA methylation 
Shin et al. (QS: 3) showed that choline supplementation was associated with global 
DNA hypermethylation in blood, but only for subjects with the MTHFR 677CC genotype 
(79). However, another intervention study (QS: 4) showed no effect of choline 
supplementation on global DNA methylation in blood (78). In addition, in a cross-
sectional study by Boeke et al. (QS: 6), choline and betaine intake was not associated 
with global DNA methylation in blood in pregnant women (12). In an intervention study 
by Jiang et al. (QS: 5) a higher supplemental choline intake was not associated with 
methylation of promoter CRH and NR3C1 in blood among pregnant women (78). 
Minerals and trace elements 
Minerals and trace elements in infancy, childhood, and adolescence and DNA 
methylation 
In a cross-sectional study among children aged 5 to 12 years, Perng et al (QS: 4) 
investigated the association of plasma levels of ferritin and serum levels of zinc with 
global DNA methylation in blood, but no significant associations were observed (7).  
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Minerals and trace elements in adulthood and DNA methylation 
Marques-Rocha et al. (QS: 5) showed that higher intakes of both copper and iron were 
associated with global DNA hypermethylation in blood (67). In contrast, Gomes et al 
(QS: 3) reported that higher intakes of magnesium were associated with DNA 
hypomethylation in blood (31). Two studies (QS: 3 and 5) examined associations 
between zinc intake and global DNA methylation in blood, but both observed no 
significant associations (31, 32). Furthermore, Tapp et al. (QS: 5) reported that higher 
plasma levels of selenium were associated with global DNA hypermethylation in rectal 
mucosa, but only in women (57). McChelland et al. (QS: 6) reported that higher serum 
levels of phosphate were associated with global DNA hypomethylation in blood (80). In 
an intervention study by Hubner et al. (QS: 3) no effect was observed of calcium 
supplementation on global DNA methylation in blood (51).  
For gene-specific studies, Shimazu et al. (QS: 6) investigated the associations 
of salt intake with methylation of miR-124a-3, EMX1 and NKX6-1 in gastric mucosa, but 
observed no significant associations (81). Tapp et al. (QS: 6) examined associations of 
plasma selenium levels with methylation of HPP1, APC, SFRP1, SFRP2, SOX17, WIF1, 
ESR1, MYOD, N33 and an index of these genes. They observed that higher levels of 
selenium were associated with hypermethylation of N33, but only in males. No 
significant associations were observed for the other genes or index (57). 
Combined nutrients 
Maternal combined vitamins and minerals and offspring DNA methylation 
In an intervention study, Khulan et al. examined the effect of maternal micronutrient 
supplementation on genome-wide DNA methylation in cord blood (QS: 6) and 
peripheral blood during infancy (QS:6) (82). In cord blood 14 CpG sites were identified 
in males and 21 CpG sites in females, with no overlap between the two. In addition, in 
infant blood 108 CpG sites were identified in males and 106 CpG sites in females, with 
only 5 (XIRP1, MEOX1, GNA11, C1orf54, KRTAP21-1) in agreement between male and 
female infants. Within each sex a significant proportion of the identified CpG sites in 
cord bloods were also observed in infants (males 7/14: MEOX1, SPAG4L, SPATA22, 
NRN1L, C1orf54, PIP, PTPN20B; females 8/21: HSPC176, XIRP1, BPIL1, MGMT, CHIT1, 
C14orf152, KLRC2, DEFB123). 
Combined vitamins and minerals in adulthood and DNA methylation 
Two studies investigated the association between folate and vitamin B12 combined 
with global DNA methylation. Piyathilake et al. (QS: 6) reported that higher vitamin B12 
and folate in plasma were associated with global hypermethylation in PBMCs, but not 
in cervical cells (8). However, in an intervention study by Fenech et al. (QS: 6) vitamin 
B12 and folate supplements had no effect on global DNA methylation (43). Pusceddu et 
al. (QS:5) studied the effect of vitamin B12, vitamin B6, folate, vitamin D and calcium 
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supplementation on global DNA methylation After intervention LINE-1 
hypermethylation was observed (83). For gene-specific studies, Stidley et al. (QS: 6) 
observed that higher intake of multivitamins was associated with hypomethylation of 
methylation index (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and GATA5) 
(10). In an intervention study by Zhou et al. (QS: 5), vitamin D and calcium 
supplementation led to hypomethylation of CYP24A1, but had no effect on CYP2R1, 
CYP27A1, and CYP27B1 (84). Kok et al. studied the effect of vitamin B12 and folate 
supplementations on epigenome-wide DNA methylation (QS: 8). After intervention 162 
CpG sites were identified as compared to baseline. Comparisons of folic acid and 
vitamin B12 versus placebo revealed one CpG sites (cg19380919) and 6 differentially 
methylated regions (DMRs), with pronounced changes in DIRAS3, ARMC8, and NODAL. 
In addition, serum levels of folate and vitamin B12 were related to DNA methylation of 
173 and 425 regions, respectively, including several members of the developmental 
HOX genes (85). 
Bioactive compounds 
Bioactive compounds in adulthood and DNA methylation 
Bollati et al (QS: 6) investigated the association of intake carotenoids, polyphenols, and 
flavonoids with methylation of CD14, Et-1, HERV-w, iNOS and TNFα in blood. They 
observed an association of higher intake of carotenoids with hypermethylation of 
HERV-w and with hypomethylation of TNFα. However, no significant association was 
observed for the other genes (9). De la Iglesia et al. (QS: 6) observed that that higher 
lycopene intake was associated with PON1 hypomethylation (71). Zhong et al. (QS: 6) 
reported that flavonoid intake was associated with TLR2 hypomethylation (60). Stidley 
et al (QS: 6) did not find an association of carotene, lutein, zeaxanthin, and lycopene 
intake with methylation index of genes (p16, MGMT, DAPK, RASSF1A, PAX5α, PAX5β, 
GATA4, and GATA5) in sputum (10). 
MACRONUTRIENTS 
Fat and fatty acids 
Maternal fat and fatty acids and offspring DNA methylation 
Rerkasem et al. (QS: 3) found no association between total fat intake during pregnancy 
and global DNA methylation in blood of children around 20 years of age (86). Godfrey 
et al. (QS: 3) also found no association between total fat intake during pregnancy and 
methylation of RXRA and eNOS in cord blood (87). For individual fatty acids, an 
intervention study by Lee et al. (QS: 8) found that higher ω-3 PUFA supplementation 
during pregnancy had an effect on global hypermethylation in cord blood (88). In the 
same study, Lee et al. (QS: 8) investigated gene-specific DNA methylation and found 
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that higher ω-3 PUFA supplementation during pregnancy had an effect on 
hypermethylation of IGF2, but no association was found for methylation of IFNγ, TNFα, 
IL-13, GATA3, STAT3, IL-10 and FOXP3 in cord blood (88). In an intervention by 
Amarasekera et al. (QS: 8), no significant effects of ω-3 PUFA were found on genome-
wide DNA methylation in cord blood (89).  
Maternal fat and fatty acids in infancy, childhood, and adolescence and DNA 
methylation 
Voisin et al. (QS: 5) conducted an EWAS and identified four, 130, 158 and 16 CpG sites 
in blood significantly associated with intake of total fat, (MUFA+PUFA)/SFA, MUFA/SFA 
and PUFA/SFA, respectively, in children around the age of 10 years (90). On the other 
hand, in an intervention study by Lind et al. (QS: 8) found no epigenome-wide CpG site 
associations of ω-3 PUFA supplementation as fish oil (91).  
Fat and fatty acids in adulthood and DNA methylation 
Total fat: Four studies (QS: 3-4) investigated the association between total fat intake 
and global DNA methylation in blood, of which two found that higher fat intake was 
associated with global DNA hypomethylation (31, 34), whereas the other two studies 
did not find an association (30, 35). Gómez-Uriz et al. (QS: 4) found that higher total fat 
intake was associated with TNFα hypomethylation in blood (92). However, Bollati et al. 
and Zhang et al (QS: 5 and 6) investigated the association of intake of total fat with 
methylation of CD14, Et-1, HERV-w, iNOS, TNFα and IL-6 in blood, but no significant 
association was observed (9, 30). In addition, Stidley et al. (QS: 6) found no association 
of total fat as well as animal fat intake with methylation index of genes (p16, MGMT, 
DAPK, RASSF1A, PAX5α, PAX5β, GATA4, and GATA5) in sputum (10). Brøns and Gillberg 
et al. (QS: 6) investigated the effect of high fat overfeeding in healthy men on promoter 
PPARGC1A methylation (93, 94). They found that high fat overfeeding in men with 
normal birthweight was associated with PPARGC1A hypomethylation in muscle tissue 
(93), whereas high fat overfeeding in men with low birthweight was associated with 
PPARGC1A hypermethylation in subcutaneous adipose tissue (94). In an EWAS by Irvin 
et al. (QS: 8), fatty acids were not associated with epigenome-wide DNA methylation 
after correcting for multiple testing (69). In an intervention study among healthy men, 
Jacobsen and Gillberg et al (QS: 6) investigated the effect of high fat overfeeding on 
epigenome-wide DNA methylation. They observed that high fat overfeeding affected 
methylation at 652 CpG sites (including in CDK5, IGFBP5 and SLC2A4) in subcutaneous 
adipose tissue (95). Furthermore, change in DNA methylation of 7,909 CpG sites 
(including, DNM2, MGMT, SLC2A3/GLUT3, MRC1 and ACAT2) in skeletal muscle 
biopsies was observed in response to high fat overfeeding. Within the same study, it 
was shown that these changes in genome-wide DNA methylation were more 
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pronounced in participants with a low birth weight, compared to those with a normal 
birthweight (96).    
Individual fatty acids: Zhang et al. (QS: 4) found no association between PUFA 
intake and global DNA methylation in blood (30, 35). For methylation measured in 
blood, one study found that higher ω-6 PUFA intake was associated with 
hypomethylation of TNFα (97) and another study found that higher PUFA intake was 
associated with hypermethylation of CLOCK (98). However, Zhang et al (QS: 5) and 
Bollati et al (QS: 6) observed no association of intake of total PUFA and ω-3 PUFA with 
methylation of CD14, Et-1, HERV-w, iNOS, TNFα and IL-6 in blood (9, 30). Furthermore, 
Ma et al. (QS: 7) found that higher ω-3 PUFA levels in erythrocytes were associated 
with hypomethylation of IL-6 promoter (99). In another study by Ma et al. (QS: 7), 
higher levels of erythrocyte EPA were associated with hypomethylation of ABCA1 
promoter. In addition, higher erythrocyte ALA was associated with hypomethylation of 
APOE for the CC genotype, whereas higher erythrocyte ALA was associated with 
hypermethylation of APOE for the AA genotype (100). In an EWAS by Aslibekyan et al. 
(QS:6), higher levels of ω-3 PUFA in erythrocytes were associated with 27 CpG sites 
(including NAV1, CCL17, ACTA2/FAS and AHRR) in blood. Zhang et al. (QS: 4) found no 
association between MUFA intake and global DNA methylation in blood (30, 35). 
Milagro et al. (QS: 4) found that higher intake of MUFA was associated with 
hypomethylation of CLOCK in blood (98). However, Zhang et al. (QS: 5) and Bollati et al 
(QS: 6) investigated the association of intake of MUFA with methylation of CD14, Et-1, 
HERV-w, iNOS, TNFα and IL-6 in blood, but no significant association was observed (9, 
30). Zhang et al. (QS: 4) observed that higher SFA intake was associated with global 
DNA hypomethylation when methylation was measured using pyrosequencing (35), 
whereas no association was observed when methylation was measured using PCR 
technique (30). Zhang et al. (QS: 5) and Bollati et al (QS: 6) investigated the association 
of intake of SFA with methylation of CD14, Et-1, HERV-w, iNOS, TNFα and IL-6 in blood, 
but no significant association was observed (9, 30).  
Carbohydrates and fiber 
Maternal carbohydrates and fiber and offspring DNA methylation 
Rerkasem et al. (QS: 3) investigated the association between intake of carbohydrates 
during pregnancy and global DNA methylation in their offspring around the age of 20 
years, but observed no significant association (86). Godfrey et al. (QS: 3) explored the 
association between carbohydrate intake during pregnancy and gene-specific promoter 
DNA methylation in cord tissue. They observed that higher intake of carbohydrate was 
associated with RXRA hypomethylation, but no significant association was observed 
with eNOS methylation (87).  
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Carbohydrates and fiber in adulthood and DNA methylation 
Four studies investigated the association between carbohydrate intake and global DNA 
methylation in blood. One study (QS:3) reported that higher intake of carbohydrate 
was associated with global DNA hypomethylation (31), whereas the other three studies 
(QS:4) observed no significant associations (30, 34, 35). Three studies (QS: 4-6) were 
conducted on the association of carbohydrate and fiber intake and gene-specific DNA 
methylation in blood, of which one observed that higher carbohydrate intake was 
associated with hypermethylation of BMAL1 (101), but in the other two studies no 
significant associations were observed with CD14, Et-1, HERV-w, iNOS, TNFα, and IL-6 
(9, 30).  
Protein and amino acids 
Maternal protein and amino acids and offspring DNA methylation 
Rerkasem et al. (QS: 3) observed no associations between intake of protein during 
pregnancy and global DNA methylation in their offspring around the age of 20 years 
(86). Godfrey et al. (QS: 3) found no association of protein intake during pregnancy 
with promoter methylation of RXRA or eNOS in cord tissue (87).  
Protein and amino acids in adulthood and DNA methylation 
Three studies (QS: 3-4) investigated the association between protein intake and global 
DNA methylation in blood, but no significant associations were observed (30, 31, 35). In 
addition, the four studies (QS: 3-4) that explored associations between methionine 
intake and global DNA methylation in blood showed no significant associations (29, 30, 
32, 35). Two studies (QS: 5 and 6) investigated associations of protein intake and 
methylation of CD14, Et-1, HERV-w, iNOS, TNFα, and IL-6 in blood, but reported no 
significant associations (9, 30). Similarly, two studies (QS: 5 and 6) that examined the 
associations of methionine intake with IL-6 and TLR2 promoter methylation in blood 
showed no significant associations (30, 60).  
4. DISCUSSION 
This is the first systematic review on nutrients and DNA methylation in humans. This 
review included studies examining associations between all nutrients with different 
types of methylation outcomes in all life-course stages. The majority of the studies 
performed on this topic investigated the association of folate, other B-vitamins, or fatty 
acids with DNA methylation, whereas studies for other nutrients are scarce or even 
absent, such as for vitamin K. The evidence so far shows that folate and fatty acids are 
associated with DNA methylation on a global, gene-specific, and genome-wide level. 
Several candidate gene and epigenome-wide association studies reported differential 
DNA methylation of CpG sites in response to folate (e.g. IGF2, H19, HOX), fatty acids 
(e.g. PPRAGC1A, TNFα), and vitamin D (CYP24A1). Some of these observed associations 
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were specific to life course stage (e.g. IGF2 in early life) and tissue (e.g. opposite 
directions for PPRAGC1A in muscle vs. fat tissue). However, the directions of these 
associations are inconsistent across the different studies. Reasons that may explain 
these discrepancies in findings include the differences in the type of tissue used to 
measure nutrient levels as well as DNA methylation and differences across life course 
stages.  
DNA methylation across the life course 
Age affects methylation patterns via transcriptional regulation (102). Evidence from 
our systematic review, suggests age-specific differences in folate associations with 
global DNA methylation in blood. In early life, higher folate intakes and levels were 
associated with global DNA hypomethylation (11), whereas during adulthood higher 
folate intakes and levels were associated with DNA hypermethylation (28-30, 37-42). 
This pattern could not be observed for the other nutrients due to the limited number 
of studies across the different life course stages or null associations, but we expect 
similar patterns for other nutrients. Indeed, some studies on gene-specific DNA 
methylation observed similar age-specific differences. Methylation of some genes in 
blood may be specifically prone to environmental influences during early life. For 
example, evidence from our systematic literature review shows that during pregnancy, 
at birth and during childhood, higher folate intake and levels were associated with IGF2 
hypermethylation (11, 18, 19). However, when this association was studied in adults, 
no significant associations were observed (55). Possibly, methylation of this gene is no 
longer susceptible to changes during adulthood. Similarly, higher choline intake during 
pregnancy was associated with CRH and NR3C1 hypomethylation in cord blood, but no 
association was found within pregnant women (78). Several studies included in our 
review suggested that IGF2 methylation could also be affected by vitamin B12 and 
PUFAs (17, 103). Higher folate during pregnancy and at birth was associated with PEG3 
hypomethylation in cord blood (11, 18). Due to the absence of studies in adults, we 
cannot determine age-related associations in relation to these nutrients. Future studies 
should be conducted in order to establish the life course patterns of these nutrients on 
DNA methylation. 
DNA methylation across nutrients 
We were interested in exploring how different nutrients may affect methylation of the 
same genes, because this can be indicative of which genes are susceptible to 
nutritional influences in general. As it is difficult to compare findings across studies due 
to the different population structure, lab techniques, batch effects and analytical 
methods used, we compared the associations of different nutrients with methylation 
of the same genes within the same study to discard the bias caused by heterogeneity. 
From these studies that explored associations between multiple individual nutrients 
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and gene-specific methylation for the same genes and same tissues, we observed that 
genes such as CD14, eNOS, ESR1, Et-1, IL-6, iNOS, N33 and SOX17 were not susceptible 
to any nutritional influence (9, 30, 57, 87). Methylation of some other genes, such as 
APC, HERV-w, HPP1, RXRA, TLR2, SFRP1, SFRP2 and methylation index of genes (p16, 
FHIT, RAR, CDH1, DAPK1, hTERT, RASSF1A, MGMT, BRCA1 and PALB2) showed 
susceptibility to only one nutrient (9, 57, 60, 87). This suggests that methylation of 
these genes could be responsive to one particular nutrient due to a certain pathway in 
which they are involved. However, for certain other genes, such as CLOCK, HPV 16, 
MYOD, PON1, TNFα, WIF1, ZAC1, and methylation indexes of genes (HPP1, APC, SFRP1, 
SFRP2, SOX17, WIF1, ESR1, MYOD and N33; p16, MGMT, DAPK, RASSF1A, PAX5α, 
PAX5β, GATA4 and GATA5), methylation was susceptible to multiple nutrients (9, 10, 
22, 57, 63, 71, 98). Of these genes, HPV 16 and ZAC1 were hypermethylated in 
association with folate, vitamin B2 or vitamin B12, but not other nutrients (22, 63), 
suggesting a possible role in one-carbon metabolism. Overall, these findings suggest 
that methylation of some genes is susceptible to nutritional influences in general, 
whereas methylation of other genes is only responsive to specific nutrients.  
DNA methylation across nutrient tissues 
The tissue used to measure nutrient exposure might contribute to the nutrient-
methylation association. For certain types of tissues it may be easier to detect 
associations of nutrients with DNA methylation, due to a better reflection of long-term 
status of these nutrients (104). Within studies that investigated the association 
between folate from different tissues or intake and same gene-specific methylation 
using same methylation tissue, we observed that some genes (H19 and p16INK4a (18, 
20, 64), MYOD, NR3C1_a, SFRP1, SFRP2 and methylation index (HPP1, APC, SFRP1, 
SFRP2, SOX17, WIF1, ESR1, MYOD, N33)) showed differential methylation in association 
with folate regardless of the source: for plasma, RBC and dietary folate (21, 57). 
However, methylation of HPP1, MGMT, PEG3, and WIF1 consistently showed no 
association with RBC folate, but showed differential methylation in association with 
plasma, serum or dietary folate within the same studies (11, 55, 57). Even though RBC 
folate has shown associations that are in line with other folate tissues in most studies, 
these four studies have shown discrepancies in their findings, which might be 
explained by the difference in reflection of long-term folate status between RBC and 
other tissue of folate (105). 
DNA methylation across methylation tissues 
In addition to levels from different tissues or methods used to measure intake of 
nutrients, tissue-specificity in DNA methylation is an important factor to take into 
account when interpreting findings of the studies included in this review. A few studies 
explored associations of specific nutrients with gene-specific DNA methylation 
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measured in different tissues within the same subjects. For example, an intervention 
study by Jiang et al. showed opposite directions of association between choline intake 
during pregnancy and CRH or NR3C1 methylation in placenta versus cord blood, which 
shows that associations may differ between tissues (78). Another intervention study 
showed tissue-specific PPARGC1A methylation in muscle biopsy and subcutaneous 
adipose tissue in opposite directions in association with high-fat overfeeding diet (93, 
94).  
DNA methylation of genes that were replicable 
Replication of results across different study populations is of utmost importance in 
order to confirm findings. In this systematic review, we identified different studies 
examining same nutrient and gene-specific methylation associations within the same 
stage of the life course. Different measures of folate during pregnancy were associated 
with hypomethylation of PEG3 and hypermethylation of IGF2 in offspring, and these 
findings were replicated across different studies (11, 18, 19). Methylation of TNF-α was 
not replicable across studies, possibly due to differences in population characteristics. 
One study explored this association in normal-weight young women, whereas the 
other study explored this association in overweight older adults, which may explain the 
non-replicability (9, 97).  
Genome-wide DNA methylation 
In this systematic review, we identified five EWASs of folate, of which four studies were 
conducted in relation to maternal nutrition and offspring DNA methylation (23-26), and 
one study in relation to nutrition in adulthood and DNA methylation (66). We 
investigated whether any genes whose methylation showed significant associations in 
gene-specific studies in relation to folate, were also found to be genome-wide 
significant in these EWASs. In line with the gene-specific study of Hoyo et al., who 
found an association of maternal folate supplements and erythrocytes with H19 
hypomethylation in cord blood (18, 20), Joubert et al. in their EWAS of maternal 
plasma folate also found genome-wide significant hypomethylation of H19 (24). 
Furthermore, this EWAS found hypomethylation of SNRPN which showed null 
association in relation to folate intake in a gene-specific study (11). Two EWASs of 
vitamin D levels were conducted by Mozhui et al. (26) and Zhu et al. (75) but the 
former found null association and the later showed no comparison in genes with 
previous gene-specific studies. 
Methodological considerations 
In this systematic review, a comprehensive overview is provided on the current 
evidence on associations between nutrients and DNA methylation in humans of all ages 
and during all life stages. We included studies examining nutrient intake from diet and 
supplements, as well as nutrient levels measured in blood or other tissues. 
90 PART A: Introduction 
 
Furthermore, we included studies using different tissues to measure DNA methylation, 
which enabled us to provide more insight on tissue-specific DNA methylation. The 
literature was designed by an experienced biomedical information specialist and 
multiple search engines were used, limiting the probability of undetected references. 
Furthermore, the selection process was performed by two independent reviewers. In 
order to objectively measure study quality, we used a quality score based on a 
predefined scoring system developed for systematic reviews. Study quality was 
determined by five study characteristics: study design, sample size, quality of exposure 
assessment, quality of outcome assessment, and confounder adjustment.  
Overall, most studies are of medium to high quality. A majority of studies 
(28%) have a quality score 6 and 77% of the studies were of the quality score 5 or 
above (Figure 4, Table 1). However, many studies did not properly adjust for 
confounding. Even though age, sex, and sometimes lifestyle covariates were often 
taken into account, other factors important in DNA methylation studies, such as 
leukocyte proportion, were rarely included in the models. Lack of adjustment for these 
covariates may have led to spurious findings. As the majority of the included studies 
were of observational nature, causal inference from these studies is not possible. Only 
a few studies tested for effect modification by sex of genetic variation. This should be 
considered in future studies, as some studies show that associations may be different 
for males and females or different genotypes, such as MTHFR. There were a few EWASs 
included in our review, enabling the possibility to identify novel CpG sites in relation to 
certain nutrients. Nevertheless, with this type of approach caution must be taken when 
interpreting the results. As EWAS follows a hypothesis-free approach, significant 
findings could be the result of false positives caused by multiple testing. To solve this 
issue, several statistical methods could be used, such as Bonferroni correction or false 
detection rate (FDR). Furthermore, in these type of studies that use a hypothesis-free 
approach, there is a need for replication. Therefore, to ensure that findings are true-
positives, a discovery and a replication cohort should be used. Even though almost all 
EWAS included in this review used a proper method for multiple testing, not all studies 
included a replication cohort in their study. Therefore, findings from these studies still 
need to be replicated in other cohorts in order to confirm that novel CpG sites 
identified in EWAS are true positives. On the other hand, the EWAS approach is also 
prone to type II error, or false-negatives. Usually, this is caused by lack of power due to 
a small sample size. Out of the included studies that used EWAS, only five had a sample 
size of >100 participants. Possibly, potential associations between nutrients and 
genome-wide DNA methylation may have been overlooked in studies with a small 
sample size.  
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CONCLUSIONS 
To date, promising results have been reported in the field of nutrition and DNA 
methylation in humans at different stages across the life-course. In particular, nutrients 
known to be involved in one-carbon metabolism, such as folate, have been shown to 
be related to DNA methylation at a global, gene-specific and genome-wide level. In 
addition, also other nutrients, such as fatty acids, are suggested to be involved in DNA 
methylation. However, further large-scale studies of high quality are needed to expand 
our understanding on the role of nutrition in DNA methylation and its effects on health 
and disease.  
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SUPPLEMENTARY MATERIAL 
Supplement 1: Details on the search strategy for each of the databases 
 References identified Unique references identified 
Embase.com 2337 2294 
Medline Ovid 1547 249 
Web of science 1714 943 
Cochrane 87 19 
PubMed publisher 149 133 
Google scholar 200 136 
Total 5874 3774 
Embase.com 2337   
(diet/exp OR 'dietary intake'/exp OR 'food intake'/de OR 'caloric density'/exp OR 
'caloric intake'/exp OR 'carbohydrate intake'/exp OR 'diet restriction'/exp OR 'dietary 
reference intake'/exp OR 'electrolyte intake'/exp OR 'fat intake'/exp OR 'fluid 
intake'/exp OR 'food deprivation'/exp OR 'mineral intake'/exp OR 'protein intake'/exp 
OR 'vitamin intake'/exp OR 'vitamin blood level'/exp OR 'diet supplementation'/exp OR 
'mineral supplementation'/exp OR 'vitamin supplementation'/exp OR 
supplementation/de OR 'nutrition'/de OR 'child nutrition'/de OR 'diet therapy'/exp OR 
'food intake'/exp OR 'infant nutrition'/exp OR 'maternal nutrition'/de OR nutrient/exp 
OR 'nutritional status'/exp OR  (diet OR nutrition OR ((dietar* OR food* OR beverage* 
OR alcohol* OR mineral* OR nutrient* OR micronutrient* OR macronutrient* OR 
vitamin* OR calor* OR energ* OR protein* OR fat OR folic-acid* OR folate* OR 
vegetabl* OR fruit* OR cholin* OR methionin* OR betain* OR fatty-acid* OR pufa OR 
pufas OR mufa OR mufas OR safa OR safas OR sfa OR sfas) NEAR/6 (intake* OR ingest*  
OR supplement* OR consum* OR restrict* OR depriv* OR level OR concentration OR 
blood OR plasma OR serum OR pattern*)) OR fasting OR ((well OR under) NEXT/1 
nourish*) OR ((well OR under) NEXT/1 nourish*)):ab,ti) AND  ('DNA methylation'/exp 
OR (((dna OR 'long interspersed' OR gene OR genes) NEAR/6 (demethylat* OR 
methylat* OR hypermethylat* OR hypomethylat*))):ab,ti) NOT ([animals]/lim NOT 
[humans]/lim) AND ('observational study'/exp OR 'cohort analysis'/exp OR 'longitudinal 
study'/exp OR 'retrospective study'/exp OR 'prospective study'/exp OR 'health 
survey'/de OR 'health care survey'/de OR 'epidemiological data'/de OR 'case control 
study'/de OR 'cross-sectional study'/de OR 'correlational study'/de OR 'population 
research'/de OR 'family study'/de OR 'major clinical study'/de OR 'multicenter 
study'/de OR 'comparative study'/de OR 'follow up'/de  OR 'clinical study'/de  OR 
'clinical article'/de OR 'clinical trial'/exp OR 'randomization'/exp OR 'intervention 
study'/de OR 'open study'/de OR 'community trial'/de OR 'review'/exp OR 'systematic 
review'/exp  OR (((observation* OR epidemiolog* OR famil* OR comparativ* OR 
communit*) NEAR/6 (stud* OR data OR research)) OR cohort* OR longitudinal* OR 
retrospectiv* OR prospectiv*  OR population* OR (national* NEAR/3 (stud* OR survey)) 
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OR (health* NEAR/3 survey*) OR ((case OR cases OR match*) NEAR/3 control*) OR 
(cross NEXT/1 section*) OR correlation* OR multicenter* OR multi-center* OR follow-
up* OR followup* OR clinical* OR trial OR random* OR review* OR meta-analy*):ab,ti) 
NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim) 
Medline Ovid  1547 
(exp Diet/ OR exp "Eating"/ OR "Recommended Dietary Allowances"/ OR "food 
deprivation"/ OR vitamins/bl OR "Dietary Supplements"/ OR "Nutritional Physiological 
Phenomena"/ OR exp "Diet Therapy"/ OR "Maternal Nutritional Physiological 
Phenomena"/ OR "nutritional status"/ OR  (diet OR nutrition OR ((dietar* OR food* OR 
beverage* OR alcohol* OR mineral* OR nutrient* OR micronutrient* OR 
macronutrient* OR vitamin* OR calor* OR energ* OR protein* OR fat OR folic-acid* OR 
folate* OR vegetabl* OR fruit* OR cholin* OR methionin* OR betain* OR fatty-acid* 
OR pufa OR pufas OR mufa OR mufas OR safa OR safas OR sfa OR sfas) ADJ6 (intake* 
OR ingest*  OR supplement* OR consum* OR restrict* OR depriv* OR level OR 
concentration OR blood OR plasma OR serum OR pattern*)) OR fasting OR ((well OR 
under) ADJ nourish*) OR ((well OR under) ADJ nourish*)).ab,ti.) AND  ("DNA 
Methylation"/ OR (((dna OR "long interspersed" OR gene OR genes) ADJ6 (demethylat* 
OR methylat* OR hypermethylat* OR hypomethylat*))).ab,ti.) NOT (exp animals/ NOT 
humans/) AND ("observational study"/ OR exp "Epidemiologic Studies"/ OR "health 
surveys"/ OR "multicenter study"/ OR exp "clinical study"/  OR "Random Allocation"/ 
OR "review"/ OR (((observation* OR epidemiolog* OR famil* OR comparativ* OR 
communit*) ADJ6 (stud* OR data OR research)) OR cohort* OR longitudinal* OR 
retrospectiv* OR prospectiv*  OR population* OR (national* ADJ3 (stud* OR survey)) 
OR (health* ADJ3 survey*) OR ((case OR cases OR match*) ADJ3 control*) OR (cross 
ADJ section*) OR correlation* OR multicenter* OR multi-center* OR follow-up* OR 
followup* OR clinical* OR trial OR random* OR review* OR meta-analy*).ab,ti.) NOT 
(letter OR news OR comment OR editorial OR congresses OR abstracts).pt. 
Cochrane  87 
((diet OR nutrition OR ((dietar* OR food* OR beverage* OR alcohol* OR mineral* OR 
nutrient* OR micronutrient* OR macronutrient* OR vitamin* OR calor* OR energ* OR 
protein* OR fat OR folic-acid* OR folate* OR vegetabl* OR fruit* OR cholin* OR 
methionin* OR betain* OR fatty-acid* OR pufa OR pufas OR mufa OR mufas OR safa OR 
safas OR sfa OR sfas) NEAR/6 (intake* OR ingest*  OR supplement* OR consum* OR 
restrict* OR depriv* OR level OR concentration OR blood OR plasma OR serum OR 
pattern*)) OR fasting OR ((well OR under) NEXT/1 nourish*) OR ((well OR under) 
NEXT/1 nourish*)):ab,ti) AND  ((((dna OR 'long interspersed' OR gene OR genes) 
NEAR/6 (demethylat* OR methylat* OR hypermethylat* OR hypomethylat*))):ab,ti)  
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Web of science   1714 
TS=(((diet OR nutrition OR ((dietar* OR food* OR beverage* OR alcohol* OR mineral* 
OR nutrient* OR micronutrient* OR macronutrient* OR vitamin* OR calor* OR energ* 
OR protein* OR fat OR folic-acid* OR folate* OR vegetabl* OR fruit* OR cholin* OR 
methionin* OR betain* OR fatty-acid* OR pufa OR pufas OR mufa OR mufas OR safa OR 
safas OR sfa OR sfas) NEAR/5 (intake* OR ingest*  OR supplement* OR consum* OR 
restrict* OR depriv* OR level OR concentration OR blood OR plasma OR serum OR 
pattern*)) OR fasting OR ((well OR under) NEAR/1 nourish*) OR ((well OR under) 
NEAR/1 nourish*))) AND  ((((dna OR "long interspersed" OR gene OR genes) NEAR/5 
(demethylat* OR methylat* OR hypermethylat* OR hypomethylat*)))) AND 
((((observation* OR epidemiolog* OR famil* OR comparativ* OR communit*) NEAR/5 
(stud* OR data OR research)) OR cohort* OR longitudinal* OR retrospectiv* OR 
prospectiv*  OR population* OR (national* NEAR/2 (stud* OR survey)) OR (health* 
NEAR/2 survey*) OR ((case OR cases OR match*) NEAR/2 control*) OR (cross NEAR/1 
section*) OR correlation* OR multicenter* OR multi-center* OR follow-up* OR 
followup* OR clinical* OR trial OR random* OR review* OR meta-analy*)) NOT 
((animal* OR rat OR rats OR mouse OR mice OR murine) NOT (human* OR patient*))) 
AND DT=(article) 
PubMed publisher   149 
(Diet[mh] OR "Eating"[mh] OR "Recommended Dietary Allowances"[mh] OR "food 
deprivation"[mh] OR vitamins/bl[mh] OR "Dietary Supplements"[mh] OR "Nutritional 
Physiological Phenomena"[mh] OR "Diet Therapy"[mh] OR "Maternal Nutritional 
Physiological Phenomena"[mh] OR "nutritional status"[mh] OR  (diet OR nutrition OR 
((dietar*[tiab] OR food*[tiab] OR beverage*[tiab] OR alcohol*[tiab] OR mineral*[tiab] 
OR nutrient*[tiab] OR micronutrient*[tiab] OR macronutrient*[tiab] OR vitamin*[tiab] 
OR calor*[tiab] OR energ*[tiab] OR protein*[tiab] OR fat OR folic-acid*[tiab] OR 
folate*[tiab] OR vegetabl*[tiab] OR fruit*[tiab] OR cholin*[tiab] OR methionin*[tiab] 
OR betain*[tiab] OR fatty-acid*[tiab] OR pufa OR pufas OR mufa OR mufas OR safa OR 
safas OR sfa OR sfas) AND (intake*[tiab] OR ingest*[tiab]  OR supplement*[tiab] OR 
consum*[tiab] OR restrict*[tiab] OR depriv*[tiab] OR level OR concentration OR blood 
OR plasma OR serum OR pattern*[tiab])) OR fasting OR well nourish*[tiab] OR under 
nourish*[tiab])) AND  ("DNA Methylation"[mh] OR (((dna OR "long interspersed" OR 
gene OR genes) AND (demethylat*[tiab] OR methylat*[tiab] OR hypermethylat*[tiab] 
OR hypomethylat*[tiab])))) NOT (animals[mh] NOT humans[mh]) AND ("observational 
study"[mh] OR "Epidemiologic Studies"[mh] OR "health surveys"[mh] OR "multicenter 
study"[mh] OR "clinical study"[mh]  OR "Random Allocation"[mh] OR "review"[mh] OR 
(((observation*[tiab] OR epidemiolog*[tiab] OR famil*[tiab] OR comparativ*[tiab] OR 
communit*[tiab]) AND (stud*[tiab] OR data OR research)) OR cohort*[tiab] OR 
longitudinal*[tiab] OR retrospectiv*[tiab] OR prospectiv*[tiab]  OR population*[tiab] 
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OR (national*[tiab] AND (stud*[tiab] OR survey)) OR (health*[tiab] AND survey*[tiab]) 
OR ((case OR cases OR match*[tiab]) AND control*[tiab]) OR (cross section*[tiab]) OR 
correlation*[tiab] OR multicenter*[tiab] OR multi-center*[tiab] OR follow-up*[tiab] OR 
followup*[tiab] OR clinical*[tiab] OR trial OR random*[tiab] OR review*[tiab] OR meta-
analy*[tiab])) NOT (letter[pt] OR news[pt] OR comment[pt] OR editorial[pt] OR 
congresses[pt] OR abstracts[pt]) AND publisher[sb] 
Google scholar 
diet|nutrition|dietary|nutrients|micronutrients|macronutrients|vitamins|"folic 
acid"|folate|vegetables|fruit|choline  
"dna demethylation|methylation|hypermethylation|hypomethylation" 
 
 
Supplement 2: Detailed selection criteria 
Inclusion 
criteria 
 
1. Any study design 
 Including cross-sectional studies, case-control studies, cohort studies or 
intervention studies. 
2. Studies investigating associations of dietary factors with DNA methylation.  
 Nutrients: Including nutrient blood levels; intake of nutrients; or dietary 
supplements. 
 DNA methylation: Including global DNA methylation, gene specific DNA 
methylation, or genome-wide DNA methylation.  
3. Studies conducted at any age or life stage (e.g., during pregnancy, childhood, adulthood, 
etc.) 
4. No language or date restriction 
Exclusion 
criteria 
 
1. Studies not carried out in humans  
2. In vitro studies  
3. Studies conducted in only patients with chronic diseases (cancer, diabetes, CHD, etc.). Note: 
some studies have healthy control groups and report associations within these groups 
separately, these should be included. 
4. Letters, reviews, opinions papers, guidelines, case-reports (n<5), editorials 
5. Studies examining only the following exposures: 
 eating disorders;  
 alcohol dependency/alcoholism (but not actual alcohol intake);  
 weight loss (unless the weight-loss intervention is solely a restricted diet, not 
combined with other lifestyle changes).  
 Dietary patterns or food groups without examining individual nutrients  
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Supplement 3: Quality score 
Two independent reviewers evaluated the quality of included studies using the 
following quality score. The score is composed of 5 items, and each item was allocated 
0, 1 or 2 points. This allowed a total score between 0 and 10 points, 10 representing 
the highest quality. The following items are included in the score: 
1. Study design 
o 0 for cross-sectional studies 
o 1 for longitudinal studies (including repeated measurements) 
o 2 for interventional studies 
2. Population 
o 0 if n<30  
o 1 if n 30 to 100 
o 2 if n>100 
3. Exposure 
o Observational studies  
 0 if the study used no appropriate standard diet or nutrient 
concentration assessment method (see below) or if not 
reported 
 1 if the study used food records, a 24h recall or an FFQ  
 2 if the study used blood levels  
o Interventional studies 
 0 if the intervention diet was not described or not blinded 
 1 if the intervention diet was adequately single-blinded 
 2 if the intervention is adequately double-blinded 
4. Outcome 
o 0 Global DNA methylation 
o 1 Gene-specific DNA methylation 
o 2 Genome-wide DNA methylation  
5. Adjustments 
o 0 if findings are not controlled for potential confounders*   
o 1 if findings are controlled for at least basic confounders: age and 
sex, and multiple testing in case of an EWAS 
o 2 if an intervention study is adequately randomized or if findings are 
controlled for additional confounders (on top of those described 
above), such as: technical covariates, WBC, BMI, smoking, alcohol, 
etc. 
* ‘Controlled for’ includes: adjustment for in the statistical analyses (e.g. with 
multivariable regression); stratification in the analyses (e.g. men and women 
separately); or restriction or narrow selection criteria of study participants on this 
covariate. 
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ABSTRACT 
Aim: Homocysteine is a sensitive marker of one-carbon metabolism. Higher 
homocysteine levels have been associated with global DNA hypomethylation. We 
investigated the association between plasma homocysteine and epigenome-wide DNA 
methylation in leukocytes. 
Methods: Methylation was measured using Illumina 450k arrays in 2,035 individuals 
from 6 cohorts. Homocysteine-associated differentially methylated positions (DMPs) 
and regions (DMRs) were identified using meta-analysis. 
Results: Three DMPs cg21607669 (SLC27A1), cg26382848 (AJUBA) and cg10701000 
(KCNMA1) at chromosome 19, 14 and 10, respectively, were significantly associated 
with homocysteine. In addition, we identified 68 homocysteine-associated DMRs, the 
most significant of which was a 1.8 kb spanning domain (TNXB/ATF6B) at chromosome 
6. 
Conclusion: We identified novel epigenetic loci associated with homocysteine levels, of 
which the specific role needs to be further validated. 
 
SUMMARY POINTS 
1) Plasma homocysteine is significantly associated with a modest number of 
differentially methylated positions (DMPs) in leukocyte DNA. 
2) 68 DMRs related to 114 genes were significantly associated with plasma 
homocysteine. These genes were involved in folate biosynthesis, 
glycosaminoglycan biosynthesis, arachidonic acid metabolism and 
glycerophospholipid metabolism. 
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INTRODUCTION 
Homocysteine (Hcy), an intermediate of the one-carbon metabolism, is an independent 
risk factor of diseases like osteoporotic fractures [1] and cardiovascular disorders [2]. In 
addition, Hcy is often used as sensitive marker of folate- and vitamin B12 deficiency. 
Recent intervention trials were not able to show that lowering of plasma Hcy by B-
vitamin intervention led to a reduction in disease risk such as myocardial infarction [3-
5] and osteoporotic fractures [6]. Identification of the underlying pathophysiological 
mechanism of Hcy is warranted to understand its role as biomarker of several disease 
states.  
Hcy is formed by a demethylation reaction from methionine. In the 
methionine cycle, s-adenosylmethionine (SAM) donates its methyl group to the DNA 
resulting in s-adenosylhomocysteine (SAH) as a by-product and a potent inhibitor of 
this methyltransferase reaction. SAH is hydrolyzed to Hcy in a reversible manner. 
Elevated Hcy in a condition known as hyperhomocysteinemia (HHcy) is associated to 
and increased SAH level, which is linked to alterations in DNA methylation [7-9]. This is 
one of the possible mechanisms in Hcy-related pathologies and the rational to study 
the effect of Hcy on genome-wide DNA methylation. 
Hcy is a sensitive marker of one-carbon metabolism and will increase when 
remethylation or transsulfuration is impaired. Shortage of folate, vitamin B12 or 
vitamin B6 result in elevated Hcy levels. Although folate levels are important, we 
believe it is not necessary to correct for folate in our analysis as Hcy is strongly 
correlated to folate and belongs to the same pathway. This would have cancelled out 
the effect of Hcy itself on DNA methylation. The general hypothesis of this study was 
that Hcy is associated with changes in DNA methylation irrespective of the cause. 
Normal circulating Hcy levels ranges from 8 to 10 µmol/L for women and 10 
to 12 µmol/L for men [10]. Mild or moderate HHcy is referred to Hcy concentrations 
between 15-30 µmol/L, whereas intermediate and severe HHcy is referred to Hcy 
concentrations between 30-100 µmol/L and >100 µmol/L, respectively [10-12]. HHcy 
has been shown to be associated with both global- and gene-specific DNA 
hypomethylation, which was recently reviewed by us [13].. In candidate gene studies of 
animal models, genes whose methylation have shown association with Hcy are the 
hypomethylation of imprinted genes (e.g. IGF2/H19 locus) [14, 15], cardiac Trp53 [16], 
leukocytic mTERT promoter [17], brain Nr3c1 exon region [18], brain Ppp2r1a [19] and 
liver 5’ portion of Soat2 [20], and hypermethylation of the aortic Nr3c1 promoter [21] 
and liver Fads2 promoter [22]. In human studies, HHcy has been shown to be 
associated with altered methylation of the RFC1 gene [23]. For patients with vascular 
disorders, HHcy has shown association with hypomethylation of the leukocytic hTERT 
promoter [17], leukocytic SHC1 promoter [24], punch aortic NOS2 proximal promoter 
[25], and hypermethylation of the blood ESR1 promoter [26] and internal mammary 
artery NOS2 proximal promoter [25]. For patients with colorectal, esophageal and 
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breast cancer, HHcy has shown association with hypermethylation of ESR1 promoter 
[27] and exon 1 [28], MLH1 promoter [29], RARB promoter exon [28], BRCA1 and 
RASSF1 promoter [30]. 
In animal models, HHcy was also shown to associate with global 
hypomethylation [18, 31-33]. Human studies included mostly small-scale studies in 
renal or vascular patients with HHcy in which global DNA hypomethylation was 
observed [10, 34, 35]. Most studies showed significant associations of Hcy with DNA 
methylation, however, also null associations have been found [36, 37]. Hence, the 
association between Hcy and DNA methylation is complex, contradictory and remains 
to be fully understood. Mild HHcy can occur due to either genetic or environmental 
factors such as low intake of B vitamins.  Regardless of the cause, Hcy itself is thought 
to be the most prominent key player in altering DNA methylation patterns and 
associated disease risks.  
In the current manuscript, we explored the association of Hcy in relation to 
genome-wide CpG site level in leukocytes to assess its role in DNA methylation. In this 
study, we performed a meta-analysis in 2,035 individuals of 6 individual cohorts using 
the high-resolution Infinium Illumina 450k BeadChip arrays.  
MATERIALS AND METHODS 
Cohorts 
Six cohorts participated in the analysis, Rotterdam study [38] (RS, n=700), Leiden 
Longevity Study [39] (LLS, n=550), Cohort on Diabetes and Atherosclerosis Maastricht 
[40] (CODAM, n=186), MARseille THrombosis Association study [41] (MARTHA, n=293), 
Estonian Biobank [42] (EGCUT, n=96), and French-Canadian family study on Factor V 
Leiden (F5L) thrombophilia [41] (F5L, n=210). This added up to a total sample size of 
2,035 for the meta-analysis. The ethics review committees approved each study at 
their relevant organizations. Characteristics of each study are provided in Table 1 and 
Text S1. 
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Homocysteine measurements 
Total Hcy was measured in EDTA plasma. Measurements in non-fasting state were 
performed in the LLS and EGCUT study, while rest of the studies measured Hcy in 
fasting state. Details of each method is depicted in Table 1. Since the absolute values of 
Hcy in all studies were skewed to the right, logarithmic transformation of base 10 was 
used to achieve normal distribution. For a sample to be considered as an outlier, an 
outlier detection strategy [43] was used with four parameters of the Hcy log10 
transformed data: quartile 1 (Q1), quartile 3 (Q3), interquartile range (IQR) and a 
multiplying factor (M). The lower end outliers (LO) were detected by the formula, 
LO=Q1–(M*IQR), and upper end outliers (UO) were detected using UO=Q3+(M*IQR). 
Any value less than or equal to LO and greater than or equal to UO was considered as 
an extreme outlier, using the multiplying factor 3. A logarithmic transformation of base 
10 and removal of outliers showed a clear improvement towards normal distribution 
[Figure S1]. 
DNA methylation assessment 
Genomic DNA was extracted from whole blood and was bisulfite converted. Infinium 
Illumina HumanMethylation 450k BeadChip arrays (Illumina Inc., San Diego, USA) were 
used to perform DNA methylation profiling according to the manufacturers’ protocol. 
This assay covers methylation status of a wide range of CpGs at more than 450,000 
sites at regions of CpG islands, shores and shelves. The sites annotate to various gene 
regions like promoters, enhancers, gene bodies, exons and UTRs [44]. Standard beta 
values were considered for the methylation analysis in all studies. These contain values 
ranging from 0 to 1, representing the percentage of methylation. Beta values are 
calculated from the methylated (M) and unmethylated (U) probe intensities using the 
formula of β=M/(M+U+α), with the default alpha (α) of 100. These values were 
normalized using methods, such as DASEN [45] or SWAN [46]. Details of DNA 
methylation assessment, pre-processing methods, and sample and probe quality 
control used by each cohort are provided in Text S1 and Table S1.  
Differentially Methylated Positions (DMPs) 
Statistical analysis to identify DMPs was performed using R programming scripts, which 
were send around to each cohort and run by each cohort separately with log10 
transformed Hcy as the exposure variable and DNA methylation as an outcome. This 
association analysis was performed using linear mixed models of the lme4 package in 
R. The association model was adjusted for technical covariates and biological 
covariates like age, sex and differential white blood cell (WBC) counts. Array number 
and position on array were used as technical covariates, and were treated as random 
effects. For cohorts that did not contain measured WBC counts, the counts were 
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inferred using the Houseman method as implemented in the minfi package [47] [Table 
1]. 
Association analyses provided summary statistics from each study. A fixed 
effect meta-analysis was performed in 2,035 individuals of 6 cohorts using the classical 
approach of the METAL software [48] that combines effect size estimates and standard 
errors of each study summary statistics. Probes with SNPs at single base extension site 
were removed to avoid confounding and spurious signals. Probes with improper 
binding were also removed to avoid co-hybridization with alternate homologous 
sequences [49]. In addition, we removed probes that were present in less than 4 
studies since each cohort had different probe exclusions. This resulted in 468,108 
probes remaining. Benjamini-Hochberg (BH) method was used to define statistical 
significance for a false discovery rate (FDR) less than 0.05. The genomic inflation factor 
(λ) was calculated [50] and cohort heterogeneity was considered by taking into account 
the heterogeneity I2 parameter [48]. CpGs for nearby genes were annotated using the 
Genomic Regions Enrichment of Annotations Tool (GREAT) [51]. This assigns extension 
up to 5 kb upstream and 1 kb downstream to a basal regulatory region from its 
transcription start site and a maximum up to 1 Mb extension distance, as defined by 
UCSC [52]. 
IGF2/H19 locus 
We also looked up for the three DMRs of IGF2/H19 locus at chromosome 11, which 
were previously related with Hcy [14, 15]. The seven 450k array CpGs underlying the 
three DMRs of this locus were identified using literature [36, 53, 54]. Multiple testing 
using the Bonferroni method was applied on these 7 CpGs to test for their significance 
with Hcy. 
Enrichment of previously found folate-associated CpGs 
Because Hcy is associated with folate, we additionally focused our analysis on the 
previously found 443 CpGs in cord blood of newborns associated with maternal plasma 
folate during pregnancy [55]. In order to check for their significant enrichment, we 
compared their p-values with the p-values of randomly selected 443 CpGs from the 
array, using the Fisher’s exact test.  
Differentially Methylated Regions (DMRs) 
DMRs were identified using the python library of the comb-p software [56]. Absolute p-
values from the meta-analysis of DMP analysis were given as input to combine them 
[57] adjacently at varying distance lags of 50 base pairs (bp) in a sliding-window of 500 
bp, in order to calculate auto-correlation between them. As weighted according to this 
auto-correlation, each p-value is adjusted according to its adjacent p-values. An FDR 
correction using the BH method is then calculated on these adjusted p-values. A peak-
finding algorithm then finds enrichment regions on these FDR corrected adjusted p-
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values, and using Stouffer-Liptak correction as implemented in comb-p [56, 58, 59], it 
then assigns new p-values to the identified regions using the original absolute p-values 
from the meta-analysis. Finally, these assigned new p-values of the of the identified 
regions are multiple tested using the Sidak correction [60], where the defined 
statistical significance for the identified regions was Sidak corrected P less than 0.05. 
The number of tests for a region in the Sidak correction is the total bases covered by 
input probes divided by the region size [56]. 
Differentially Methylated Regions (DMRs): Pathway Analysis 
For the pathway analysis, we annotated the regions for genes using the tool GREAT 
[51]. We used WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) [61] online resource 
for pathway analysis. KEGG database were used for enrichment. BH method in 
WebGestalt was used to define statistical significance for an FDR less than 0.05. 
RESULTS 
Cohort characteristics 
Meta-analysis comprised of 6 cohorts with a total of 2,035 individuals. All individuals 
were of European ancestry. The study design was mainly population based, but also 
included cohorts with increased risk of diabetes, cardiovascular disorders and venous 
thromboembolism. Study characteristics for all the participating cohorts are given in 
Table 1. 
Differentially Methylated Positions (DMPs) 
Meta-analysis on 468,108 CpGs was done on the summary statistic of the 6 cohorts 
[Figure S2] comprising of 2,035 individuals. The p-values of this analysis showed a 
genomic inflation factor of 1.2 [Figure S3]. Three DMPs [Table 2A, Figure 1] were 
significantly associated with Hcy (FDR less than 0.05). All 3 DMPs showed 1% increase 
in methylation with each unit increase in the 10 logarithmic Hcy value. The DMP 
cg21607669 located near the gene SLC27A1 at chromosome 19 had the lowest p-value 
of 7.71E-08 (FDR=0.04). The 2 other DMPs were cg26382848 (nearest gene AJUBA) 
located at chromosome 14 with p-value 1.67E-07 (FDR=0.04) and cg10701000 (nearest 
gene KCNMA1) located at chromosome 10 with p-value 2.38E-07 (FDR=0.04). These 3 
DMPs showed no substantial cohort heterogeneity I2 (I2 less than 35). The direction of 
effects were mostly similar between all studies [Figure 2A, 2B & 2C]. 
IGF2/H19 locus 
We did a lookup for CpGs at the 3 DMRs of the IGF2/H19 gene (DMR0, DMR2, H19-
DMR3), that have been previously studied in humans [36, 53, 54]. Data from our 450k 
arrays contained 7 CpGs at these DMRs: 2 at DMR0, 4 at DMR2 and 1 at H19-DMR3. 
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However, none of the 7 CpGs showed an association with Hcy with a Bonferroni cut off 
of 7.14E-03 [Table 2B, Figure S5]. 
Enrichment of previously found folate-associated CpGs 
For the previously found 443 CpGs in cord blood of newborns associated with maternal 
plasma folate during pregnancy [55], we compared their nominal p-values with 443 
randomly selected CpGs in the array using 100 permutations. Based on our significant 
threshold (P less than 0.05), 20 of the 443 folate-related CpGs met the threshold as 
compared to the 32 of the 443 randomly selected CpGs in the array. Using the fisher’s 
exact test, we found no significant enrichment (p-value=0.97) in the folate-related 
CpGs. 
Differentially Methylated Regions (DMRs) 
We identified 68 DMRs significant at Sidak P less than 0.05 [Table 3, Figure 3, Figure 
S4]. The most significant was the DMR at chromosome 6 (spanning a region of 1,8 Kb) 
with a p-value of 4.34E-24 (Sidak P = 1.12E-21) containing 55 CpGs. CpGs within this 
region were annotated to gene TNXB and ATF6B. Pathway analysis on the 114 genes 
annotated to the 68 DMRs showed 14 significant pathways [Table 4]. Top 5 pathways 
were metabolic pathways, folate biosynthesis, glycosaminoglycan biosynthesis – 
heparan sulfate, phagosome and MAPK signaling pathway. Furthermore, results of the 
GO enrichment analysis showed many biological processes related to embryogenesis 
and development [Table 5]. 
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Figure 1. Manhattan plot showing the association between homocysteine and genome-wide 
DNA methylation in 2,035 samples, with 3 significant DMPs at chromosomes 10, 14 and 19, 
at FDR less than 0.05 (red line). Nearest genes for these 3 DMPs are reported. 
 
Figure 3. Manhattan plot showing the association between homocysteine and genome-wide 
DNA methylation in 2,035 samples, with 68 significant DMRs, at FDR less than 0.05 (red line) 
of autocorrelation adjusted p-values in comb-p. Nearest genes for the top 5 DMRs are 
reported. 
Chromosome 
Chromosome 
-l
o
g 1
0
(p
) 
-l
o
g 1
0
(p
) 
CHAPTER 4: Homocysteine levels and DNA methylation 143 
 
 
 
 
 
 
Figure 2A. Forest plot showing the association between homocysteine and the first 
significant DMP cg21607669 across the 6 cohorts. 
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Figure 2B. Forest plot showing the association between homocysteine and the second 
significant DMP cg26382848 across the 6 cohorts. 
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Figure 2C. Forest plot showing the association between homocysteine and the third 
significant DMP cg10701000 across the 3 cohorts. 
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DISCUSSION 
This is the first large-scale epigenome-wide site-specific collaborative meta-analysis 
studying the relationship between plasma Hcy levels and methylation at a genome 
wide level. Our results show that plasma Hcy concentrations were associated with 3 
DMPs and 68 DMRs. Identification of this relatively low number of DMPs is surprising, 
given the central role of Hcy in the methylation cycle. 
The most significant of the 3 DMPs, cg21607669 is located at chromosome 19 
near the promoter region of the gene SLC27A1 (+40 bp downstream). SLC27A1 assists 
in the transport of fatty acids across cell membrane, and its highest levels are found in 
muscle and adipose tissue [62]. Results from a recent meta-analysis demonstrated that 
omega-3 polyunsaturated fatty acid supplementation was associated with Hcy lowering 
[63]. It was hypothesized that the omega-3 fatty acid, docosahexaenoic acid (DHA) 
upregulates metabolic enzymes of the one-carbon pathway like methionine adenosyl-
transferase resulting in increased SAM bioavailability [63]. The exact role of 
hypermethylation of SLC27A1 should be further investigated to understand its possible 
role in the relation between polyunsaturated fatty acids and HHcy.  
The second significant DMP, cg26382848 is located at chromosome 14 near 
the promoter region of the gene AJUBA (-39 bp upstream). AJUBA plays a role in 
cellular processes such as cell migration, proliferation and differentiation [64, 65]. It 
functions as a negative regulator of the retinoic signalling [66] and Hippo signalling 
pathway [67], and is involved in tumors [68]. However, the precise role of this gene is 
less clear and future replication studies are necessary to establish the role of this gene 
in relation to Hcy.  
The third significant DMP cg10701000 at chromosome 10 annotated to the 
nearby gene KCNMA1 (-143,626 bp upstream). KCNMA1 is a potassium calcium-
activated channel and has its prominent role in many physiological processes of 
smooth muscles, hair cells and diseases of nervous system and cancer [69]. A recent 
study has shown that elevated cellular Hcy increases the activity of potassium calcium-
activated channel in GH3 pituitary cells [70], while two other previous studies have 
reported that Hcy inhibits these channels of artery smooth muscle cells [71, 72]. Our 
finding of hypermethylation near the KCNMA1 gene supports the involvement of Hcy in 
potassium calcium-activated channel. 
We specifically studied the IGF2/H19 locus, the most frequently studied locus 
in relation to Hcy levels, and found  that, none of the CpGs on the array that were 
annotated to this locus showed an association with Hcy. We, could therefore not 
corroborate results from 2 earlier studies that did find a relationship between Hcy 
levels and methylation at the IGF2/H19 locus [14, 15]. The reason could be that these 
studies were performed in HHcy mice models with heterogeneous knockout of the CBS 
gene, fed with high methionine and low folate diet. CBS deficiency is an inborn error of 
metabolism which leads to Hcy concentrations much higher at intermediate to severe 
154 PART B: Homocysteine and DNA methylation 
 
levels, as compared to the ones present in our study. Furthermore, in human studies of 
patients with HHcy and uremia, the influence of Hcy on H19 methylation is also 
observed at a concentration of Hcy much higher at intermediate levels, as compared to 
the mild levels present in our study, and the monoallelic expression of H19 is shown to 
be reversed by folate supplementation [10]. Therefore, our results cannot be directly 
extrapolated in other populations where Hcy is higher especially in chronic renal failure 
and rare diseases of metabolism. However, our results are in line with another human 
study which did not find differences in intermediate HHcy patients with CBS deficiency 
and controls [36]. These patients were under Hcy-lowering therapy which would have 
prevented the association with H19 DMR. Therefore, mildly elevated Hcy levels do not 
seem to be related to differences in methylation of the IGF2/H19 region in circulating 
leukocytes. Furthermore, focusing our analysis on the previously found CpGs in 
newborns in relation to maternal plasma folate during pregnancy, we did not find 
significant enrichment. We expected some enrichment because of the strong 
association of Hcy with folate. The reason for not finding enrichment could be related 
to the different study design of mother-offspring relationship compared to population-
based cohorts. 
Regional analysis using the comb-p software identified 68 DMRs significant at 
Sidak P less than 0.05. The most significant was 1.8 Kb DMR located at chromosome 6 
spanning 55 CpGs. This DMR was annotated to the gene TNXB and ATF6B. TNXB is 
located within the class III region of the major histocompatibility complex [73] had 
multiple CpG sites previously shown to be hypermethylated in anorexia nervosa 
patients compared to controls [74, 75]. Another gene located near this DMR is the 
Activating Transcription Factor 6 Beta (ATF6B) gene. This gene is involved in the 
unfolded protein response during ER stress and has been shown to be activated upon 
Hcy treatment to human endothelial cells [76]. More specifically a putative ATF6-
binding motif was identified, which was shown to be demethylated upon treatment 
with Hcy, supporting our findings of possible involvement of altered methylation of 
ATF6B in relation to HHcy. 
Among the other DMRs there were a number of interesting regions that had 
prior studies connecting Hcy to the genes annotated near the CpGs. For example, the 
DMR Chr.6:32,145,146-32,146,780 is annotated to the genes AGPAT1 and RNP5. This 
region was previously found associated to serum vitamin B12 in elderly subjects with 
elevated Hcy in our previous study of B-vitamins for the PRevention Of Osteoporotic 
Fractures (B-PROOF) [77]. Other DMRs, Chr.7:27,142,100-27,142,811 and 
Chr.7:27,187,269-27,187,692 were annotated to the HOX genes, which were previously 
shown to be differentially methylated after a 2-year intervention with folic acid and 
vitamin B12 [77]. Another gene DPEP1 annotated to the DMR Chr.16:89,689,811-
89,690,263, is involved in renal function and contains SNPs previously shown to be 
associated with Hcy [78-80]. Furthermore, gene PADI4 of DMR Chr.1:17,634,543-
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17,634,717 previously showed to citrullinate DNMT3A, and therefore interacting with it 
to control DNA methylation [81]. And lastly, 2 out of 8 CpGs of DMR Chr.5:54,281,198-
54,281,734 were significantly shown associated with maternal plasma folate levels 
during pregnancy, in cord blood [55]. These regions are promising to be replicated in 
future studies. 
DMR analysis is recommended as a part of the analysis pipeline in addition to 
CpG site analysis [82, 83]. It has been shown that methylation is regulated in genomic 
regions, which merits the identification of DMRs in addition to single CpGs. Several 
software packages are available to perform DMR analysis, with their own strengths and 
weaknesses (i.e. Bumphunter, DMRcate) [84]. In this paper we applied comb-p, which 
constructs regions based on the autocorrelation between the p-values at varying lags in 
a sliding window, which is a good approach for the unevenly spaced CpGs in the 450k 
array [56]. A recent paper has shown that Comb-p has good sensitivity. However, if the 
data signal is weak, comb-p has the tendency to return false-positives particularly in 
presence of low effect size [85]. We therefore decided to check the DMR results of 
comb-p in the Rotterdam Study subset of 700 individuals, and compare them with the 
DMR results of another package, DMRcate [84]. Of the 49 significant DMRs within the 
subset of 700 individuals we found using comb-p package, we saw an overlap of 60%, 
with the DMRs found using DMRcate (data not shown). Results of comp-b seem valid 
but further studies are also necessary to validate these findings further. 
Pathway analysis on the 114 genes annotated to the 68 DMRs identified 
pathways related to metabolism such as folate biosynthesis, glycosaminoglycan 
biosynthesis, arachidonic acid metabolism and glycerophospholipid metabolism. This 
could suggest how elevated Hcy can affect other important pathways via DNA 
methylation impairment. Folate pathways contained 2 genes: ALPPL2 and ALPP. An 
important paralog of these genes, which is ALPL, previously showed polymorphisms 
that were associated with vitamin B6 that suggests its possible role in vitamin B6 
catabolism [86]. However, these genes need to be further replicated because of its low 
number in the pathway. Results of the GO enrichment analysis showed many biological 
processes related to embryogenesis and development, where Hcy has most variedly 
shown to play a role by previous studies. 
Most of the studies until now investigated this association by measuring DNA 
methylation at a global level. The strength of our study is that the association of mild 
HHcy with genome-wide DNA methylation using 450k arrays was studied. Second, this 
is the largest epigenome wide association study on Hcy including 2,035 individuals.  
Limitations of our study are that clinical heterogeneity between cohorts may 
have prevented us of finding additional true significant associations. Cohorts were 
either population based, or cases with venous thromboembolism, or have a mildly 
increased risk to develop type 2 diabetes and/or cardiovascular disease. Hcy 
concentrations and related mechanisms may vary with such different 
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pathophysiologies [87]. Furthermore, Hcy median concentrations were generally low in 
each cohort, with only 10.2-32.3% of individuals in the mild HHcy range >15 µmol/L 
[Table 1], which could explain the subtle findings. Second, we acknowledge that Hcy 
levels were measured using different techniques in each study, either in fasting or non-
fasting state, as well as there were differences in sample collections per cohort. 
However, the methylation analyses were done in each cohort separately, and the 
results of each separate study were then meta-analysed. Our results are therefore not 
biased by the differences in Hcy measurement methods, state of fasting, or sample 
collection. Nevertheless, these heterogeneity across cohorts could have resulted in 
null-findings. Third, we did not account for differences in nutritional folate and/or 
vitamin B12 intake and B-vitamin supplementation, or homocysteine-related diseases 
like renal insufficiency that could have confounded the results of our study [87]. We 
also did not account for the genetic background of individuals, especially MTHFR 
677C>T that is associated with Hcy [88]. We could have accounted for these 
confounding factors, but not all of this data was available to us. In addition, these 
confounding factors like folate, vitamin B12 and MTHFR 677C>T belong to the same 
pathway and are highly correlated with Hcy. This would have cancelled out the effect 
of Hcy itself on DNA methylation. We had hypothesized that Hcy is associated with 
DNA methylation regardless of the cause. However, adjusting for MTHFR 677C>T in the 
linear mixed model analysis in RS-III and CODAM did not change the findings (data not 
shown). Forth, we did not account for population stratification in the methylation 
analysis of each cohort because all individuals were of European ancestry. But in order 
to check the influence of this, we reran the analysis only in the Rotterdam Study by 
additionally adjusting for 4 genetic PCs. The results still showed no significant DMPs 
(FDR<0.05). In addition, the 3 significant DMPs of meta-analysis showed same direction 
of effects with and without the 4 genetic PCs correction [Figure S6]. Therefore, adding 
additional genetic PCs as covariates did not seem necessary and moreover, would 
reduce statistical power. Fifth, Hcy effect could be exclusive to certain other tissues like 
heart, liver and brain. Future studies still need to explore such findings. And lastly, even 
though we included 2,035 individuals from all the possible studies to our knowledge 
who had Hcy and DNA methylation data measured at the same time point, statistical 
power might still be low to identify significant DMP signals. As such, replication was not 
easily tractable, a main limitation of our results. 
CONCLUSIONS 
In conclusion, our meta-analysis showed 3 DMPs at chromosome 19, 14 and 10 with 
nearby genes of SLC27A1 and AJUBA, and 68 DMRs associated with Hcy concentrations. 
Knowing the prominent role of Hcy in donation of methyl groups, we expected to find 
more DMPs. However, DMR analysis does show promising findings, but their role in 
relation to one-carbon metabolism needs to be further investigated. 
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ADDITIONAL INFORMATION 
Supplementary Information accompanies this paper at 
https://www.futuremedicine.com. 
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ABSTRACT 
Background: DNA methylation is affected by the activities of the key enzymes and 
intermediate metabolites of the one-carbon pathway, one of which involves 
homocysteine. We investigated the effect of the well-known genetic variant associated 
with mildly elevated homocysteine: MTHFR 677C>T independently and in combination 
with other homocysteine-associated variants, on genome-wide leukocyte DNA-
methylation. 
Methods: Methylation levels were assessed using Illumina 450k arrays on 9,894 
individuals of European ancestry from 12 cohort studies. Linear-mixed-models were 
used to study the association of additive MTHFR 677C>T and genetic-risk score (GRS) 
based on 18 homocysteine-associated SNPs, with genome-wide methylation. 
Results: Meta-analysis revealed that the MTHFR 677C>T variant was associated with 35 
CpG sites in cis, and the GRS showed association with 113 CpG sites near the 
homocysteine-associated variants. Genome-wide analysis revealed that the MTHFR 
677C>T variant was associated with 1 trans-CpG (nearest gene ZNF184), while the GRS 
model showed association with 5 significant trans-CpGs annotated to nearest genes 
PTF1A, MRPL55, CTDSP2, CRYM and FKBP5. 
Conclusions: Our results do not show widespread changes in DNA-methylation across 
the genome, and therefore do not support the hypothesis that mildly elevated 
homocysteine is associated with widespread methylation changes in leukocytes. 
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INTRODUCTION 
DNA methylation, an important epigenetic mechanism has gained interest in the field 
of cancer and aging over the last decade [1, 2]. DNA methylation is affected by the 
activities of the key enzymes and intermediate metabolites of the one-carbon pathway, 
one of which involves homocysteine (Hcy). 
Our aim was to investigate the role of genetically defined Hcy levels on 
genome-wide DNA methylation. A number of earlier studies have reported a link 
between Hcy and DNA methylation [3]. In these studies, DNA methylation was 
quantified as a global measure, that represents the total methyl cytosine content of 
the DNA. In animal models, both diet- and genetically- induced elevated Hcy have been 
related to altered global methylation patterns in tissues of aorta, brain, liver and colon. 
In human subjects, global DNA methylation in blood was not consistently altered with 
elevated Hcy. The relationship between Hcy and methylation can be subject to 
substantial bias, given the strong relationship between several lifestyle factors, 
diseases and Hcy. A way to circumvent this bias is to use genetic factors determining 
Hcy concentrations as an instrument to study the relationship between Hcy and 
methylation. The use of genetically defined elevated Hcy eliminate the effects that are 
possibly caused by measurement errors, confounding and reverse causality. One of the 
most consistent genetic variants causing elevated Hcy is the MTHFR 677C>T 
(rs1801133), which explains 5.3% variance in Hcy [4]. Furthermore, we recently 
published 18 variants including MTHFR 677C>T to be robustly associated with Hcy [5]. 
The Genetic Risk Score (GRS) of these 18 Hcy-associated variants explained 5.9% 
variance in Hcy [5]. In the current study, we used MTHFR 677C>T independently and 
the combined weighted GRS of these 18 variants, to test whether genetically defined 
elevated Hcy concentrations are associated with DNA methylation changes in blood 
cells. 
A number of studies [3] have examined the relationship between the MTHFR 
677C>T variant and global DNA methylation in humans. In 5 studies, individuals with 
the MTHFR 677TT genotype were compared to those with the MTHFR 677CC genotype 
[6-10]. Lower global methylation in blood cells was observed in two studies [6, 7]. The 
remaining three studies showed no association in the lymphocyte or colonic tissue. All 
published studies until now had small sample sizes of less than 200. To the best of our 
knowledge, associations of genetically defined Hcy with site-specific CpG methylation 
on a genome-wide scale have not been done up to now. In order to investigate this, we 
analyzed DNA methylation data measured with the Infinium Illumina 450k arrays, in a 
large meta-analysis of 9,894 individuals comprising 12 cohorts. We hypothesize that 
genetically defined elevated Hcy is associated with altered DNA methylation. 
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MATERIALS AND METHODS 
Study population 
All participants provided a written informed consent, and each study was approved at 
the relevant organizations by their respective ethics review committees [RS, 
Institutional review board (Medical Ethics Committee) of the Erasmus Medical Center; 
LLS, Ethical committee of the Leiden University Medical Center; LL, Ethics committee of 
the University Medical Centre Groningen; NTR, Central Ethics Committee on Research 
Involving Human Subjects of the VU University Medical Centre; CODAM, Medical 
Ethical Committee of the Maastricht University; MARTHA, “Departement santé de la 
direction générale de la recherche et de l'innovation du ministère” (Projects DC: 2008-
880 & 09.576); EGCUT; Research Ethics Committee of the University of Tartu; F5L, 
Research ethics boards of the University of Toronto and the Ottawa Hospital Research 
Institute; FHS, IRB (institutional review board); KORA, Local Ethics Committee; 
LBC1921, Lothian Research Ethics Committee (Wave 1: LREC/1998/4/183); LBC1936, 
Multi-Centre Research Ethics Committee for Scotland (Wave 1: MREC/01/0/56), and 
the Lothian Research Ethics Committee (Wave 1: LREC/2003/2/29)]. 
The analyses comprised of large population with 9,894 participants from 12 
cohorts of European ancestry. Most of the cohorts were part of either the Cohorts for 
Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium [11] and/or 
Biobank-based Integrative Omics Studies (BIOS) consortium [12]. All participants 
provided a written informed consent for the DNA collection and its use for genetic 
analyses. Each study was approved at the relevant organizations by their respective 
ethics review committees. Cohort-specific characteristics are provided in the S1 Text 
and S1 Table. 
MTHFR 677C>T and homocysteine-associated SNPs 
18 independent Hcy-associated SNPs from our GWAS meta-analysis [5], were selected 
to assess the relationship between mildly elevated Hcy concentrations and genome-
wide DNA methylation. The genotypes of these SNPs were extracted from the 
genotyping data. Cohort-specific details of the quality control and the SNP imputation 
methods are provided in the S2 Table. 
DNA methylation assessment 
Whole blood samples were collected from the participants for DNA extraction. The 
genomic DNA was bisulfite converted using the Zymo EZ-96 DNA-methylation kit (Zymo 
Research, Irvine, CA, USA). Methylation profiling was performed using the Infinium 
Illumina HumanMethylation 450k BeadChip arrays (Illumina Inc., San Diego, USA) 
according to the manufacturers’ protocol. Beta values from 0 to 1, which represent the 
percentage of methylation, were calculated from the extracted raw methylated (M) 
and unmethylated (U) probe intensities and a default alpha (α) of 100. This is defined 
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by the formula of β=M/(M+U+α). Normalization was performed on these raw beta 
values using DASEN [13] or SWAN [14] methods. Poor quality probes were excluded 
based on the detection p-values mostly >0.01 in >5% of samples. Cohort-specific data 
preprocessing methods are provided in the Table 1. Global methylation levels per 
sample was calculated by the mean of all CpGs as well as mean according to CpG 
islands, shores, shelves or non-coding regions [15].  
Statistical analysis 
Two models were run independently by each participating study. Firstly, an additive 
model for MTHFR 677C>T alone was used to investigate its independent association 
with genome-wide DNA methylation in a linear manner. For the MTHFR 677C>T 
variant, genotypes were coded as CC=0, CT=1 and TT=2 to study the effect in 
methylation per MTHFR 677T allele. 
In the second analysis, a weighted Genetic Risk Scores (GRS) was constructed 
from all the 18 Hcy-associated variants to investigate their combined and additive 
effect on genome-wide DNA methylation. Weighted GRS were calculated on the basis 
of their effect sizes [5] and number of corresponding risk alleles. The product of the 
two was calculated for each SNP and then summed up for all SNPs. The GRS was 
calculated using the equation below, where N is the number of elevated Hcy causing 
risk alleles for each SNP (0, 1 or 2 per genotype). 
𝑮𝑹𝑺 =
 0.1583 𝑥 𝑁(𝑟𝑠1801133: 𝐴) +  0.0542 𝑥 𝑁(𝑟𝑠2275565: 𝐺) +
 0.0718 𝑥 𝑁(𝑟𝑠234709: 𝐶) +  0.0435 𝑥 𝑁(𝑟𝑠4660306: 𝑇) +
 0.0453 𝑥 𝑁(𝑟𝑠1801222: 𝐴) +  0.101 𝑥 𝑁(𝑟𝑠12134663: 𝐶) +
 0.0529 𝑥 𝑁(𝑟𝑠12780845: 𝐴) +  0.056 𝑥 𝑁(𝑟𝑠2851391: 𝑇) +
 0.0449 𝑥 𝑁(𝑟𝑠9369898: 𝐴) +  0.0422 𝑥 𝑁(𝑟𝑠838133: 𝐴) +
 0.0864 𝑥 𝑁(𝑟𝑠7422339: 𝐴) +  0.1242 𝑥 𝑁(𝑟𝑠7130284: 𝐶) +
 0.0963 𝑥 𝑁(𝑟𝑠154657: 𝐴) +  0.0597 𝑥 𝑁(𝑟𝑠548987: 𝐶) +
 0.0395 𝑥 𝑁(𝑟𝑠42648: 𝐺) +  0.0512 𝑥 𝑁(𝑟𝑠2251468: 𝐶) +
 0.045 𝑥 𝑁(𝑟𝑠957140: 𝐺) +  0.090 𝑥 𝑁(𝑟𝑠12921383: 𝐶) (1) 
Both the analyses were based on linear mixed models of lme4 package in R. 
We also analyzed the effect of MTHFR 677C>T and GRS on global methylation levels, 
where we calculated the overall mean levels per individual as well as categorized the 
means as per CGI annotations [15]. The models were adjusted for technical covariates 
and biological covariates like age, sex and differential white blood cell (WBC) counts 
(see S1 Table for details about covariates for each cohort). The technical covariates 
were cohort-specific and treated as random effects. WBC counts were either used as 
measured counts, or they were imputed based on the Houseman method as 
implemented in the minfi package [17], or the modified version of the Houseman 
method (Documentation and R script: https://github.com/mvaniterson/wbccPredictor) 
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that uses partial least-squares [18] to handle multivariate responses and high-
dimensional covariates and has been previously used [19]. This method from van 
Iterson used the R package pls [18] to fit the linear model based on the DNA 
methylation data, to predict the white blood cell composition as percentages that sum 
up to almost 100%. Age and gender were used as covariates. 
Meta-analysis 
Summary statistics for the two models were obtained from each study. Because of the 
different probe exclusions in each cohort [Table1], we removed probes that were 
present in ≤4 studies. We also excluded probes with SNPs at single base extension site, 
and probes with improper binding [12], leaving a total of 465,694 probes for the meta-
analysis. Meta-analysis was performed using the fixed effect model in METAL [20], with 
the classical approach that uses effect size estimates and standard errors as input 
obtained from the individual study summary statistics for each CpG probe. The output 
of meta-analysis gave the combined effect size estimates, standard errors and p-values 
per probe. These p-values were corrected using the Benjamini Hochberg method of 
false discovery rate (FDR), where FDR <0.05 was considered statistically significant. For 
the MTHFR 677C>T model, positive effect sizes correspond to percentage increase in 
methylation per MTHFR 677T allele. For the GRS model, positive effect sizes 
correspond to percentage increase in methylation per unit increase in GRS. We also 
took into account heterogeneity of the meta-analysis by I2 which was calculated using 
METAL per probe and excluded significant probes if I2<40. We also calculated the 
genomic inflation factor (λ) [21] to estimate the inflation in test statistics that may be 
caused by population structure or other unknown confounding factors. This λ was 
estimated for the distribution of p-values using the median method, which is defined as 
the ratio of the observed median of the test statistic distribution and the expected 
median 0.455 [21, 22]. 
Genomic Regions Enrichment of Annotations Tool (GREAT) was used for 
annotating CpGs for nearby genes, that assigns a basal regulatory region to extend up 
to 5 kb upstream and 1 kb downstream from its transcription start site and a maximum 
extension distance up to 1 Mb [23], as defined by UCSC [24]. Furthermore, strength of 
the instrument or allele score was calculated using the F-statistics, using the tool, 
mRnd [25]. We took into account cohort heterogeneity I2 and excluded significant 
probes if I2<40. 
Identifying cis- and trans-CpG effects 
We defined the CpGs as “cis” when the CpG was annotated within 1Mb upstream or 
downstream of the SNP. Trans-CpGs were defined as CpGs that were associated with 
the SNP, and were annotated >1Mb apart. We defined the CpGs in the GRS model the 
same way by accounting for the bp distance of the CpGs from each of the 18 SNPs. For 
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the significant trans-CpGs that were 1-5Mb apart from any of the 18 SNPs, we 
performed a conditional analysis adjusting for that SNP to investigate whether they 
were trans-CpGs associated with Hcy GRS or long range cis-CpGs driven by the nearby 
SNPs that were part of the GRS. In the conditional analysis, if the bonferroni corrected 
p-values were no longer significant, we considered those trans-CpGs as long-range cis-
CpGs. For the significant trans-CpGs that were >5Mb apart from any of the 18 SNPs, we 
looked up for their tested individual association with each of the 18 SNPs in our 
previous trans-CpG mapping analysis [12]. This is to see whether the association of 
these trans-CpGs was Hcy GRS driven or driven by a single SNP that was a part of GRS. 
In order to confirm these trans-CpG effects, we performed a similar conditional 
analysis by including the respective SNP as a covariate in the model. Both conditional 
analyses were performed on a subset of 3,786 samples from 6 cohorts, and the results 
were compared with the unconditional analysis in the same subset. 
H19/IGF locus 
Three Differentially Methylated Regions (DMRs) of IGF2/H19 locus at chromosome 11 
have been reported to be related with homocysteine [26, 27]. We identified seven 
CpGs on the 450k array that were underlying the three DMRs of this locus, for their 
association with MTHFR 677C>T variant or GRS. Bonferroni method was applied on 
these 7 CpGs to check for multiple testing. 
Enrichment of folate-associated CpGs 
We further focused our analysis on the 443 previously identified CPGs, of which 
methylation in cord blood of newborns were associated with maternal plasma folate 
levels [28]. We compared the p-values of these 443 CpGs from the MTHFR 677>T and 
the GRS results, and compared them to the p-values of 100 random CpGs with 1000 
permutations, to check for their significant enrichment, using the Fisher’s exact test. 
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RESULTS 
Population Characteristics 
The meta-analysis included 9,894 adults from 12 cohorts. Studies were population-
based, except for the Cohort on Diabetes and Atherosclerosis Maastricht, MARseille 
THrombosis Association study and the French-Canadian family study, where individuals 
were selected based on mildly increased diabetes mellitus type 2 and cardiovascular 
risk factors, cases of venous thrombosis and probands with venous thromboembolism, 
respectively. 
Meta-analysis of MTHFR 677C>T and GRS model 
The explained variance in Hcy by MTHFR 677C>T is 5.3% [4] and by GRS is 5.9% [5]. For 
a sample size of 9,894, the F-statistics of the additive MTHFR 677C>T and GRS was 554 
and 621, respectively. Meta-analysis of 456,694 probes identified 35 cis- [S3 Table] and 
1 trans- [S5 Table, Table 2] CpGs for the MTHFR model [Fig 1a] and 113 cis- [S4 Table] 
and 30 trans- [S6a, S7a and S8 Tables] CpGs for the GRS model [Fig 1b]. The λ was 1.01 
for the MTHFR 677C>T SNP and 0.92 for GRS [S1 Fig].  
Cis-CpGs  
Meta-analysis on 465,694 CpGs of the MTHFR 677C>T variant showed association with 
35 cis- CpGs on chromosome 1 with FDR<0.05 [Fig 1a, S3 Table]. These cis-CpGs 
showed a range from 2.4% increase to 1.7% decrease in methylation per MTHFR 677T 
allele. The nearest genes associated with this cis-region included MTHFR itself, 
AGTRAP, CLCN6, NPPA, NPPB, PLOD1, MFN2 and TNFRSF8. For the GRS model, we 
observed 113 cis-CpGs with FDR<0.05 [Fig 1b, S4 Table]. Out of the 113, 16 cis-CpGs 
showed overlap with the MTHFR 677C>T analysis, which involved a smaller region of 
238 Kb [Fig 1c]. 
Trans-CpGs 
For the MTHFR 677C>T model, meta-analysis of 465,694 CpGs identified 1 significant 
trans-CpG which was located on chromosome 6 [Fig 1a, S5 Table]. This trans-CpG 
(cg05411165) showed 1% decrease in methylation per MTHFR T allele. It was 
annotated near ZNF184 (25414 bp upstream) and HIST1H2BL (309398 bp downstream). 
For the GRS model, we observed 30 significant trans-CpGs [Fig 1b]. These trans-CpGs 
showed a range from 5.6% increase to 5.1% decrease in methylation per 0.1 unit 
increase in GRS. Of these 30 trans-CpGs, 23 were negatively associated with the GRS 
model. To assess overlap between two models, we evaluated association of the trans-
CpG of the MTHFR 677 C>T model within the GRS model. This trans-CpG (cg05411165) 
showed a 10% decrease in methylation in the GRS model but was not FDR significant 
(raw p-value  = 0.01). 
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Critical evaluation of the 30 trans-CpGs of GRS model demonstrated that 14 
trans-CpGs were located in a large region of 3,08 Mb length within chromosome 6. The 
GRS model consists of 18 SNPs including a SNP on chromosome 6.  The 14 trans CpG 
identified with the GRS model were at a distance between 1 and 5 Mb away from the 
Hcy-associated variant rs548987 of the SLC17A3 gene at chromosome 6 [S6a Table]. 
Conditional analysis: Chromosome 6 region near rs548987 
To investigate whether the 14 trans-CpGs on chromosome 6 near rs548987 were 
influenced by this variant, we performed conditional analysis on a subset of 3,786 
samples from 6 cohorts. After correction of the model for rs548987 as a covariate, 
none of the 14 trans-CpGs were significant at a bonferroni threshold of 3.57E-03 [S6b 
Table]. 
Conditional analysis: Influence of SNPs within the GRS model 
To further investigate the remaining 16 trans-CpGs from the 30, whether any of them 
were driven by a single variant, rather than the combined effect of the 18 
homocysteine-associated variants, we checked the trans-CpG mapping analysis of the 
single SNPs using the BIOS dataset [12]. We observed that 7 of the 16 remaining trans-
CpGs located >5 Mb from the Hcy-associated variants, were directly associated with 
either rs548987 SNP of SLC17A3 gene at chromosome 6, or rs154657 SNP of DPEP1 
gene at chromosome 16 [S7a Table]. After correction for these 7 trans-CpGs by 
including the respective SNP as a covariate in the model, none of the 7 trans-CpGs 
remained significant at a bonferroni threshold of 7.14E-03 [S7b Table]. After correction 
for cis-effects of Hcy-associated SNPs in the GRS model, we identified a remaining list 
of 9 Hcy-associated trans-CpGs, 4 of which had substantial heterogeneity I2 [S8 Table]. 
Overlapping trans-CpG between MTHFR and GRS models 
When doing a lookup in the MTHFR 677C>T model for the finally identified 5 trans-
CpGs, all of them showed similar direction of effect, but did not achieve genome-wide 
significance (Lowest raw p-value = 3.36E-03) [Table 2]. 
Trans-CpGs affecting Gene Expression 
We evaluated whether methylation levels of the observed trans-CpG from the MTHFR 
677C>T model and 5 trans-CpGs from the GRS model were associated with expression 
levels of the nearby genes, in the BIOS dataset [12]. None of the trans-CpGs was 
associated with mRNA expression differences of nearby genes. 
H19/IGF2 locus 
We specifically focused on the IGF2-H19 region for differential methylation, since 
methylation at this locus has repeatedly been linked to the homocysteine metabolism 
in a number of studies [29-31]. S4 Fig shows the results of the whole IGF2-H19 region, 
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and the 7 CpGs annotated to 3 DMRs of the IGF2/H19 gene that had previously been 
reported to be differentially methylated (DMR0, DMR2, H19-DMR3). Data from our 
450k arrays contained 2 CpGs at DMR0, 4 CpGs at DMR2 and 1 CpG at H19-DMR3. 
None of them showed an association with MTHFR 677C>T or GRS with a Bonferroni cut 
off of 7.14E-03 [S9 Table, S4 Fig]. 
Enrichment of previously found folate-associated CpGs 
Next we focused on a set of 443 CpGs that were identified to be differentially 
methylated in children at birth according to the folate levels in the mothers [28]. We 
found a highly significant enrichment for significant p-values in the MTHFR model in 
the 443 CpGs as compared to a random set of other CpGs (>3 times enrichment of 
significant p-values, enrichment p=0.0079). However, we did not find a significant 
enrichment for the GRS model. 
Global DNA methylation changes 
In addition to genome-wide DNA methylation changes we analyzed the effect of 
MTHFR 677C>T and GRS models on overall mean methylation levels. There was no 
significant association between the MTHFR 677C>T or GRS on global methylation 
overall or mean methylation of CpG islands, shores, shelves or non-coding regions 
[Table 3] [15]. 
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Figure 1a. Manhattan plot. Association between MTHFR 677C>T (rs1801133) and genome-
wide DNA methylation in 9,894 samples, with 35 cis-meQTLs at chromosome 1 (black/grey) 
and 1 trans-meQTL at chromosome 6 (green) with FDR<0.05. 
 
Figure 1b. Manhattan plot. Association between GRS of 18 Hcy-associated SNPs and 
genome-wide DNA methylation in 9,894 samples, with 113 cis-meQTLs (black/grey) and 30 
trans-meQTLs (green), at FDR<0.05. 
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Figure 1c. Regional manhattan plot (chr1: 11824095- 12184574) for MTHFR 677C>T and 
GRS – cis overlap. 35 (black) and 16 (green) cis-meQTLs of the MTHFR 677C>T and GRS 
model respectively, in 9,894 samples. The overlap involved a small region of 238 kb (green 
rectangular line). 
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DISCUSSION 
This is the first large-scale study to investigate the effect of Hcy-associated SNPs on 
genome-wide DNA methylation using the Illumina 450k arrays in 9,894 individuals. The 
results showed no widespread trans-effects of the MTHFR 677C>T SNP on DNA 
methylation, apart from 1 trans-CpG at chromosome 6. The GRS model showed 5 
trans-CpGs, after carefully examining the direct effects of individual SNPs with 
conditional analyses. 
In this current study, we used MTHFR 677C>T independently and the 
combined weighted GRS of the 18 Hcy-associated variants [5], to test whether mildly 
elevated Hcy concentrations induce DNA methylation changes in blood cells. Our goal 
was to investigate genetically defined elevated Hcy on genome-wide DNA methylation. 
The use of genetic variants is less sensitive to confounding and bias as compared to 
classical epidemiological studies [32].  
We calculated the strength of our exposure variables: MTHFR 677C>T and 
GRS using the F-statistics. For a strong exposure, the value of the F-statistics is 
expected to be greater than 10 [33]. With our large sample size (n=9,894) and 
proportion of variance explained being 5.3 to 5.9%, the F-statistics was 554 and 621 
respectively, indicating very high strength and enough power of our analysis. However, 
we did not observe widespread trans-effects despite of having strong additive MTHFR 
677C>T and GRS. 
We observed a single trans-CpG for the MTHFR 677C>T variant. This CpG is 
located near ZNF184 and HIST1H2BL. Both these genes are thought to play a role in 
transcriptional regulation. For the GRS, we found 30 trans-CpGs associated, 14 of which 
are spread over a region of 3,08 Mb at chromosome 6. These CpGs were annotated to 
genes that included ZNF322 and HIST1H2BJ, HLA-J, HLA-A, HLA-G, but also the proximal 
region of ZFP57 gene, which was previously identified as a folate-sensitive region in a 
genome-wide methylation study of 23 women [34]. However, when we performed a 
conditional analysis on these 14 CpGs in this region, by adjusting for the nearby variant 
rs548987 of the SLC17A3 gene, the effect sizes significantly attenuated and the 
nominal p-values were no more significant. The results indicate that this region was 
influenced by the rs548987 SNP of SLC17A3 gene and was not Hcy-associated. 
We finally observed 5 trans-CpGs associated to genetically defined Hcy using 
the GRS, after carefully examining the direct effects of individual SNPs with conditional 
analyses and discarding CpGs that showed substantial cohort heterogeneity I2. A total 
of 3 CpGs showed hypomethylation, one of which was annotated to the FKBP5 gene. 
FKBP5 encodes for the FK506-binding protein 51 (FKBP51) whose expression has 
recently been shown to decrease DNMT1 activity and thereby decreasing global 
methylation [35]. 
Furthermore, when looking at our methylation-expression results [12], none 
of the 5 trans-CpGs was associated with mRNA expression differences of nearby genes. 
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The possible explanation for these negative findings could be that these CpG sites 
might have an effect further away on trans-genes. Conversely, it has been shown that 
the methylation-expression correlation in cis are not best predicted using the CpG 
position alone, but by using specific chromatin marks [36]. Furthermore, it could also 
be that these correlations are specific to other tissues, but not in blood. 
We observed that the IGF2-H19 locus did not show association with 
methylation according to genetically defined elevated homocysteine. This is in contrast 
to the previous findings in mice, where tissue-specific changes in H19 DMR methylation 
were found in liver, brain and aorta, and increased expression of H19 was found in 
aorta [26, 27]. Similar to what we found, the H19-DMR3 between CBS deficient 
patients and controls also did not show a significant difference, in a previous study 
[29]. Our results show that this imprinted locus is not deregulated by long-term 
genetically defined mildly elevated homocysteine. However, previously it was reported 
that MTHFR 677C>T variant shows changes in DNA methylation in peripheral blood 
mononuclear cells, only through an interaction with folate [7]. Hence, further studies 
are needed to study the effect of MTHFR 677C>T variant in the presence of blood 
folate levels. 
We did not see widespread methylation changes associated to mildly 
elevated plasma Hcy concentrations. This result is not in line with a number of earlier 
reports, which have shown global methylation changes in association with the MTHFR 
677C>T variant and Hcy concentrations [3]. Previous two studies on this topic have 
shown contradictory results. There has been reports that showed a lower circulating 
global methylation level in individuals with the MTHFR 677TT genotype [6],[7]. 
However, there are also a few negative studies that showed no relation between the 
MTHFR 677TT genotype and global methylation levels [8-10]. All these studies had 
modest sample sizes (upto 300 individuals were studied), and measured methylation 
on a global level using the LINE-1 assay, which measures a repetitive sequence, of 
which the function is unknown. In contrast, we here studied a genome wide site-
specific analysis focused on functional regions of the genome [15]. We here show 
convincing evidence that there is no association between the MTHFR 677C>T or GRS on 
overall methylation levels, nor is there a relationship between methylation of CpG 
islands, shores, shelves or non-coding regions separately, which supports the previous 
null associations. 
Furthermore, in order to test for causal effect in a mendelian randomization 
study, an instrument, which is in our case MTHFR 677C>T or GRS, should satisfy the 3 
basic assumptions [37, 38]. One, the instrument should be associated with the 
exposure, which is in our case Hcy. Two, the instrument should not affect the outcome, 
which is in our case DNA methylation, except through the exposure Hcy. Three, the 
instrument should not be associated with any confounder of the exposure-outcome 
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association. Although assumptions one and two are satisfied in our case [5], the GRS 
model might  violate assumption three [37, 38]. 
The GRS model contains a few SNPs which are, in addition to the association 
with Hcy, also associated with other traits. For example, the variants near to HNF1A 
gene have been associated with a number of other traits [39-44]. This could also be the 
reason why the results of the MTHFR 677C>T and GRS models are quite different. 
Nevertheless, the MTHFR 677C>T variant explains most of the variation in Hcy, as 
compared to the other variants in the GRS model and is therefore a strong instrument 
to examine the effect of deregulation of the one-carbon metabolism on methylation. 
The relationship between MTHFR 677C>T and DNA methylation is modified by 
folate levels. Only in individuals with low folate status, the effect of the MTHFR 677TT 
genotype is seen [7]. Unfortunately, we were unable to study this interaction, since 
folate levels were not available in our study. Another prerequisite to be able to 
perform MR is that the relationship between Hcy and methylation is known. The 
relationship between Hcy and DNA methylation is only known in studies until now 
where methylation is measured at a global level. Therefore, the estimation of the 
causal effect could not be done. Unfortunately, we also did not have Hcy data available 
in all cohorts of this study, and therefore were unable to perform a full mendelian 
randomization study. We rather focused on the association of genetically defined 
elevated Hcy levels with DNA methylation. 
We did not find widespread differences in methylation related to genetically 
defined homocysteine levels. The association was not observed in global methylation 
levels nor in widespread CpGs including the previously known H19/IGF2 locus. There 
are a number of possible explanations for this finding. First, it is known that the 
relationship between MTHFR 677C>T and DNA methylation is modified by folate levels, 
as described above. The effect of MTHFR 677C>T is seen in individuals with low folate 
status [7], which could have masked possible relationships between the MHTFR variant 
and methylation. A second possible explanation for the relative low number of 
identified CpGs, is that we have studied the wrong tissue. Most methylation measures 
are conducted in blood leukocytes as this tissue is readily available. However, the 
causal effect of Hcy could be specific to other tissues like liver, heart and brain. 
Therefore, the possible effect of mildly elevated Hcy on such specific tissues cannot be 
excluded. Third, there is little variation in the one-carbon metabolism in the normal 
population. This metabolism is pivotal to cell survival and function and therefore tidily 
regulated. It could be that there is a correlation between homocysteine and more 
pronounced effects on methylation when homocysteine levels are more extreme. 
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CONCLUSIONS 
We observed 1 trans-CpG (nearest genes ZNF184 and HIST1H2BL) on chromosome 6 
associated with the MTHFR 677C>T variant. The GRS model showed 5 significant trans-
CpGs, which do not overlap with the MTHFR trans-CpG. In conclusion, our results do 
not show widespread statistically significant trans-effects of MTHFR and GRS models, 
and therefore do not support the hypothesis that genetically defined mildly elevated 
Hcy concentrations are associated with widespread methylation changes in leukocytes. 
More studies with measured Hcy concentrations are needed to confirm this. 
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ABSTRACT 
One-carbon metabolism provides a direct link between dietary folate/vitamin B12 
exposure, the activity of the enzyme methylenetetrahydrofolate reductase (MTHFR) 
and epigenetic regulation of the genome via DNA methylation. Previously, Friso et al. 
(2002) showed that the common c.677C>T polymorphism in MTHFR influences global 
DNA methylation status through a direct interaction with folate status and (indirectly) 
with homocysteine (tHcy) levels. To build on this observation, we investigated whether 
interaction between mildly elevated plasma tHcy and the c.677C>T polymorphism is 
associated with site-specific changes in DNA methylation in humans. We used data on 
plasma tHcy levels, c.677C>T polymorphism, and site-specific DNA methylation levels 
for a total of 915 Caucasian females and 335 males from the TwinsUK (n=610) and 
Rotterdam study (n=670). We carried out methylome-wide association analyses in each 
cohort to model the interaction between levels of tHcy and c.677C>T genotypes on 
DNA methylation beta values. Our meta-analysis identified a total of 13 probes 
significantly associated with [rs1801133 x tHcy] levels (FDR<0.05). The most significant 
associations were with a cluster of probes at the AGTRAP-MTHFR-NPPA/B gene locus 
on chromosome 1 (FDR=1.3E-04), with additional probes on chromosomes 2, 3, 4, 7, 
12, 16 and 19. Our top 2 hits on chromosome 1 were functionally associated with 
variability in expression of the TNFRSF8 gene/locus on this chromosome. This is the 
first study to provide a direct link between perturbations in one-carbon metabolism, 
through an interaction of tHcy and the activity of MTHFR enzyme on epigenetic 
regulation of the genome via DNA methylation. 
SIGNIFICANCE STATEMENT 
A previous study by Friso et al. (PNAS 2002) has shown that folate status is associated 
with reduced genomic DNA methylation through a direct interaction with the common 
c.677C>T polymorphism in the MTHFR gene. This has highlighted an important 
epigenetic mechanism that links dietary exposure to aberrant genome regulation. To 
build on this observation, we sought to provide a direct link between perturbations in 
folate mediated one-carbon metabolism and epigenetic regulation of the genome via 
site-specific DNA methylation through an interaction between total 
plasma homocysteine - an integrative biomarker of one-carbon metabolism - and the 
activity of MTHFR enzyme. We identify a number of sites/loci that are dynamically 
regulated by this interaction. 
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INTRODUCTION 
One-carbon metabolism (1-CM), comprising of the folate cycle and methionine 
pathway, plays fundamental roles in a variety of essential biochemical processes 
pertinent to healthy development and ageing, most notably provision of methyl 
residues (-CH3) to DNA, proteins and hormones [1]. Perturbations in 1-CM function can 
occur either through low dietary exposure to 1-carbon donors, the most studied of 
which is folate, malabsorption of the cofactor vitamin B12, and/or genetic variation 
within genes that play important functions in normal 1-CM, most notably the MTHFR 
c.677C>T (SNP rs1801133). The consequences of perturbed 1-CM, irrespective of the 
cause, include reduced remethylation of homocysteine (tHcy) into methionine leading 
to elevated plasma tHcy levels, as well as a reduction in cellular methylation potential 
[2]. 
Mild elevations in plasma tHcy has been unequivocally associated with 
increased risk of a myriad of adverse outcomes in observational studies, including 
cardiovascular and cerebrovascular disease, as well as increased rate of cognitive 
impairment and vascular dementia [3-5]. Whilst there is strong interest and growing 
evidence linking 1-CM function to aberrant DNA methylation [6-9], there are currently 
no systematic studies investigating the combined contribution of 1-CM function and 
the activity of the enzyme methylenetetrahydrofolate reductase (MTHFR) to epigenetic 
regulation of the genome via DNA methylation. Notably, a previous study by Friso et al. 
(2002) has shown that the common c.677C>T polymorphism in MTHFR influences 
global DNA methylation status through a direct interaction with folate status [10]. The 
Friso et al. study very elegantly showed that whilst global DNA methylation was 
independently associated with folate status, tHcy levels, and the MTHFR c.677C>T 
polymorphism, the association was principally driven by the interaction between the 
TT genotypes in MTHFR and low folate status culminating in a 50% reduction in the 
level of genomic DNA methylation in this group. Importantly, homozygosity for the 
c.677C>T polymorphism, especially in combination with low folate status, is also known 
to predispose to high plasma levels of fasting tHcy [11]. 
To build on these important observations and to systematically assess the 
impact of this interaction on site-specific DNA methylation patterns across the 
methylome in humans, we used total plasma Hcy (tHcy), MTHFR c.677C>T 
polymorphism, and site-specific DNA methylation levels from the Illumina 450k array of 
1,280 individuals from two cohorts; TwinsUK (n=610) and Rotterdam study (n=670) 
respectively. We decided to focus on tHcy, as opposed to folate status, for two 
reasons. First, inadequate data coverage for folate meant that we were able to carry 
out the desired MWAS analysis in only n=200 samples from TwinsUK; folate levels were 
not available in the RS samples with methylation data. Secondly, we were more 
interested in unravelling the relationship between MTHFR c.677C>T, site-specific DNA 
methylation and tHcy. As tHcy has been shown to be a powerful integrative biomarker 
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of 1-CM function in health and disease we focused our analyses on this biomarker. Our 
overarching hypothesis was that elevated tHcy, a direct proxy for low folate status, in 
subjects harbouring at least one copy of the rs1801133 T allele is significantly 
associated with decreased DNA methylation levels at specific sites in the methylome. 
To this end, we performed a meta-analysis of the two cohorts to identify differentially 
methylated positions (DMPs) associated with MTHFR c.677C>T x tHcy interaction.  
Through this study we examined an important paradigm and gained novel mechanistic 
insight into the epigenetic consequences of this gene-nutrient interaction.              
MATERIAL AND METHODS 
Study populations 
A total of 610 female twins from the TwinsUK registry (Table 1) and 670 participants 
from the Rotterdam study cohort with data on age, sex, height/weight used to 
calculate BMI, total plasma tHcy concentrations, smoking status, cell counts and site-
specific DNA methylation based on the 450k array were included in the study. All 
participants were of North European descent and between 18 and 87 years old. In the 
TwinsUK cohort, we excluded subjects from the study that were on (i) any long-term 
medication(s) and/or with self-reported history of chronic diseases including 
hypertension or on any B-vitamin dietary supplements in the three months before 
participation. The Rotterdam cohort consisted of a randomly selected sub-sample of 
the Rotterdam study cohort (supplementary notes). We also excluded samples in both 
cohorts that showed evidence of being potential outliers or showing residual 
methylation array batch effects using iterative robust regression methods (see 
Methods). 
This study was conducted according to the guidelines laid down in the 
Declaration of Helsinki and all procedures involving human subjects/patients were 
approved by the St. Thomas’ Hospital Research Ethics Committee (EC04/015 TwinsUK) 
and Institutional review board (Medical Ethics Committee) of the Erasmus Medical 
Centre. Written informed consent was obtained from all subjects. 
GENOME-WIDE DNA METHYLATION ANALYSIS 
Methylation array data preparation and quality control 
Genomic DNA was isolated from whole blood using the NORGEN DNA Purification Kit in 
TwinsUK (Norger Biotek Corporation) according to the manufacturer’s protocol or by 
standardized salting out methods in Rotterdam. Approximately 700ng of each DNA 
sample was bisulphite converted using the EZ-96 DNA Methylation Kit (Zymo Research) 
according to the supplier’s protocol. Bisulphite-treated DNA was then quantified using 
the NanoDrop ND-100 (NanoDrop Technologies). 
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Methylation profiling was performed on the bisulphite-converted DNA 
samples using the Illumina Infinium HumanMethylation450 BeadChip. Briefly, 5 µl of 
each bisulphite-converted DNA sample was processed following the Illumina protocol. 
The HumanMethylation450 BeadChip targets 485,764 methylation sites across the 
genome and interrogates the methylation state of each site using two assay designs: 
the Infinium I assay which has two bead types per CpG site, one each for the 
methylated and unmethylated states; and the Infinium II assay which has one bead 
type and determines methylation state with a single base extension step. The 
BeadChips were scanned with the Illumina HiScan SQ scanner and the raw data was 
imported to the GenomeStudio v.2010.3 software with the methylation module 1.8.2 
for extraction of the image intensities. 
Signal intensities for the methylated and un-methylated states were then 
quantile normalized for each probe type separately and beta values were calculated 
using R. The methylation state of each site is represented by a beta value (β), which is 
the ratio of the intensity of the methylated bead type (M) to the combined locus 
intensity (M+U+α) and ranges from 0 to 1. Data normalization [12] was performed on 
raw β values using Bioconductor packages implemented in R [13]. 
MTHFR 677C>T polymorphism 
Genotypes for the MTHFR c.677C>T single nucleotide polymorphism (SNP rs1801133) 
were extracted from existing whole-genome Illumina/HumanHap array data from each 
cohort and utilised for the study analyses. 
Exploratory Analysis and Model Fitting 
Following Friso et al., we first used genomic methylation summary data from both the 
TwinsUK and Rotterdam Study cohorts to assess the relationship between genome-
wide methylation and plasma tHcy levels and to control for technical variation in order 
to select a best-fit model to implement as part of the methylome wide association 
study. To do this, we first calculated the median genomic methylation level for each 
sample based upon the Illumina 450k array data that passed quality control. Using 
univariate and multiple regression analyses, median genomic methylation levels were 
regressed upon technical covariates to control for plate layout and batch effects, 
measured blood cell composition and key demographic variables such as age, sex, 
smoking status and body mass index.  
Removal of outliers 
Samples with different collection dates between methylation and tHcy data and 
samples that showed evidence of residual methylation array batch effects were 
identified. Only samples with tHcy values within the 95% of the distribution (between 
5-30μmol/l) were retained and included in the analysis. Additional sample outliers 
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were identified and removed (TwinsUK n=40 and Rotterdam n= 27) by regressing 
genomic median methylation levels upon total tHcy plasma using iterative robust 
regression methods implemented in Stata (rreg procedure) and R (rlm function). 
STATISTICAL ANALYSIS 
Methylome-wide association study (MWAS) 
DNA methylation at each Illumina probe was assessed for association with tHcy 
stratified by the MTHFR c.677C>T polymorphism (with rs1801133 genotypes coded 0 
for CC and 1 for CT/TT). In TwinsUK, a mixed linear regression model was implemented 
in R using the LME4 package with DNA methylation at each probe regressed upon age, 
batch, cell count data and position on the BeadChip as fixed effects, and zygosity and 
family identifier included as random effects for the Null model.  A similar model was 
implemented in Rotterdam Study, but batch effects were used as random effects. The 
Full model was identical to the Null but included two additional variables of interest to 
model the interaction between tHcy and the rs1801133 genotype. The interaction 
model for each methylation probe was parameterised to include two nested 
interaction terms with the first parameter (tHcy0) used to estimate the regression 
coefficient between probe methylation and tHcy for individuals with the rs1801133 
genotype CC and a second parameter (tHcy1) to model the strength of association 
between methylation and tHcy for individuals with the CT/TT genotypes. Both 
regression lines were conservatively assumed to share the same intercept term for the 
MWAS. The potential interaction at each probe was then assessed by comparison of 
the full- and nested sub-model using a likelihood ratio (LLR) test. The model p value 
generated to assess potential differential methylation at each probe was calculated 
using the likelihood ratio test statistic, which is asymptotically Chi-squared with k 
degrees of freedom, where k is the number of model parameters estimated. For this 
test, the p-value of the effect of tHcy stratified by c.677C>T was calculated from the 
Chi-square distribution with 2 degrees of freedom. Multiple test correction was 
performed using the qvalue package in R. CpG probes with a false discovery rate (FDR) 
< 5% were considered significant.  
Meta-analysis of MWAS results 
All MWAS probe p-values from each cohort were meta-analysed using Fisher’s 
combined probability test. Only those probes in which the direction of effect for the 
probe methylation response to tHcy concentration was consistent between the two 
cohorts were reported in the final meta-analysis (referred to here as concordant 
probes). This gave rise to a total of 182,227 concordant probes with potentially 
consistent results. All probes declared to be differentially methylated were also 
explicitly tested for a significant interaction term in order to ensure results were driven 
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by the interaction between tHcy and the MTHFR polymorphism that compromises 
folate metabolism and not just by tHcy levels or the genotype in isolation. To obtain a 
p-value for the interaction between c.677C>T and tHcy, a Wald test was used to assess 
the difference in slope for the two regression lines fitted to the nested interaction 
model (i.e. as presented in a scatterplot of methylation vs tHcy with two fitted 
regression lines). Equivalently, a cross classification model was used, which includes 
one main effect for c.677C>T, a main effect for tHcy and an interaction term between 
the two main effects (c.677C>T x tHcy). A multiple test correction was performed as 
described above. Probes that were significant with a false discovery rate of 5% or less, 
nominally significant and showing similar direction of effect in both cohorts were 
declared to be significant in the meta-analysis. 
In-silico functional annotation of MWAS results 
To characterise the genomic locations and properties of each region encompassing the 
most significant probes from the MWAS, the locations and relationship to specific 
genomic features were annotated using the Illumina Infinium HumanMethylation450 
BeadChip manifest file and Genomic Regions Enrichment of Annotations Tool 
(great.stanford.edu). Finally, we looked at the association between any significant 
probes from the meta-analysis and differential gene expression using data from the 
BIOS QTL browser [14, 15]. 
Differentially Methylated Region Analysis 
Where statistically significant probes from the meta-analysis were located in close 
proximity to one another other, the region was further analysed. For each of the top 
probes, the regression beta coefficients were stratified by genotype and plotted. A 
lowess fitted trend line was overlaid to assess the region as a differentially methylated 
site in response to disrupted folate and methionine metabolism. 
RESULTS 
A total of 1,280 Caucasian individuals from 2 independent cohorts – TwinsUK and 
Rotterdam study – with existing data on plasma tHcy, genotype data on the MTHFR 
c.677C>T polymorphism, and site-specific DNA methylation levels from the Illumina 
450k array were included in the present study. Briefly, the TwinsUK cohort (n=610) was 
composed of generally healthy women with age ranging from 26-81 years (mean age= 
58). The Rotterdam cohort (n=670) was a population-based sample of men and women 
(54%) with a mean age of 60 years. Table 1 provides demographic, biochemical, and 
descriptive summaries for each cohort.  
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Table 1. Study population characteristics for TwinsUK and Rotterdam Study samples. 
Values are presented as medians and standard deviations (SD). 
  TwinsUK Rotterdam 
N 610 670 
Age (years) 58.2 (9.4) 59.8 (8.1) 
BMI (kg/m2) 25.7 (4.8) 27.4 (4.8) 
Smoking, % Never 13.7 27.3 
Sex, % female 100 54 
Methylation Beta 0.68 (0.02) 0.52 (0.02) 
Homocysteine (µmol/L) 12.3 (3.4) 12.2 (3.6) 
CELL COUNTS 
  
Granulocytes 4.00 (1.4) 4.2 (1.5) 
Lymphocytes 1.8 (0.6) 2.4 (0.7) 
Monocytes 0.4 (0.2) 0.4 (0.4) 
Neutrophils 3.8 (1.4) - 
Exploratory Analysis and Model Fitting results 
We carried out mixed linear and robust iterative regression analyses to test for the 
interaction between total genomic methylation and tHcy stratified by MTHFR c.677C>T 
genotype in both TwinsUK and Rotterdam cohort. Our analysis showed that the 
observed association between total genomic methylation and tHcy is primarily driven 
by individuals with high tHcy values and carrying one or more copies of the MTHFR 
c.677C>T allele. Whilst the interaction term is only marginally significant (P=0.08, 
adjusted for age, smoking status and technical covariates), the result is consistent with 
Friso et al. (PNAS 2002) and the over-arching hypothesis for this study. Figure 1A 
illustrates that the negative relationship between genomic methylation and tHcy is only 
significant for individuals with the CT/TT genotype (p= 0.02) and not for those with the 
CC genotype (p=0.93) in individuals from TwinsUK. In the Rotterdam cohort, we failed 
to replicate this finding and the results indicate a null relationship between genomic 
methylation and tHcy levels. 
Our exploratory analyses identified estimated cell count and technical factors 
such as batch effect and position on the BeadChip to be strongly associated with total 
genomic DNA methylation. These were all included as nuisance covariates in the final 
model used for the methylome-wide association study (MWAS) to control for technical 
variation. Of the phenotypic variables, age had the largest influence on genomic DNA 
methylation.  
The final model selected to take forward for the MWAS included tHcy levels 
stratified by MTHFR rs1801133 (coded CC vs CT/TT), observed blood cell counts, age, 
BMI, batch effect and BeadChip position as fixed effects and family identifier and 
zygosity as random effects (TwinsUK) or alternatively, gender as fixed effect and 
array/bead chip positions as random effects (Rotterdam Study). 
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Cohort-specific MWAS and meta-analyses 
We carried out individual cohort MWAS followed by a meta-analysis of the results 
generated for a total of 1,280 individuals of European ancestry (Table 2). The analysis 
of the TwinsUK data identified a total of 127 CpGs associated with [tHcy x c.677C>T] as 
the predictor (FDR≤ 5%). Analysis of the Rotterdam study alone included no significant 
probes at FDR threshold ≤ 5% for these data. Figures 2 presents the QQ and Manhattan 
plots for the TwinsUK and Rotterdam study methylome scan. Meta-analysis identified 
13 significant hits (Table 2) with consistent direction of effects between both cohorts. 
These included sites on chromosome 1 (meta-analysis p=3.7E-09, NPPA), chromosome 
2 (p=6.2E-07, DYNC2LI1/PLEKHH2), chromosome 3 (p=7.5E-06, VEPH1/SHOX2), 
chromosome 4 (p=2.3E-06, PROM1), chromosome 7 (p=9.5E-07, GLI3/C7orf25), 
chromosome 12 (p=4.8E-06, ALG10), and chromosome 19 (p=5.4E-06, HIF3A).  
Female-only MWAS and meta-analysis 
When meta-analysis was restricted to females only for both cohorts – based on the 
rational that the TwinsUK cohort was primarily composed of female subjects – the total 
number of significant probes dropped from 13 to 7 but otherwise remained the same 
(chromosome 1: cg06770735, cg06193043; chromosome 3: cg04897900; chromosome 
4: cg17858192; chromosome 12: cg10588893; chromosome 17: cg12432807 and 
chromosome 19: cg00192046). This is consistent with our assumption that the 
epigenetic signals at these loci do not differ between women and men, with the 
reduced number of observed significant probes due to the reduced power for the 
female-only analysis (n=960).   
Chromosome 1 Analysis 
Since all 4 significant probes on chromosome 1 (Figure 3A & B) were within 119Kb of 
one another, with two probes 148bp apart (cg06193043 and cg24844545), the extent 
to which the rest of the surrounding probes showed coordinated changes in DNA 
methylation in response to increasing tHcy were investigated. For the probes within a 
50kb region surrounding the index probe cg24844545 (indicated by a dashed line in the 
figure), there appears to be correlated responses to tHcy, with the direction of the 
response dependent on genotype at rs1801133 (see Figure 3C) and the response 
consistent between the two cohorts. The correlated response at this locus is likely to 
indicate a [tHcy x c.C677T] dependent, differentially methylated region.  
In-silico functional annotation of MWAS results 
Finally, we used the BIOS QTL [14] browser to gain functional insight into the 13 
significant probes from the meta-analysis and assess their putative impact on 
differential gene expression. Of the 13 sites, our top 2 hits on chromosome 1 
(cg06193043 and cg24844545) were shown to be functionally associated with 
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variability in expression of the TNFRSF8 gene/locus on this chromosome although no 
obvious link can be drawn between aberrant methylation at these sites, differential 
gene expression of the TNFRSF8 gene/locus and 1-CM function. None of the other sites 
were shown to be associated with cis or trans differential gene expression. 
 
Figure 1.  Graphical representation of the genomic methylation model. Median genomic 
methylation levels were regressed upon homocysteine (tHcy) stratified by MTHFR c.677C>T 
genotype, illustrating a differential impact of tHcy on genomic methylation levels by 
genotype in (A) TwinsUK and (B) Rotterdam. (A) TwinsUK data shows a significant negative 
relationship between median genomic methylation and serum homocysteine for individuals 
with rs1801133 genotypes CT/TT (p=0.02), but no relationship for individuals carrying the 
CC genotype (p=0.93; interaction or difference between the 2 slopes, p = 0.08). (B) 
Rotterdam data shows no significant relationship between median genomic methylation 
and serum homocysteine for all individuals, regardless of genotype. 
 
 
Interaction p = 0.6 Interaction p = 0.08 
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Figure 2. QQ and Manhattan plots for the (A) TwinsUK, (B) Rotterdam Study full cohort 
MWASs, (C) and Meta-analysis. 
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Figure 3. Chromosome 1 methylation probe association with tHcy is contingent upon 
MTHFR genotype: (A) TwinsUK and (B) Rotterdam Study. This figure illustrates the 
differential methylation for the probes on chromosome 1 with probe methylation plotted 
on the Y-axis and tHcy plotted on the X-axis with individuals distinguished by whether they 
carry a CC MTHFR c.C677T genotype (green) or a CT/TT genotype (red). All four 
chromosome 1 probes show an interaction between tHcy and SNP in both TwinsUK and 
Rotterdam Study. The strength of relationship between probe methylation and tHcy 
significantly differs depending upon the MTHFR genotype carried. (C) Correlated response 
to [tHcy x c.C677T] for the probes within a 50kb region surrounding the index probe 
cg24844545 (indicated by a dashed line in the figure). 
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DISCUSSION 
There is growing evidence suggesting that perturbations in 1-carbon metabolism (1-
CM), in part due to variable dietary exposure or genetic variation - for example the 
common MTHFR c.677C>T polymorphism within the MTHFR gene - can affect patterns 
of DNA methylation and affect the regulation of gene expression throughout the 
course of life[2, 16]. A large number of epidemiological studies, including observational 
and experimental, have now shown associations between either low/normal levels of 
folate/vitamin B12 or  mild elevations in plasma tHcy – an integrative marker and 
indicator of perturbed 1-CM - and increased risk of a range of vascular and 
neurodegenerative diseases[4, 17, 18]. Interestingly, a previous study by Friso et al. 
(2002) was the first to highlight that the relationship between folate status and global 
DNA methylation is strongly modulated by the MTHFR c.677C>T polymorphism and the 
activity of the MTHFR enzyme. However, to date there are no studies that have sought 
to identify differentially methylated sites in the human genome that are dynamically 
affected by the interaction between plasma tHcy and the MTHFR c.677C>T 
polymorphism.  
To this end, we carried out a methylome-wide association study in two large, 
independent cohorts followed by a meta-analysis of the results, to identify specific 
sites across the methylome that are differentially methylated as a consequence of the 
interaction between MTHFR c.677C>T polymorphism and mild tHcy elevation.  
Methylome-wide association studies of total homocysteine 
Our initial exploratory analysis in TwinsUK underlined a significant negative 
relationship between DNA methylation and tHcy levels only with CT/TT genotype, but 
not CC. This is in accordance with previous studies that have investigated the 
interrelationships between concentrations of tHcy, the MTHFR c.677C>T polymorphism 
and global DNA methylation [19-21]. It’s important to note that contrary to approach 
used by Friso et al.’s and subsequent studies [22, 23], our study did not explicitly use 
folate status and instead focused on tHcy as the principle exposure variable of interest. 
As explained previously in the introduction, the available TwinsUK data on folate was 
measured by a clinical laboratory that used a cut-off value of >20 ng/ml, all values 
above 20 ng/ml were assigned >20 ng/ml making nearly a third of the data unreliable 
and therefore not amenable to quantitative association analysis. We also had 
substantially fewer subjects with both folate and methylation data; N=200 as opposed 
to N= 610 with complete tHcy and methylation data.  More importantly, however, 
although motivated by the findings from the Friso et al. study, we were more 
interested in unravelling the consequences of the interaction between aberrant 1-CM 
function, MTHFR c.677C>T and site-specific DNA methylation. Levels of total Hcy have 
been shown to be a powerful integrative biomarker of 1-CM function in health and 
disease and would allow a more holistic approach.  
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Our results show that the previous observations by Friso et al. (2002) on 
global DNA methylation are supported by our meta-analysis of 2 independent MWAS 
which identified a total of 13 differentially methylated positions (DMPs) on 
chromosomes 1, 2, 3, 4, 7, 12 and 19 significantly associated with [c677C>T x tHcy] 
levels. The most significant associations were with a cluster of probes at the AGTRAP-
MTHFR-NPPA/B gene cluster on chromosome 1. In-silico analysis showed that 
differential methylation at this region is functionally associated with variability in 
expression of the TNF Receptor Superfamily Member 8 (TNFRSF8) gene[14].   
Two recent MWASs by Mandaviya et al. (2017) have sought to identify 
associations between (1) tHcy; and (2) the MTHFR C677T variant and site-specific 
leukocyte DNA methylation levels [24, 25]. They identified 3 DMPs at or near genes 
SLC27A1, AJUBA and KCNMA1 on chromosome 19, 14 and 10, respectively – as well as 
68 differentially methylated regions (DMR) – associated with tHcy levels[24]. They 
further identified a DMR pertaining to the MTHFR locus in cis (≤ 1Mb upstream or 
downstream) and a single trans-CpG (> 1Mb upstream or downstream) associated with 
the MTHFR C677T variant [25]. Notably, the DMR at the MTHFR locus, identified by 
Mandaviya et al. to be associated with the MTHFR c.677C>T variant, overlaps with our 
top hits in the present study that include 4 CpGs at the AGTRAP-MTHFR-NPPA/B gene 
cluster on chromosome 1.  So, could our top hit actually be a genetically-driven finding 
as opposed to a true consequence of the interaction between MTHFR c677C>T and 
tHcy given (1) the inherent lack of power associated with finding true interactions; and 
(2) that the MTHFR DMR was not associated with tHcy? The data provides strong 
evidence for an interaction between rs1801133 genotype and serum homocysteine 
levels that impacts upon site-specific methylation levels and as such, we believe that 
our results represent a more realistic biological consequence of the interaction 
between 1-CM and genetic variation. It is also important to note that a true interaction 
between two or more exposure variables does not preclude main effect associations 
although a true biological interaction can manifest in the absence of independent main 
effects. So, it is very likely that both the MTHFR c.677C>T variant and the interaction 
[c.677C>T x tHcy] are associated with the DMR at the MTHFR locus.  Furthermore, we 
would like to highlight that none of the other findings by Mandaviya et al. overlap with 
any of the remaining 9 loci identified at other chromosomes in the current study, 
emphasising the importance of appropriately modelling and identifying site-specific 
DNA methylation outcomes that are dynamically responsive to this interaction. 
DMPs in AGTRAP-MTHFR-NPPA/B gene cluster on chromosome 1 and cardiovascular 
function 
Our top hits pertain to a cluster of probes at the AGTRAP-MTHFR-NPPA/B gene locus 
on chromosome 1. The NPPA gene encodes for a protein from the natriuretic peptide 
family, which is involved in the control of extracellular fluid volume and electrolyte 
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homeostasis. Similarly, the protein NPPB‘s biological functions include natriuresis, 
diuresis, as well as the inhibition of renin and aldosterone secretion thus potentially 
playing a role in regulating blood pressure and cardiovascular function. Also, the 
adjacent gene AGTRAP encodes for the angiotensin II receptor associated protein, 
which is postulated to be involved in the regulation of blood pressure. Recent studies 
suggest that AGTRAP, or ATRAP, which is expressed in heart tissue plays a regulatory 
role of the cardiac SERCA2a uptake of calcium, and that it is associated with long-term 
inhibition of ventricular hypertrophy when hypomethylated [26, 27].  
We used data from the BIOS QTL browser to assess whether differential 
methylation at the AGTRAP-MTHFR-NPPA/B gene cluster was functionally associated 
with variability in expression of any genes in cis of this gene cluster (±500kb)[14]. Our 
in-silico look up identified the expression of the TNFRSF8 gene on chromosome 1 to be 
significantly associated with differential methylation of the probe cg06193043 probe at 
this gene cluster (P= 1.5E-04). TNFRSF8 encodes a protein of the tumor necrosis factor-
receptor superfamily (CD30) that mediates the signal transduction pathway leading to 
NF-kB activation and so is a positive regulator of apoptosis. Expression of CD30 has 
been previously associated with autoimmune function [28] and cancer therapy [29] but 
no over-obvious link can be drawn to 1-CM function.  
DMPs in HIF3A are associated with aspects of metabolic syndrome 
The CpG sites at loci on chromosomes 2 (PLEKHH2), 7 (SH2B2) and 19 (HIF3A) were 
shown to be significantly associated with [c.677C>T x tHcy] levels in both cohorts and 
thought to play roles in aspects of metabolic syndrome. HIF3A is thought to act as a 
transcriptional regulator in adaptive response to low oxygen tension and plays a role in 
glucose, lipid and amino acid metabolism as well as adipocyte differentiation [30, 31]. 
Interestingly, hyper-methylation at the HIF3A locus has been previously positively 
associated with variability in BMI [32], adipose tissue dysfunction [33], and risk of 
gestational diabetes mellitus[34]. There have also been speculations about the role of 
genetic variants in the PLEKHH2 region as a potential risk factor for diabetic 
neuropathy [35].  To date, no human studies have been carried out to investigate site-
specific DNA methylation patterns related to 1-CM that may influence risk of obesity 
and metabolic syndrome. There is compelling evidence in mouse models to suggest a 
role of 1-CM in mediating the risk of metabolic syndrome through altered DNA 
methylation and how the provision of methyl donor supplements can avert 
transgenerational effects of obesity [36].  There is however robust observational data 
both supporting or refuting an observational link between 1-CM function – through 
studies on tHcy, folate, or vitamin B12 as well as genetic studies, based on either the 
MTHFR polymorphism alone [37] or a cassette of genetic markers [38] - and aberrant 
metabolic function [39, 40], obesity, or type 2 diabetes [41, 42]. Results from the 
current study add further evidence to this literature and motivate future functional 
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work on these identified loci which may allow more robust conclusions to be drawn 
with regard to the role of 1-CM function in metabolic disease aetiology [34, 43, 44]. 
DMPs in genes associated with cellular structure/function and cancer 
Finally, we also identified significant associations with CpG sites on chromosome 2 
(located within/near genes DYNC2LI1, NCAPH, NEURL3) and 4 (PROM1) which are 
thought to play putative roles in cellular structure and function. NCAPH has been found 
to be highly expressed in colon cancerous (CC) tissue and harbours a number of 
mutations in CC patients, serving as a prime therapeutic target for CC [45].  Similarly, 
PROM1 (CD133) is associated with recurrent glioma [46] and melanoma [47]. Due to 
their involvement in cellular differentiation and transport, we can hypothesise that 
alterations in the expression of these genes due to epigenetic modifications caused by 
1-CM imbalance may lead to cell metabolism imbalances, potentially leading to a 
number of complications, including cellular atrophy, neurodegeneration and different 
types of cancers. 
Strengths and limitation 
Our study has specific strengths and limitations which warrant further discussion. Our 
study is the first to systematically investigate site-specific DNA methylation as a 
consequence of interaction between the MTHFR c.677C>T polymorphism and tHcy. 
Furthermore, the utility of two independent cohorts followed by a meta-analysis 
reduces potential biases, the chance of false positive findings whilst possibly increasing 
our power to detect loci of significant biological effect. Finally, utilising an established 
MWAS analytical approach incorporating and correcting for technical and biological 
covariates into our analysis provides reassurance that our results represent genuine 
findings.  
A potential limitation of our study is the unbalanced constituency of gender 
among our cohorts. For historical reasons, the TwinsUK cohort is predominantly made 
up of female twins whereas the Rotterdam cohort included a balanced number of 
males and females. Thus, inherent male/female differences in either the exposure 
(tHcy) and/or outcome (site-specific DNA methylation levels) may distort the molecular 
consequences to the discordant tHcy levels in males and females. Such gender 
differences have been identified in tHcy levels previously.  Total Hcy concentrations 
have been found to be significantly higher in men than in women in both the 
Framingham Offspring Cohort study and the Hordaland Homocysteine study which 
demonstrated ~11% higher tHcy in men than women[48, 49]. In our study, we also 
note a significant difference in tHcy levels between males and females in the 
Rotterdam cohort matching those reported in the HHS (~11%). To overcome this 
limitation, we included sex as a covariate in the Rotterdam MWAS and notably we 
identified some of the same significant loci in both the female-only meta-analysis and 
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the full cohort (male + females) meta-analysis. Another potential limitation is that DNA 
was extracted from whole blood and so the site-specific methylation values represent 
those from across various types of leukocytes. To minimise the influence of cell 
composition we adjusted our analysis for either measured or estimated leukocytes 
composition but there is still a possibility that observed differential methylation was 
confounded by either tHcy or ageing induced shifts in leukocyte distribution. Finally, 
although we used the latest technology for assessing DNA methylation patterns from 
across the human genome, the450 BeadChip array still only targets ~2% of all CpGs in 
the genome. Thus, although not strictly a shortcoming of our study, it is quite likely 
that we would have missed a number of relevant genomic regions. 
CONCLUSIONS 
This study has allowed us to test and further examine an important paradigm that 
there are associations between DNA methylation patterns and [c.677C>T x tHcy] at 
specific sites in the epigenome, and to gain novel potential mechanistic insight into the 
epigenetic consequences of this gene by nutrient/metabolite interaction. Indeed, 
identifying [c.677C>T x tHcy]-sensitive DMPs, and their effect on nearby genes has 
provided a step forward in (1) identifying loci that can be used as candidate genes or 
regions in specific diseases, and (2) generating opportunities for better/well-informed 
study design, driving us towards more targeted preventative public health approach.   
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ABSTRACT 
Background: Folate and vitamin B12 are essential micronutrients involved in the 
donation of methyl groups in cellular metabolism. Folate and vitamin B12 intake have 
been shown to increase DNA methylation in mostly animal studies. However, 
associations between intake of these nutrients and genome-wide DNA methylation 
levels have not been studied comprehensively in humans. 
Objective: To assess whether folate or vitamin B12 intake are asssociated with 
genome-wide changes in methylation in leukocytes. 
Design: A large-scale epigenome-wide association study of folate and vitamin B12 
intake was performed on DNA from 5,841 participants from 10 cohorts using Illumina 
450k arrays. Folate and vitamin B12 intakes were calculated from food frequency 
questionaires. Continuous and categorical (low vs. high intake) linear regression mixed 
models were applied per cohort, controlling for confounders. Meta-analysis was 
performed to identify significant differentially methylated positions (DMPs) and regions 
(DMRs). Pathway analysis was done on the DMR annotated genes using the WEB-based 
GEne SeT AnaLysis Toolkit. 
Results: Folate intake was associated with 6 novel DMPs annotated to FAM64A, 
WRAP73, FRMD8, CUX1 and LCN8 genes, which have a role in cellular processes 
including centrosome localization, cell proliferation and tumorigenesis. Regional 
analysis showed 74 folate associated DMRs annotated to 117 genes. The most 
significant DMR was a 400 bp spanning region annotated to LGALS3BP that is 
implicated in immune response and tumorigenesis. Signaling pathways regulating 
pluripotency of stem cells are overrepresented among the folate associated DMR 
genes. Vitamin B12 intake was associated with 29 DMRs annotated to 48 genes, of 
which the most significant was a 1,100 bp spanning region annotated to CABYR, which 
is involved in lung and hepatocellular cancers. Vitamin B12 intake was not associated 
with  DMPs. 
Conclusions: We identified several novel differentially methylated loci that could be 
mechanistic indicators of low folate and vitamin B12 intake.  
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INTRODUCTION 
Folate and vitamin B12 are essential micronutrients of the one-carbon pathways that 
are involved in the donation of methyl groups to the DNA, RNA and proteins [1]. Folate 
is a methyl-donor itself, where its active form, 5-methyltetrahydrofolate, donates its 
methyl group to the re-methylation of homocysteine to methionine. Vitamin B12 is a 
cofactor in this reaction. 
Folate and vitamin B12 status has been connected to diverse diseases. Low 
levels of folate and vitamin B12 during pregnancy are independently associated with 
the risk of neural tube defects in the child [2-4]. IN addition, low levels of folate and/or 
vitamin B12 are associated with risk for a wide range of diseases, such as 
cardiovascular diseases and osteoporosis [5-8]. Severe vitamin B12 and folate 
deficiencies result in megaloblastic anemia, which for vitamin B12 deficiency is 
associated with severe neurological abnormalities [9]. Diagnosis of vitamin B12 
deficiency is hampered by the lack of diagnostic accuracy of available biomarkers. DNA 
methylation is a possible mechanism underlying the previously identified relationships 
between folate or vitamin B12 deficiency and disease risk, and specific alterations in 
methylation patterns could serve as future biomarkers for these nutrient related 
disease risks. Therefore, it is important to assess the association of these nutrients with 
DNA methylation. 
The relationship between folate and/or vitamin B12 intake and DNA 
methylation has been investigated mostly in studies examining individuals with a 
particular disease, which might confound the observed associations [10-12]. A limited 
number of human studies were conducted in disease-free individuals [13-17]. 
Importantly, in all previous studies, global DNA methylation levels were assessed either 
as total 5-methyl cytosine content, or LINE-1 or Alu repeat methylation as a proxy for 
global methylation status in blood leukocytes. The results from these studies were 
inconsistent [13-17]. The relation between maternal folate intake and fetal DNA 
methylation was investigated in a few studies showing that maternal intake was 
associated with changes in DNA methylation [18-20]. The previous studies related to 
folate and vitamin B12 and DNA methylation have been limited with respect to 
outcome (e.g. global methylation levels only), sample size and participants (e.g. 
maternal-fetal exposures), and to date there are no large-scale epigenome-wide 
association studies (EWASs) in adults examining the relationship between B-vitamin 
intake and DNA methylation. 
In this study, we undertook a large-scale EWAS of folate and vitamin B12 
intake, analysing the association with methylation at up to 485,512 CpGs assessed in 
whole blood measured in up to 5,841 individuals across ten cohorts from Europe and 
North America. Since folate and vitamin B12 are important in the transfer of methyl 
groups to DNA, we hypothesize that low intake of folate or vitamin B12 is associated 
with genome-wide DNA hypomethylation in the normal population.  
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MATERIALS AND METHODS 
Study populations 
Data from 10 cohorts with a total of 5,520 individuals of European ancestry and 321 
African American individuals were included in this meta-analysis. Written informed 
consent was given by all participants for genetic research. Descriptions of each cohort 
are provided in Text S1. For all participating studies, individuals with prevalent cancer 
were excluded from analyses due to potential differences in dietary patterns in 
response to their disease [21, 22] and different methylation patterns [23, 24]. 
DNA methylation assessment 
Genomic methylation profiling was performed on whole blood in 10 cohorts using the 
Infinium Illumina HumanMethylation 450k BeadChip arrays (Illumina Inc., San Diego, 
USA) according to the manufacturer’s protocol. The Genetics of Lipid Lowering Drugs 
and Diet Network (GOLDN) study used CD4+ T cells from buffy coats. The Illumina array 
measures methylation status of 485,512 CpG sites in the gene and non-gene regions of 
CpG islands, shores and shelves of the human genome [25]. Poor quality samples and 
probes were excluded based on cohort-specific criteria [Table S1]. Quantile [26], 
DASEN [27], Subset-quantile Within Array Normalization (SWAN) [28], Beta MIxture 
Quantile dilation (BMIQ) [29] or Functional normalization [30] was used to correct the 
raw beta values that represents the methylation percentage per CpG for every sample. 
The normalized beta values were used for the association analysis in each cohort. 
Data collection and Dietary assessment 
Dietary intake data were derived in each cohort from structured self-administered food 
frequency questionnaires (FFQs) varied from 78 to 560 food items [Table 1]. Exposure 
variables for the nutrients folate and vitamin B12 were calculated in micrograms per 
day from dietary intake data using national food composition tables [Table 1]. This 
included foods with folic acid fortification if this was the case, but did not include B-
vitamin supplement intake. Participants with missing dietary data, or who reported 
very low (<500) or very high (>5000) total energy intake were excluded. 
In order to reduce the magnitude of the systematic measurement error of the 
FFQ, each nutrient was adjusted for total energy intake, using the residual method 
[31]. Next, unstandardized residuals from this regression of each nutrient and total 
energy intake were used for association analyses. B-vitamin supplement intake was 
available in all cohorts for use as a covariate. Since these supplement data were 
recorded in different forms (B-vitamins, multivitamins or folic acid supplements) and 
different units (frequency per day or per week) in each cohort, we harmonized these 
data across all cohorts by grouping individuals as supplement users and non-users. 
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STATISTICAL ANALYSES 
Differentially Methylated Positions (DMPs): Cohort-specific association analyses 
Each participating cohort used linear mixed models to investigate the associations 
between each nutrient and genome-wide DNA methylation. Models were adjusted for 
age, sex, body mass index (BMI), differential white blood cell (WBC) counts, smoking 
status, physical activity, B-vitamin supplement intake, and alcohol (grams per day or 
drinks per week) and coffee (grams per day or servings per day) consumption as fixed 
effects, except for those studies for whom some covariates were not present [Table 2]. 
Technical covariates such as array number and position on array were also adjusted 
for, and were treated as random effects. Differential WBC counts were either 
represented as percentage of measured cell counts, or imputed using the Houseman 
method [32]. We first used a continuous model (Model 1), where the unstandardized 
residuals of each nutrient were used as continuous variables to estimate their 
association with genome-wide DNA methylation. To determine whether large 
differences in nutrient intake effect DNA methylation, we also performed a categorical 
analysis where the individuals of each residual nutrient were divided into tertiles, and 
the first and third tertiles were used to define low and high nutrient intakes, 
respectively (Model 2). Food intake measured by FFQ is prone to measurement error, 
but is ideal for ranking individuals based on their intake [33]. Thus, a model based on 
categorical ranks rather than absolute intake is the recommended analytical approach. 
In addition, we performed a sensitivity analysis of both folate and vitamin B12 intake in 
non-users of B-vitamin supplements only (Model 3). 
Differentially Methylated Positions (DMPs): Meta-analyses 
Figure 1 shows the stepwise study design that was followed. Using the software 
GWAMA [34], fixed effect meta-analyses as weighted by inverse variance were 
performed from the summary statistics of each participating cohort on the continuous 
(Model 1), categorical (Model 2) and supplement non-users sensitivity models (Model 
2a) of folate and vitamin B12 intake EWASs. An additional sensitivity meta-analysis was 
also performed with limitation to studies that had FFQ data at the same time point as 
DNA methylation measurements (Model 2b). Heterogeneity (I2) was considered to 
account for differences between cohorts using fixed effect meta-analysis. The probes 
with SNPs at single base extension and probes with improper binding [35] were 
excluded to avoid spurious signals and co-hybridization with alternate homologous 
sequences. All participating cohorts had different probe exclusions for quality control 
and therefore at this stage, we removed probes if they were not present in at least 5 
cohorts. The significance was defined by the Benjamini-Hochberg (BH) method [36] of 
the false discovery rate (FDR) <0.05. The gene annotations for the DMPs we identified 
were performed using the Genomic Regions Enrichment of Annotations Tool (GREAT) 
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[37] with University of California, Santa Cruz (UCSC) [38] where they assigned a 
regulatory domain consisting of a basal domain to each gene, that extends up to 5 kb 
upstream and 1 kb downstream from its transcription start site. The DMP is annotated 
with a gene if it overlaps with its basal domain, In addition, DMP is annotated to a gene 
if an extension is reached up to the basal regulatory domain of the nearest upstream 
and downstream genes within 1 Mb. The genomic inflation factor (λ) [39] were 
computed to estimate the rate of false positives due to population structure. Although 
such measure has been successfully applied in genome-wide association studies 
(GWAS), its application to EWAS may not confer the same benefit due to the inherent 
nature of the correlation structure in CpG sites of interdependent pathways and 
environment exposure [40]. 
Differentially Methylated Regions (DMRs) 
We identified DMRs for each nutrient using the software comb-p [41], through analysis 
of the nominal p-values of DMPs generated from the meta-analysis (Figure 1, Model 3). 
Nominal p-values of DMPs were adjusted according to their weighted correlation with 
adjacent p-values using the Stouffer–Liptak–Kechris method, in a sliding window of 500 
base pairs (bp) with varying lags of 50 bp [41]. Regions were identified by the peak 
finding algorithm on the adjusted p-values that qualified according to the BH FDR 
threshold <0.05. The identified regions were then given new p-values and corrected for 
multiple testing using the Sidak correction [41]. The significance for DMRs was defined 
as Sidak <0.05 for each nutrient. The gene annotations for the identified DMRs were 
performed using the GREAT tool [37] with the same extensions as applied for the DMP 
gene annotations. 
Pathway analysis was performed for genes annotated to the DMRs related to 
each nutrient, using the WEB-based GEne SeT AnaLysis Toolkit [42]. 
Overrepresentation enrichment analysis was performed for the GREAT annotated 
genes of the folate and vitamin B12 associated DMRs, respectively, and compared 
against the reference genome, in the KEGG pathways. The multiple testing was set to 
FDR <0.05 and the minimum number of genes in a functional gene set category was set 
to two. 
Previously published DMPs using Illumina 450k arrays  
We also investigated whether previously published DMPs related to maternal folate 
[19, 20] and DMPs related to folate and vitamin B12 intervention [43] were associated 
with folate and vitamin B12 intake in our population-based meta-analysis in adults. 
Gonseth et al. observed four DMPs (cg22664307, cg21039708, cg15219145 and 
cg13499966) in neonatal blood which were associated with maternal folate intake 
(n=167) [19]. In a second study examining cord blood methylation with maternal 
plasma folate (n=1988), 443 DMPs in cord blood were identified [20]. In a 2-year folic 
CHAPTER 7: Dietary B-vitamins and DNA methylation 215 
 
 
 
acid and vitamin B12 intervention study, one DMP (cg19380919) had the greatest 
change in methylation in the treatment group compared to the controls with marginal 
significance [43]. We compared the nominal p-values and beta coefficients to examine 
the direction of effects. In addition, we also checked for the enrichment of these 
previously found DMPs in our meta-analysis by comparing these CpGs to the same 
number of randomly selected CpGs from the array using 100 permutations. From both 
the CpG sets, the number of CpGs that had nominal p-value <0.05 were determined 
and compared. Using Fisher’s exact test, the significant enrichment was then 
determined. 
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RESULTS 
Cohort Characteristics 
Among the European cohorts, the median intakes of dietary folate ranged from 193 
µg/d in the Leiden Longevity Study to 415 µg/d in the Rotterdam Study. Among the 
American cohorts, the median intakes of dietary folate ranged from 234 µg/d in the 
Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study to 405 µg/d in the 
Framingham Heart Study (FHS). Among the European cohorts, the median intake of 
dietary vitamin B12 ranged from 4.0 µg/d in the Leiden Longevity Study (LLS) to 7.4 
µg/d in the Young Finns Study (YFS). For the American cohorts, the median intake of 
dietary vitamin B12 ranged from 4.5 µg/d in the GOLDN study to 6.3 µg/d in the ARIC 
Study. Characteristics of each participating study are given in Table 1. 
Study participants were adults (44-100% women) with the mean age ranging 
from 40-77 years. There were 7-25% current smokers and 3-58% of B-vitamin, 
multivitamin or folic acid supplement users. Since the use of supplements may be a 
confounder to the analysis, we also performed a sensitivity analysis in non-users of B-
vitamin, multivitamin or folic acid supplements. Further characteristics such as BMI, 
WBC counts, physical activity, alcohol and coffee intake of each cohort are provided in 
Table 2. 
MODELS 
Model 1: Continuous (Differentially methylated positions) 
Meta-analysis of the 5,815 individuals from the EWAS analysis of the folate intake 
continuous model showed no significant DMP associations (FDR <0.05). Meta-analysis 
of the 5,302 individuals of the EWAS analysis of the vitamin B12 intake continuous 
model also showed no significant DMP associations (FDR <0.05). 
Model 2: Categorical (Differentially methylated positions) 
Meta-analyses of 3,894 individuals evaluated categorically from the EWASs of folate 
intake showed 6 significant DMP associations (FDR <0.05) [Table 3, Figure 2 (a-g) and 
S2]. These 6 DMPs showed consistent association with nominal significance (p <0.05) in 
the continuous model [Table 3]. The most significant DMP was at cg23465990 
(P=3.87E-08, FDR=0.018) on chromosome 17, annotated to the nearest gene FAM64A 
(605 bp upstream), and showed 0.12% decrease in methylation per micrograms per 
day increase in residual folate intake. Other significant DMPs at cg11832534, 
cg03249011, cg14398883, cg00826902 and cg14145338 were annotated to the nearest 
genes WRAP73 (2,648 bp downstream), FRMD8 (41931 bp downstream), CUX1 (62,673 
bp upstream), WRAP73 (2,692 bp downstream) and LCN8 (3,667 bp downstream), 
respectively of chromosomes 1, 11, 7 and 9. All identified DMPs were negatively 
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associations between folate intake and methylation levels with 0.12-0.79% decrease in 
methylation per micrograms per day increase in residual folate intake. 
EWAS results of the vitamin B12 intake categorical model did not show 
significant DMPs in the meta-analysis of 3,566 individuals [Figure S2]. Of the 6 
significant DMPs from the folate intake analysis, two DMPs (cg23465990 and 
cg14398883) showed borderline nominal significance in the same direction as folate 
intake in the categorical model of vitamin B12 intake (p = 0.02 and 0.04, respectively) 
[Table S3]. 
Model 2a: Sensitivity model in supplement non-users 
A sensitivity analysis was further performed to reduce heterogeneity in the models 
caused by the use of B-vitamin supplements. This may potentially help with finding 
new true positive DMPs. In sensitivity analyses performed in supplement non-users, 
there were no significant DMPs in the meta-analysis of 2,183 individuals for the 
categorical model of folate intake [Figure S3]. The 6 significant DMPs identified in the 
full categorical model were nominally associated (p <0.05) in the same direction with 
folate intake in the non-users [Table 3]. The effect sizes were similar to the full 
categorical model with 0.12-0.74% decrease in methylation per micrograms per day 
increase in residual folate intake. Furthermore, no significant DMPs were identified 
either in the individual cohort results nor the meta-analysis of 1,855 individuals for the 
categorical model of vitamin B12 intake. 
Model 2b: Sensitivity model time of measurements 
To determine whether there is a confounding effect by studies with a time-lag between 
DNA methylation and folate or vitamin B12 intake assessment, a second sensitivity 
meta-analysis was performed including only studies where DNA methylation 
measurements and FFQ collection were assessed at the same time. The FHS, YFS and a 
subset of the RS cohort had FFQ collection 4-7 years apart of DNA collection, and 
therefore, these three cohorts were left out in model 2b. Meta-analysis of the 2,183 
individuals for the categorical model of folate intake did not result in significant DMPs 
[Figure S4]. The 6 significant DMPs associated with folate intake in the full categorical 
model had consistent associations with nominal significance [Table 3]. Furthermore, 
sensitivity meta-analysis of the 1,865 individuals for the categorical model of the 
vitamin B12 intake also did not identify significant DMPs. 
Model 3: Categorical (Differentially methylated regions) 
Folate intake 
We additionally performed DMR analysis using p-values of the folate and vitamin B12 
intake meta-analyses of the categorical model (Model 2). By investigation of significant 
regions (Sidak P<0.05) using the software comb-p, we observed 74 significant DMRs 
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associated with folate intake [Table 5, Figure 4a]. Most (73/74) DMRs were negatively 
associated with methylation. The most significant DMR associated with folate intake 
was the chr17:76,975,944-76,976,358 (P =1.47E-14) containing a 414 bp region of 8 
DMPs, which annotates to the LGALS3BP gene. Overrepresentation enrichment 
analysis for the 117 genes of the folate associated 74 DMRs showed one significant 
pathway: signaling pathways regulating pluripotency of stem cells (P =1.61E-04). 
Vitamin B12 intake 
Regional analysis using comb-p found 29 significant DMRs with Sidak P<0.05 associated 
with vitamin B12 intake [Table 6, Figure 4b], of which 15 showed negative direction of 
effects. The most significant DMR associated with vitamin B12 intake was the 
chr18:21,718,458-21,719,569 (P =1.09E-13) containing a 1,111 bp region of 18 DMPs, 
and annotates to the promoter region of the gene CABYR. The vitamin B12 associated 
DMRs did not overlap with the folate intake associated DMRs. Enrichment analysis for 
the 48 genes of the vitamin B12 associated 29 DMRs did not reveal significant 
pathways. 
PREVIOUSLY PUBLISHED DMPS USING ILLUMINA 450K ARRAYS  
Maternal folate exposure and cord blood DMPs 
We analysed previously identified DMPs that have previously been reported to be 
associated in neonates with maternal folate intake. In the current folate intake meta-
analysis (Categorical Model 2), one (cg15219145) of the four previously identified 
DMPs from the Gonseth et al study [19] showed a nominal significance (P <0.05) with 
similar direction. None of these four CpGs were significant with vitamin B12 intake 
[Table S4]. Next, 28 and 27 of the 443 previously identified DMPs in newborns from the 
Joubert et al study [20] were associated with folate and vitamin B12 intake respectively 
in the same direction with nominal significance (P <0.05) in our study [Table S5]. 
However, no enrichment of significant p-values was found in these 443 DMPs in either 
folate (p = 0.60) or vitamin B12 (p = 0.22) intake models in our study.  
Folic acid and Vitamin B12 Intervention study 
The previously identified DMP (cg19380919) of a 2-year folic acid and vitamin B12 
intervention study [43] was not associated with either folate intake (p = 0.78) or 
vitamin B12 intake (p = 0.43) in the current study [Table S6]. 
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Figure 2a: Manhattan plot of the folate categorical model, adjusted for BMI, WBC counts, 
smoking status, physical activity, B-vitamin supplement intake, and alcohol and coffee 
consumption and batch effects: showing the association between folate intake and 
genome-wide DNA methylation (model 2), with 6 significant DMPs at FDR <0.05 (red line), in 
3,894 individuals. Nearest genes for these 6 DMPs are reported. 
 
Figure 2b: Manhattan plot of the vitamin B12 categorical model, adjusted for BMI, WBC 
counts, smoking status, physical activity, B-vitamin supplement intake, and alcohol and 
coffee consumption and batch effects: showing the association between vitamin B12 intake 
and genome-wide DNA methylation (model 2), with no significant DMPs at FDR <0.05 (red 
line), in 3,566 individuals. 
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Figure 3a: Forest plot of the categorical folate intake model 2: showing the association 
between folate intake and the most significant DMP cg23465990 (FAM64A) across all 
studies and in meta-analysis of 3,791 individuals. 
 
 
Figure 3b: Forest plot of the categorical folate intake model 2: showing the association 
between folate intake and the DMP cg11832534 (WRAP73) across all studies and in meta-
analysis of 3,894 individuals. 
Effect size 
Effect size 
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Figure 3c: Forest plot of the categorical folate intake model 2: showing the association 
between folate intake and the DMP cg03249011 (FRMD8) across all studies and in meta-
analysis of 3,894 individuals. 
 
 
Figure 3d: Forest plot of the categorical folate intake model 2: showing the association 
between folate intake and the DMP cg14398883 (CUX1) across all studies and in meta-
analysis of 3,894 individuals. 
Effect size 
Effect size 
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Figure 3e: Forest plot of the categorical folate intake model 2: showing the association 
between folate intake and the DMP cg00826902 (WRAP73) across all studies and in meta-
analysis of 3,894 individuals. 
 
 
Figure 3f: Forest plot of the categorical folate intake model 2: showing the association 
between folate intake and the DMP cg14145338 (LCN8) across all studies and in meta-
analysis of 3,894 individuals. 
Effect size 
Effect size 
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Figure 4a: Manhattan plot of the folate intake categorical model 3: showing the 
association between folate intake and genome-wide DNA methylation, with 74 significant 
DMRs at Sidak <0.05 in 3,894 samples. The red line represents the threshold of FDR <0.05 of 
the correlation adjusted p-values. Green circles are the CpGs that are present within the 
DMRs, whereas black/grey circles are the single CpGs that do not represent DMRs. Nearest 
genes for the top 5 DMRs are reported. 
 
Figure 4b: Manhattan plot of the vitamin B12 intake categorical model 3: showing the 
association between vitamin B12 intake and genome-wide DNA methylation, with 29 
significant DMRs at Sidak <0.05 in 3,565 samples. The red line represents the threshold of 
FDR <0.05 of the correlation adjusted p-values. Green circles are the CpGs that are present 
within the DMRs, whereas black/grey circles are the single CpGs that do not represent 
DMRs. Nearest genes for the top 5 DMRs are reported. 
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DISCUSSION 
We have conducted the first large-scale EWAS of the association between folate and 
vitamin B12 intake and genome-wide DNA methylation in humans. We identified 6 
novel DMPs and 74 DMRs significantly associated with dietary folate intake, and 29 
DMRs significantly associated with dietary vitamin B12 intake. These novel epigenetic 
loci might become promising future biomarkers in folate- and vitamin B12 related 
pathologies. 
We identified 6 novel DMPs for folate intake, of which several were located 
close to genes with functional relevance to centrosome, cell proliferation and 
tumorigenesis. The most significant DMP at cg23465990 is annotated to the gene 
family with sequence similarity 64 member A (FAM64A) on chromosome 17. FAM64A 
protein interacts with Calmodulin (CALM) and leukemogenic CALM/AF10 fusion 
protein, where it is identified as a marker for cell proliferation control [44, 45]. The 
DMPs at cg11832534 and cg00826902 on chromosome 1 are annotated to WD repeat 
containing, antisense to TP73 (WRAP73). WRAP73 protein is localized in the 
centrosome and it ensures proper spindle morphology [46]. It is a centriolar satellite 
and functions in ciliogenesis by promoting ciliary vesicle docking [47]. The DMP at 
cg14398883 on chromosome 7 is annotated to cut like homeobox 1 (CUX1). CUX1 is a 
tumor suppressor and its deficiency leads to tumor growth via the activity of 
phosphoinositide 3-kinase signaling [48]. The DMP at cg03249011 annotated to FERM 
domain containing 8 (FRMD8) is in an enhancer region on chromosome 11. FRMD8 is 
associated with survival rate in patients of lung adenocarcinoma [49]. Lastly, the DMP 
at cg14145338 is annotated to lipocalin 8 (LCN8) on chromosome 9. LCN8, along with 
other related lipocalin genes, express in epididymis and are suggested to be involved in 
male fertility [50].  Further studies are needed to understand how these CpGs with 
seemingly no obvious link with B-vitamin homeostasis are involved in folate 
metabolism. In addition, validation is needed to characterize the causal relation of 
vitamin B intake on the function of these CpGs on nearby genes and one-carbon 
metabolism. 
In contrast to the relatively small number of DMPs for folate intake, we 
observed 74 significant DMRs in association with folate intake, with several of potential 
relevance to immune function and stem cell function. The most significant DMR was 
the chr17 locus spanning 414 bp region including 8 CpGs annotating to the galectin 3 
binding protein (LGALS3BP) gene, which is implicated in immune response. Signaling 
pathways regulating pluripotency of stem cells are overrepresented among the genes 
annotated near the folate associated DMR CpGs, comprised of AKT serine/threonine 
kinase 3 (AKT3), inhibitor of DNA binding 2, HLH protein (ID2), Wnt family member 6 
(WNT6), WNT9B and WNT10A genes. This suggests a relationship between folate 
intake and methylation of genes involved in development related pathways [51]. In 
addition, downregulation of LGALS3BP associates with some cancers through WNT 
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signalling [52, 53]. Studies show a relation between low folate intake and some cancers 
[54-57], indicating that this relation could be via hypermethylation of LGALS3BP. 
We identified one significant DMP at cg18642459 on chromosome 12 
annotated to the FGF6 gene. FGF6 plays a role in cellular differentiation and a potential 
role in muscle regeneration [58-60]. Vitamin B12 was previously shown to play a role in 
reparative regeneration of skeletal muscle [61] which could involve hypermethylation 
of the FGF6 gene. In contrast to the limited findings for vitamin B12 and DMP, regional 
analysis showed 29 significant DMRs associated with vitamin B12 intake. The most 
significant DMR was the chr18 locus spanning 1,111 bp containing 18 DMPs and a 
promoter of calcium binding tyrosine phosphorylation regulated (CABYR). CABYR is 
expressed in lung and hepatocellular cancers [62, 63]. No significant pathways were 
observed in the enrichment analysis for the vitamin B12 associated DMR genes, 
possibly due to the limited number of genes. Differential methylation findings for the 
vitamin B12, were similar to those of folate, in that DMR associations were more 
numerous than those of DMP. Surprisingly, there was no overlap of DMPs or DMRs 
between the folate and vitamin B12 intake despite the correlation between folate and 
vitamin B12 intake. Thus, suggesting that their roles may be specific to different genes 
and pathways. 
To investigate whether the previously identified transgenerational effects of 
maternal folate intake or levels on methylation in newborns, also generalize in adults 
[19, 20], we conducted a look up in our population-based meta-analysis of leukocytes 
in adults. A minority showed nominal significance with mostly negative direction of 
effects, and no significant enrichment was found in these previously identified folate-
associated DMPs in both folate and vitamin B12 intake in our study. This suggests that 
the folate-related DMPs in newborns and adults are not similar and might differ across 
the life course. 
In a two-year intervention study (BPROOF) with folic acid and vitamin B12, a 
single DMP (cg19380919) annotated to endothelial PAS domain protein 1 (EPAS1) was 
reported compared to placebo. This DMP was not significant in our meta-analyzed 
findings for either folate (p = 0.78) or vitamin B12 intake (p = 0.43) [Table S6]. A 
possible explanation for this difference is that the intervention study was specific to 
individuals with elevated homocysteine (greater than 15 µmol/L) [43], whereas 
participants in our study were generally healthy. In addition, in this intervention study 
the change in methylation over a 2-year time period was assessed, which might lead to 
different findings compared to our association study in which data at a single time 
point was investigated.  
We hypothesized that low levels of folate give rise to DNA hypomethylation 
[13, 16, 17]. However, all 6 folate associated DMPs and most (73/74) DMRs were 
negatively associated with folate intake. For vitamin B12 intake, we see this negative 
association in 15 of the 29 DMRs. The occurrence of general hypomethylation with 
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higher folate is contrary to our hypothesis, where higher folate would transfer 
additional methyl groups and result in relative genome-wide hypermethylation. 
However, our results are in line with the study from Ono et al., who showed that higher 
folate intake was associated with lower global methylation [15]. Our results are also in 
line with the studies with maternal folate intake which showed a majority of identified 
DMPs in newborns to be negatively associated to folate intake [19, 20]. An intervention 
study of folic acid supplementation in a mice demonstrated inhibition of 
methylenetetrahydrofolate reductase (MTHFR) activity and reduced S-
adenosylmethionine (SAM) and SAM/S-adenosylhomocysteine [64]. The inhibition of 
MTHFR due to higher folate intake may explain the relatively lower DNA methylation 
observed in our study. 
Our study is also consistent with earlier work in that we observed more DMPs 
and DMRs correlated with folate intake as compared to vitamin B12 intake [13-17]. 
Based on the amount of DMPs and DMRs identified, folate seems to have a larger 
effect on DNA methylation. This may be due to impaired vitamin B12 uptake by 
medications, health disorders, genetic defects and other lifestyle factors. As a result of 
these conditions, vitamin B12 intake in elderly people does not necessarily reflect 
vitamin B12 status [65]. Alternately, folate may have a larger relationship with 
leukocyte DNA methylation as compared to vitamin B12 [13-17]. 
The strengths of our study are that this is the first epigenome-wide 
association study and meta-analysis conducted in a large sample size of 5,841 
individuals from 10 well characterized cohorts, using the Illumina 450k methylation 
data. The nutrient data was harmonized across studies and all studies ran similar 
models with the same covariates. 
While our study has yielded a number of interesting findings, among the most 
important insights is that folate or vitamin B12 intake, a major determinant of B-
vitamin status, is not related to large-scale differences in genome-wide methylation 
profiles. There are a number of possible explanations for these observations. First, 
dietary data is prone to measurement errors, which can lead to misclassification and 
can compromise our ability to detect statistically significant associations. However, we 
addressed these limitations by using categorical models. While this analysis reduces 
statistical power due to the one-third reduction in sample size, greater effects were 
observed because the comparison is made between extreme tertile groups of the 
nutrient intakes. Second, vitamin B12 intake does not provide a good reflection of 
vitamin B12 status in older individuals as a consequence of issues related to absorption 
[66]. Given the fact that the mean ages in the majority of the cohorts were over 60 
years, it is highly likely that use of intake could result in misclassification of vitamin B12 
status. Third, although we removed individuals with prevalent cancer because of their 
potentially adopted dietary patterns [21, 22], the possibility of changes in dietary 
habits due to other reasons such as lifestyle changes cannot be excluded. Also, there 
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may be ethnic variation, since the ARIC sample is of African-American origin. 
Furthermore, there were differences in nutrient intake ranges across cohorts which 
could be related to the number and type of food items used in the FFQs, and the types 
of food composition reference tables used to calculate the nutrient data. Large 
differences in median intakes were also seen in Netherlands based studies, where the 
Rotterdam Study (RS) used 389 food items and the Leiden Longevity Study (LLS) used 
183 food items. Fourth, despite our inclusion of the known confounders as covariates, 
the possibility of inter-correlations of these confounders with each other or belonging 
along the causal pathway could nullify the findings. Fifth, we did not account for the 
most common MTHFR 677C>T variant that affects DNA methylation through its interact 
with folate status [67]. Sixth, our study includes DMPs that approach borderline 
significance and have modest effect sizes. In such cases, the comb-p package for DMR 
analysis may return false positive DMRs [68]. Therefore, replication of our findings 
would be necessary before definite conclusions can be drawn. We should therefore 
interpret all findings of the DMR analysis with caution. Seventh, the variation in intake 
may not be large enough for overall hypomethylation. It may be that the genes and 
regions that are identified here, are only the most sensitive ones. Also, none of the 
cohorts had median intake of vitamin B12 that was lower than the European or 
American RDI. This could mean that the vitamin B12 intake was consistently high 
enough and our population was relatively healthy to prevent any measurable effects 
on methylation. Lastly, we acknowledge the possibility that blood cells may not be the 
ideal tissue for evaluating the association between B-vitamin intake and methylation, 
and that larger tissue-specific effects may be present but remain undetected in our 
study. 
Among the European cohorts, the median intake of dietary folate ranged 
from 193 µg/d in the Leiden Longevity Study to 415 µg/d in the Rotterdam Study. This 
is slightly lower than the European recommended dietary allowance (RDA) of 200 µg/d 
[69]. The Rotterdam Study had the highest median folate intake being 415 µg/d. 
Among the American cohorts, the median intakes of dietary folate were 234 and 360 
µg/d in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) and CHS 
cohorts, respectively, which is less than the American RDA of 400 µg/d (except for 
ARIC) [69]. The Framingham Heart Study (FHS) and ARIC fulfilled the American RDA for 
their median dietary folate intake being 406 and 448 µg/d, respectively. Furthermore, 
there could be misclassification of folate intake in the GOLDN study. This is because 
dietary data was collected between 2002-2004 after the mandated folic acid 
fortification was implemented. However, the food composition table that was used for 
nutrient calculations originated from before fortification was implemented (i.e. before 
1996, table 1]. 
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CONCLUSIONS 
We observed 6 DMPs associated with dietary folate intake. Regional associations 
showed 74 DMRs for dietary folate intake and 29 DMRs for dietary vitamin B12 intake. 
Our meta-analysis identified several novel differentially methylated loci that could 
serve as potential biomarkers in folate and vitamin B12 related pathologies. Further 
studies should validate results by measuring folate and vitamin B12 levels in plasma. 
ADDITIONAL INFORMATION 
Supplementary material is available on request.  
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ABSTRACT 
Background - DNA methylation leaves a long-term signature of smoking exposure and 
is one potential mechanism by which tobacco exposure predisposes to adverse health 
outcomes, such as cancers, osteoporosis, lung, and cardiovascular disorders. 
Methods and Results - To comprehensively determine the association between 
cigarette smoking and DNA methylation, we conducted a meta-analysis of genome-
wide DNA methylation assessed using the Illumina BeadChip 450K array on 15,907 
blood derived DNA samples from participants in 16 cohorts (including 2,433 current, 
6,518 former, and 6,956 never smokers). Comparing current versus never smokers, 
2,623 CpG sites (CpGs), annotated to 1,405 genes, were statistically significantly 
differentially methylated at Bonferroni threshold of p<1x10-7 (18,760 CpGs at False 
Discovery Rate (FDR)<0.05). Genes annotated to these CpGs were enriched for 
associations with several smoking-related traits in genome-wide studies including 
pulmonary function, cancers, inflammatory diseases and heart disease. Comparing 
former versus never smokers, 185 of the CpGs that differed between current and never 
smokers were significant p<1x10-7 (2,623 CpGs at FDR<0.05), indicating a pattern of 
persistent altered methylation, with attenuation, after smoking cessation. 
Transcriptomic integration identified effects on gene expression at many differentially 
methylated CpGs. 
Conclusions - Cigarette smoking has a broad impact on genome-wide methylation that, 
at many loci, persists many years after smoking cessation. Many of the differentially 
methylated genes were novel genes with respect to biologic effects of smoking, and 
might represent therapeutic targets for prevention or treatment of tobacco-related 
diseases. Methylation at these sites could also serve as sensitive and stable biomarkers 
of lifetime exposure to tobacco smoke. 
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INTRODUCTION 
Cigarette smoking is a major causal risk factor for various diseases including cancers, 
cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD)1, and 
osteoporosis1. Worldwide cessation campaigns and legislative actions have been 
accompanied by a reduction in the number of cigarette smokers and corresponding 
increases in the number of former smokers. In the US, there are more former smokers 
than current smokers1. Despite the decline in the prevalence of smoking in many 
countries, it remains the leading preventable cause of death in the world, accounting 
for nearly 6 million deaths each year2. 
Even decades after cessation, cigarette smoking confers long-term risk of 
diseases including some cancers, chronic obstructive pulmonary disease, and stroke1. 
The mechanisms for these long-term effects are not well understood. DNA methylation 
changes have been proposed as one possible explanation. 
DNA methylation appears to reflect exposure to a variety of lifestyle factors3, 
including cigarette smoking. Several studies have shown reproducible associations 
between tobacco smoking and altered DNA methylation at multiple cytosine-
phosphate-guanine (CpG) sites4–15. Some DNA methylation sites associated with 
tobacco smoking have also localized to genes related to coronary heart disease5 and 
pulmonary disease16. Some studies have found different associated CpGs in smokers 
versus non-smokers8,11. Consortium-based meta-analyses have been extremely 
successful in identifying genetic variants associated with numerous phenotypes, but 
large-scale meta-analyses of genome-wide DNA methylation data have not yet been 
widely employed. It is likely that additional novel loci, differentially methylated in 
response to cigarette smoking remain to be discovered by meta-analyzing data across 
larger sample sizes comprising multiple cohorts. Differentially methylated loci with 
respect to smoking may serve as biomarkers of lifetime smoking exposure. They may 
also shed light on the molecular mechanisms by which tobacco exposure predisposes 
to multiple diseases. 
A recent systematic review13 analyzed published findings across 14 
epigenome-wide association studies of smoking exposure across various DNA 
methylation platforms of varying degrees of coverage and varying phenotypic 
definitions. Among these were 12 studies (comprising 4,750 subjects) that used the 
more comprehensive Illumina Human Methylation BeadChip 450K array (Illumina 
450K), which includes and greatly expands on the coverage of the earlier 27K platform. 
The review compares only statistically significant published results and is not a meta-
analysis which can identify signals that do not reach statistical significance in individual 
studies17. 
In the current study, we meta-analyzed association results between DNA 
methylation and cigarette smoking in 15,907 individuals from 16 cohorts in the 
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium 
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using a harmonized analysis. Methylation was measured on DNA extracted from blood 
samples using the Illumina Human Methylation BeadChip 450K array. In separate 
analyses, we compared current smokers and past smokers to non-smokers and 
characterized the persistence of smoking-related CpG methylation associations with 
the duration of smoking cessation among former smokers. We integrated information 
from genome-wide association studies (GWAS) and gene expression data to gain 
insight into potential functional relevance of our findings for human diseases. Finally 
we conducted analyses to identify pathways that may explain the molecular effects of 
cigarette exposure on tobacco-related diseases. 
MATERIALS AND METHODS 
Study participants 
This study comprised a total of 15,907 participants from 16 cohorts of the Cohorts for 
Heart and Aging Research in Genetic Epidemiology Consortium (Supplementary Table 
1). The 16 participating cohorts are ARIC, FHS Offspring, KORA F4, GOLDN, LBC 1921, 
LBC 1936, NAS, Rotterdam, Inchianti, GTP, CHS European Ancestry (EA), CHS African 
Ancestry (AA), GENOA, EPIC Norfolk, EPIC, and MESA. Of these, 12,161 are of 
European Ancestry (EA) and 3,746 are of African Ancestry (AA). The study was 
approved by institutional review committees for each cohort and all participants 
provided written informed consent for genetic research. 
DNA methylation sample and measurement 
For most studies, methylation was measured on DNA extracted from whole blood, but 
some studies used CD4+ T cells or monocytes (Supplementary Table 1). In all studies, 
DNA was bisulfite-converted using the Zymo EZ DNA methylation kit and assayed for 
methylation using the Infinium HumanMethylation 450 BeadChip, which contains 
485,512 CpG sites. Details of genomic DNA preparation, bisulfite conversion, and 
methylation assay for each cohort can be found in the online Supplementary Materials. 
Raw methylated and total probe intensities were extracted using the Illumina 
Genome Studio methylation module. Preprocessing of the methylated signal (M) and 
unmethylated signal (U) was conducted using various software tools, primarily DASEN 
of wateRmelon18 and BMIQ19, both of which are R packages. The methylation beta (β) 
values were defined as β = M/(M+U). Each cohort followed its own quality control 
protocols, removing poor quality or outlier samples and excluding low quality CpG sites 
(with detection p-value>0.01). Each cohort evaluated batch effects and controlled for 
them in the analysis. Details of these processes can be found in the online 
Supplementary Materials. 
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Smoking phenotype definition 
Self-reported cigarette smoking status was divided into three categories. Current 
smokers were defined as those who have smoked at least one cigarette a day within 12 
months prior to the blood draw, former smokers were defined as those who had ever 
smoked at least one cigarette a day, but had stopped at least 12 months prior to the 
blood draw, and never smokers reported never having smoked. Pack years was 
calculated based on self-report as the average number of cigarettes per day smoked 
divided by 20 multiplied by the number of years of smoking, with zero assigned to 
never smokers. A few cohorts recorded the number of years since each former smoker 
had stopped smoking. 
Cohort specific analyses and meta-analysis 
Each cohort analyzed its data using at least two linear mixed effect models. Each model 
was run separately for each CpG site. Model 1 is as follows: 
β = Smoking phenotype + Sex + Age + blood count + technical covariates, (1) 
where blood count comprises the fractions of CD4+ T-cells, CD8+ T-cells, NK cells, 
monocyte, and eosinophils either measured or estimated using the Houseman et al. 
method20. The blood count adjustment was performed only in cohorts with whole 
blood and leukocyte samples. Familial relationship was also accounted for in the model 
when applicable (e.g., for FHS, see Supplementary Material for details). Acknowledging 
that each cohort may be influenced by a unique set of technical factors, we allow each 
cohort to choose its cohort-specific technical covariates. Model 2 added to model 1 
body mass index (BMI) because it is associated with methylation at some loci, making it 
a potential confounder21. Only three cohorts participated in model 2 analysis: FHS, 
KORA, and NAS. Model 3 substituted smoking phenotypes for pack years. Only three 
cohorts participated in model 3 analysis: FHS, Rotterdam, and Inchianti. The pack year 
analysis was performed only on two subsets: current vs. never smokers and former vs. 
never smokers. Combining all three categories would require accurate records of time 
of quitting, which among the three cohorts was available for only FHS. To investigate 
cell type differences, we removed blood counts from Model 1 and called it Model 4. 
Only three cohorts participated in this analysis: FHS, KORA, and NAS. All models were 
run with the lme4 package22 in R23, except for FHS (See Supplementary Materials for 
details). 
Meta-analysis was performed to combine the results from all cohorts. Due to 
the variability of available CpG sites after quality control steps, we excluded CpG sites 
that were available in fewer than three cohorts. The remaining 485,381 CpG sites were 
then meta-analyzed with a random-effects model using the following formula: 
Ei = µ + si + ei, (2) 
where Ei is the observed effect of study i, µ is the main smoking effect, si is the 
between-study error for study i, and ei is the within-study error for study i, with both si 
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and ei are assumed to be normally distributed. The model is fitted using the restricted 
maximum likelihood (REML) criterion in R’s metafor24 package. Multiple-testing 
adjustment on the resulting p-values was performed using the False Discovery Rate 
(FDR) method of Benjamini and Hochberg25. In addition, we also report results using 
the Bonferroni-corrected threshold of 1 x 10-7 (~ 0.05/485,381). 
The regression coefficient β (from meta-analysis) is interpretable as the 
difference in mean methylation between current and never smokers. We multiplied 
these by 100 to represent the percentage methylation difference where methylation 
ranges from 0-100%. 
Literature review to identify genes previously associated with smoking and 
methylation 
We used the same literature search strategy published previously26. A broad query of 
NCBI's PubMed literature database using medical subject heading (MeSH) terms 
(“((((DNA Methylation[Mesh]) OR methylation)) AND ((Smoking[Mesh]) OR smoking))”) 
yielded 775 results when initially performed on January 8, 2015 and 789 studies when 
repeated to update the results on March 1, 2015. Results were reviewed by abstract to 
determine whether studies met inclusion criteria: 1) performed in healthy human 
populations, 2) agnostically examined >1,000 CpG sites at a time, 3) only cigarette 
exposure was considered, and 4) with public reporting of P-values and gene 
annotations. A total of 25 publications met inclusion criteria, listed in the fourth 
supplementary table of Joubert et al.26. CpG level results (P-values and gene 
annotations) for sites showing genome-wide statistically significant associations 
(FDR<0.05) were extracted and resulted in 1,185 genes previously associated with adult 
or maternal smoking. All CpGs annotated to these 1,185 genes were marked as 
“previously found”. 
Gene set enrichment analysis (GSEA) 
Gene-Set Enrichment Analysis (GSEA)27 was performed in the website 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) on significant findings 
to determine putative functions of the CpG sites. We selected gene ontology (GO) 
biological process (C5-BP) and collected all categories with FDR<0.05 (up to 100 
categories). 
Enrichment analysis for localization to different genomic features 
Enrichment analysis on genomic features were performed using the annotation file 
supplied by the Illumina (version 1.2, downloaded from manufacturer’s website, 
http://support.illumina.com/array/array_kits/infinium_humanmethylation450_beadch
ip_kit/downloads.html), which contains information of CpG location relative to gene 
(i.e., body, first exon, 3’ UTR, 5’UTR, within 200 base pairs of Transcriptional Start Site 
[TSS200], and TSS1500), the relation of CpG site to a CpG island (i.e., island, northern 
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shelf, northern shore, southern shelf, and southern shore), whether the CpG site is 
known to be in differentially methylated regions, and whether the CpG site is known to 
be an enhancer or a DNAse I Hypersensitive Site (DHS). Enrichment analysis was 
performed using one-sided Fisher’s exact set for each feature, using R’s fisher.test. 
Genome-wide association study (GWAS) analysis 
We intersected our results with SNPs having genome-wide association study (GWAS) p-
values≤5 x 10-8 in the NHGRI GWAS catalog (accessed November 2, 2015)28. The catalog 
contained 9,777 SNPs annotated to 7,075 genes associated with 865 phenotypes at 
p≤5x10-8. To determine the genes, we looked up each significant CpG on the 
annotation file supplied by Illumina. Enrichment analysis was performed on a per gene 
basis using one-sided Fisher’s exact test. 
For bone mineral phenotype enrichment, we included all SNPs including 
terms “bone mineral density” or “osteoporosis”. For cardiovascular disease (CVD), we 
included all SNPs containing terms “cardiovascular disease”, “stroke”, “coronary 
disease”, “cardiomyopathy”, or “myocardial infarction”. For CVD risk factors, we 
included all SNPs containing terms “blood pressure”, “cholesterol”, “diabetes”, 
“obesity”, or “hypertension”. For overall cancer enrichment, we included all SNPs 
containing terms “cancer”, “carcinoma”, or “lymphoma”, while removing those 
pertaining to cancer treatment effects. For overall pulmonary phenotype enrichment, 
we included all SNPs containing terms “pulmonary disease”, “pulmonary function”, 
“emphysema”, “asthma”, or “airflow obstruction”. 
Analysis of persistence of methylation signals with time since quitting smoking 
among former smokers 
We examined whether smoking methylation associations were attenuated over time in 
the FHS cohort, which had ascertained longitudinal smoking status of over 35 years. 
The analysis was performed on seven dichotomous variables, indicating cessation of 
smoking for 5, 10, 15, 20, 25, and 30 years versus never smokers. For example, for five 
year cessation variable, those who quit smoking five years or more are marked as ones, 
while never smokers are marked as zeroes and current smokers are excluded. For this 
analysis, we used the pedigreemm package29 with the same set of covariates as in the 
primary analysis. Sites with p<0.002 across all seven variables were deemed to be 
statistically significant compared to never-smoker levels. 
Methylation by expression (MxE) analysis 
To determine transcriptomic association of each significant CpG site, we interrogated 
such CpG sites in the FHS gene-level methylation by expression (MxE) database, at 
genome-wide false discovery rate (FDR)<0.05. The MxE database was constructed from 
2,262 individuals from the FHS Offspring cohort attending examination cycle eight 
(2005-2008) with both whole blood DN methylation and transcriptomic data based on 
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the Affymetrix Human Exon Array ST 1.0. Enrichment analysis was performed using a 
one-sided Fisher’s exact test. We defined that the methylation CpG site and the 
corresponding transcript are associated in cis if the location of the CpG site is within 
500 kilobases of the transcript’s start location. 
Analysis of ethnic discrepancy between African Ancestry (AA) and European Ancestry 
(EA) cohorts 
Meta-analysis of the current versus never smoker results of EA cohorts (FHS, KORA, 
GOLDN, LBC 1921, LBC 1936, NAS, Rotterdam, Inchianti, EPIC, EPIC Norfolk, MESA, CHS-
EA) was performed separately from those of AA cohorts (ARIC, GTP, GENOA, CHS-AA). 
Analysis of samples types for DNA extraction 
Meta-analysis was performed on the results from cohorts with whole blood/buffy coat 
samples (FHS, KORA, LBC 1921, LBC 1936, NAS, Rotterdam, Inchianti, GTP, CHS-EA, 
CHS-AA, ARIC, GENOA, EPIC, and EPIC-Norfolk). CD4+ samples in GOLDN and CD14+ 
samples in MESA, because they comprise single cohorts, are not meta-analyzed. 
Correlations of results across different cell types were performed on CpG sites with 
FDR<0.05 in at least one cell type. 
RESULTS 
Table 1 displays the characteristics of participants in the meta-analysis. The proportion 
of participants reporting current smoking ranged from 4% to 33% across the different 
study populations. The characteristics of the participants within each cohort are 
provided in Supplementary Table 1. 
Current versus Never Smokers 
In the meta-analysis of current cigarette smokers (N=2,433) versus never smokers 
(N=6,956), 2,623 CpGs annotated to 1,405 genes met Bonferroni significance after 
correction for 485,381 tests (P<1x10-7). Based on genome-wide false discovery rate 
(FDR)<0.05, 18,760 CpG sites (CpGs) annotated to 7,201 genes were differentially 
methylated. There was a moderate inflation factor30 λ of 1.32 (Supplementary Figure 
1), which is consistent with a large number of sites being impacted by smoking. Our 
results lend support many previously reported loci7,8,11,13, including CpGs annotated to 
AHRR, RARA, F2RL3, and LRRN3 (Supplementary Table 2). Not surprisingly, cg05575921 
annotated to AHRR, the top CpG identified in most prior studies of smoking, was highly 
significant in our meta-analysis (P=4.6x10-26; ranked 36, Supplementary Table 2) and 
also had the largest effect size (-18% difference in methylation) which is comparable to 
effect sizes in previous studies18. Of the 18,760 significant CpGs at FDR<0.05, 16,673 
(annotated to 6,720 genes) have not been previously reported to be associated with 
cigarette smoking – these include 1,500 of the 2,623 CpGs that met Bonferroni 
significance. The 25 CpGs with lowest p-values for both overall and novel findings are 
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shown in Table 2. Supplementary Table 2 provides the complete list of all CpGs that 
were significantly differentially methylated (FDR<0.05) in analysis of current versus 
never smokers. Adding body mass index (BMI) into the model did not appreciably alter 
the results (Supplementary Figure 2). 
Methylation can be either reduced or increased at CpG sites in response to 
smoking. For the 53.2% of FDR significant CpGs with increased methylation in response 
to current smoking the mean percentage difference in methylation between current 
and never smokers was 0.5% (SD=0.37%, range 0.06-7.3%). For 46.8% of CpGs with 
decreased methylation in response to current smoking the mean percentage difference 
was 0.65% (SD=0.56, range 0.04-18%). The volcano plot can be found in Supplementary 
Figure 3. 
We did not observe correlation between the number of significant CpGs and 
either the size of the gene or the number of exons or the coverage of the methylation 
platform. We performed a formal enrichment test for each of the 7,201 genes in 
regards to the length of the gene or number of exons and found only three for which 
associations were observed (AHRR, PRRT1, and TNF). However, given the robust 
findings for a specific CpG in AHRR in multiple studies in the literature4,7,9 as well as our 
own, and its key role in the AHR pathway which is crucial in the response to 
polyaromatic hydrocarbons, such as are produced by smoking31, it seems very unlikely 
that the AHRR findings are false positives. Likewise there is strong support in the 
literature for PRRT132 and TNF33. The enrichment results for methylation platform 
coverage also yielded the same three genes. 
In a subset of three cohorts (1,827 subjects), we investigated the association 
of the number of pack-years smoked with the 18,760 CpGs that were differentially 
methylated (FDR<0.05) between current versus never smokers. Significant dose 
responses were observed for 11,267 CpGs (60.1%) at FDR<0.05 (Supplementary Table 
3). To investigate the pathways implicated by these genes, we performed a gene-set 
enrichment analysis34 on the annotated genes. The results suggested that cigarette 
smoking is associated with potential changes in numerous vital molecular processes, 
such as signal transduction (FDR=2.8 x 10-79), protein metabolic processes (FDR=1.2 x 
10-43), and transcription pathways (FDR=8.4 x 10-31). The complete list of 99 enriched 
molecular processes can be found in Supplementary Table 4. 
Former versus Never Smokers 
Meta-analysis of former (N=6,518) versus never smokers (N=6,956) restricted to the 
18,760 CpG sites that were differentially methylated in current versus never smokers 
identified 2,568 CpGs annotated to 1,326 genes at FDR<0.05 (Supplementary Table 5). 
There were 185 CpGs (annotated to 149 genes) that also met Bonferroni correction (P< 
0.05/18760 ~ 2.67x10-6). There was no evidence of inflation30 (λ=0.98) (Supplementary 
Figure 4). We also confirmed previously reported findings for CpGs annotated to AHRR, 
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RARA, and LRRN37,8,11,13. Effect sizes of these CpGs were all weaker than in the analysis 
of current versus never smokers [61.2% ±15.3% weaker] for the 2,568 CpGs that 
remained significantly differentially methylated in former vs. never smokers compared 
with current vs. never smokers. Results for the top 25 CpGs are displayed in Table 3. 
Adding BMI to the model did not appreciably alter the results (Supplementary Figure 
5). A volcano plot can be found in Supplementary Figure 6. In a subset of three cohorts 
(3,349 subjects), analyses using pack-years confirmed a significant dose response for 
1,804 of the 2,568 CpGs (70%) annotated to 942 genes at FDR<0.05 (Supplementary 
Table 6). 
The gene-set enrichment analysis27 in the former versus never smoker 
analyses on all 1,326 genes revealed enrichment for genes associated with protein 
metabolic processes (FDR=1.1 x 10-23), RNA metabolic processes (FDR=1.4 x 10-17), and 
transcription pathways (FDR=3.9 x 10-18) (Supplementary Table 7). The gene-set 
enrichment analysis on the 942 genes for which the 1,804 CpGs exhibited dose 
responses with pack-years also revealed similar pathways to those summarized in 
Supplementary Table 7, except with weaker enrichment FDR values. 
In 2,648 Framingham Heart Study participants with up to 30 years of 
prospectively collected smoking data, we examined the 2,568 CpGs that were 
differentially methylated in meta-analysis of former versus never smokers and 
explored their associations with time since smoking cessation. Methylation levels of 
most CpGs returned toward that of never-smokers within five years of smoking 
cessation. However, 36 CpGs annotated to 19 genes, including TIAM2, PRRT1, AHRR, 
F2RL3, GNG12, LRRN3, APBA2, MACROD2, and PRSS23 did not return to never-smoker 
levels even after 30 years of smoking cessation (Figure 1, Table 4). 
The EPIC studies included cancer cases plus non-cancer controls analyzed 
together, adjusting for cancer status. The other studies were population-based samples 
not selected for disease status. To evaluate residual confounding by cancer status after 
adjustment, we repeated the meta-analysis without the EPIC studies. The effect 
estimates were highly correlated: Pearson ρ = 0.99 for current versus never smoking 
and 0.98 for former smoking versus never. 
Table 1. Participant characteristics 
Characteristics Current Smokers Former Smokers Never Smokers 
 
N=2,433 N=6,518 N=6,956 
Sex (% Male) 0.463 0.556 0.317 
Age (years)* 57.7 ± 7.7 64.8 ± 8.2 61.2 ± 9.7 
BMI (kg/m2)* 27.3 ± 5.4 28.7 ± 5.0 28.6 ± 5.3 
*weighted mean ± pooled standard deviation across cohorts 
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Enrichment analysis for genes identified in GWAS of smoking related phenotypes 
To identify potential relevance of the differentially methylated genes to smoking-
related phenotypes, we determined whether these genes had been associated with 
smoking-related phenotypes in the NHGRI-EBI GWAS Catalog28 (accessed November 2, 
2015). The catalog contained 9,777 SNPs annotated to 7,075 genes associated with 865 
phenotypes at p≤5x10-8. Of the 7,201 genes (mapped by 18,760 CpG sites) significantly 
differentially methylated in current versus never smokers, we found overlap with 1,791 
genes (4,187 CpGs are mapped to these) associated in GWAS with 700 phenotypes 
(enrichment p=2.4 x 10-52). We identified smoking-related traits using the 2014 US 
Surgeon General’s (USSG) report1. Enrichment results for a selection of smoking-
related phenotypes including coronary heart disease (CHD) and its risk factors, various 
cancers, inflammatory diseases, osteoporosis, and pulmonary traits, are available in 
Table 5. We also performed the same enrichment analysis on the 2,568 CpGs 
associated with former versus never smoking status. We identified enrichment for 
CHD, pulmonary traits, and some cancers (Table 5). More detailed results are available 
in Supplementary Tables 8 and 9. Differentially methylated genes in relation to 
smoking status that are associated in GWAS with CHD or CHD risk factors are available 
in Supplementary Table 10. We also performed enrichment analyses on phenotypes 
that have no clear relationships to smoking, such as male pattern baldness (p=0.0888), 
myopia (p=0.1070), thyroid cancer (p=0.2406), and testicular germ cell tumor 
(p=0.3602) and did not find significant enrichment. 
Enrichment analysis for genomic features 
We examined the differentially methylated CpGs with respect to localization to 
different genomic regions including CpG islands, gene bodies, known differentially 
methylated regions, and sites identified as likely to be functionally important in the 
ENCODE project such as DNAse1 hypersensitivity sites and enhancers (refer to the 
Methods section for details). We performed this analysis separately for the CpGs 
related to current smoking and past smoking (Supplementary Table 11). Trends were 
similar for the two sets of CpGs, although the power to identify enrichment was much 
greater for the larger set of 18,760 CpGs related to current smoking. There was no 
enrichment for CpG islands. In contrast, significant enrichment was observed for island 
shores, gene bodies, DNAse1 hypersensitivity sites, and enhancers.  
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Table 5. Enrichment of CpGs for genome-wide association study (GWAS) phenotypes 
that are regarded as causally related to cigarette smoking 
GWAS Phenotype Enrichment p-value 
Current vs. never smoking 
 
Coronary heart disease (CHD) and Stroke 0.0028 
    Ischemic stroke 0.0095 
CHD risk factors 1.2 × 10−12 
    Blood pressure / hypertension 8.1 × 10−6 
        Diastolic blood pressure 6.1 × 10−5 
        Systolic blood pressure 0.0008 
        Hypertension 0.015 
    Lipids 2.9 × 10−5 
        High density lipoprotein (HDL) 0.0009 
    Type 2 diabetes 0.0106 
Rheumatoid arthritis (RA) 2.9 × 10−5 
Bone mineral density (BMD) and osteoporosis 0.0467 
All pulmonary traits 2.8 × 10−6 
    All chronic obstructive pulmonary disease (COPD) 0.0295 
        Moderate to severe COPD 0.0156 
    Pulmonary function 0.0044 
Crohn’s Disease 9.5 × 10−7 
Primary biliary cirrhosis 3.4 × 10−6 
Inflammation bowel disease 3.5 × 10−5 
Ulcerative colitis 9.8 × 10−5 
All cancer 8.0 × 10−15 
    Lung adenocarcinoma 0.0015 
    Colorectal cancer 0.0014 
Former vs. never smoking 
 
CHD risk factors 7.6 × 10−5 
    Blood pressure / hypertension 5.8 × 10−5 
        Diastolic blood pressure 0.0021 
        Systolic blood pressure 0.0002 
        Hypertension 0.0023 
Rheumatoid arthritis (RA) 6.3 × 10−5 
All pulmonary traits 0.0217 
Inflammation bowel disease 5.2 × 10−6 
Crohn’s Disease 0.0064 
All cancer 7.8 × 10−6 
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Transcriptomic integration 
Of the 18,760 statistically significant CpG sites associated with current smoking in the 
meta-analysis, 1,430 were significantly associated in cis with the expression of 924 
genes at FDR<0.05 (enrichment p=3.6 x 10-215, Supplementary Table 12) using whole 
blood samples from 2,262 Framingham Heart Study participants. Of these, 424 CpGs 
associated with the expression of 285 genes were replicated at FDR<0.0001 in 1,264 
CD14+ samples from the Multi-Ethnic Study of Atherosclerosis (MESA)35. These genes 
are associated with pathways similar to those described earlier (Supplementary Table 
13).  
Comparison between African ancestry and European ancestry 
Meta-analysis of the current versus never smokers in 11 cohorts with participants of 
European ancestry (N=6,750 subjects) yielded 10,977 CpGs annotated to 4,940 genes 
at FDR<0.05. Meta-analysis the results of the smaller dataset of four cohorts with 
African ancestry participants (N=2,639) yielded 3,945 CpGs annotated to 2,088 genes at 
FDR<0.05. The effect estimates of the CpGs significant in at least one ancestry (12,927 
CpGs) were highly correlated in the combined group of individuals of either ancestry 
(Spearman ρ=0.89). The results by ancestry are shown in Supplementary Table 14. 
We performed the same ancestry-stratified analysis on former versus never 
smokers (Supplementary Table 15). Meta-analysis of the results of European ancestry 
participants yielded 2,045 CpG sites annotated to 1,081 genes at FDR<0.05. Meta-
analysis of the results of African ancestry participants yielded 329 CpG sites annotated 
to 178 genes at FDR<0.05. The effect estimates of the union of CpGs significant in at 
least one ancestry (2,234 CpGs) were correlated in the combined group of individuals 
of either ancestry (Spearman ρ=0.75). Of note, one of CpG sites showing differential 
methylation in ancestry, cg00706683, mapped to gene ECEL1P2, did not return to 
never-smoker levels 30 years after smoking cessation (Table 4). 
To more directly compare results by ethnicity removing the effect of better 
statistical power in the larger European ancestry sample size, we performed a meta-
analysis on subset of European ancestry cohorts: the Framingham Heart Study, 
Rotterdam Study, and KORA, such that the total number of smokers, the major 
determinant of power, would match that of African ancestry cohorts. In this subset, 
similar correlations of the effect estimates were observed as in the complete analyses 
suggesting that the differences in number of statistically significant CpGs are indeed 
due to better power in the European ancestry cohorts (Spearman ρ=0.87 and 0.79 for 
current versus never smokers and former versus never smokers, respectively). 
Cell type adjustment 
We adjusted our main analyses for white blood cell fractions, in studies based on either 
whole blood or leukocytes from the buffy coat of whole blood, either measured or 
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using a published method20.  Reassuringly, results before and after cell type adjustment 
were highly comparable. The correlation of regression coefficients before and after 
adjustment is 0.85 for the current vs. never smoker analysis (Supplementary Figure 7).  
Similarly for the analysis of former versus never smokers the effect estimates were 
highly correlated before and after adjustment (ρ=0.93; Supplementary Figure 8). In 
addition, in two cohorts we had results from specific cell fractions - CD4+ cells in 
GOLDN and CD14+ cells in MESA. The correlation of results between buffy coat and 
CD4+ or CD14+ for former versus never smokers are generally high (ρ > 0.74; 
Supplementary Table 16). 
Methylation profile across CpG sites 
We assessed methylation profile in FHS cohort as a representative cohort in the study. 
The profile of all 485,381 analyzed CpG sites can be found in Supplementary Figure 9. 
The profile across 18,760 CpG sites significantly associated with current vs. never 
smoking status can be found in Supplementary Figure 10. These plots indicate that 
most CpG sites with less dynamic range are largely not statistically significant in our 
results. 
DISCUSSION 
We performed a genome-wide meta-analysis analysis of blood-derived DNA 
methylation in 15,907 individuals across 16 cohorts and identified broad epigenome-
wide impact of cigarette smoking, with 18,760 statistically significant CpGs (FDR<0.05) 
annotated to over 7,000 genes, or roughly a third of known human genes. These genes 
in turn affect multiple molecular mechanisms and are implicated in smoking-related 
phenotypes and diseases. In addition to confirming previous findings from smaller 
studies, we detected over 16,000 novel differentially methylated CpGs in response to 
cigarette smoking. Many of these genes have not been previously implicated in the 
biologic effects of tobacco exposure. The large number of genes implicated in this well 
powered meta-analysis might on first glance raise concerns about false positives. 
However, on further consideration, given the widespread impact of smoking on disease 
outcomes across many organ systems and across the lifespan1, the identification of a 
large number of genes at genome wide significance is not surprising. In addition, our 
findings are robust and consistent across all 16 cohorts (Supplementary Tables 2 and 5) 
because we accounted for inter-study variability by using random effect meta-analyses, 
which is conservative when heterogeneity is present36. The implicated genes are mainly 
involved in molecular machineries, such as transcription and translation. Furthermore, 
differential methylation of a subset of CpGs persisted, often for decades, following 
smoking cessation. 
We found that genes differentially methylated in relation to smoking are 
enriched for variants associated in GWAS with smoking–related diseases1 including, 
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osteoporosis, colorectal cancers, chronic obstructive pulmonary disease, pulmonary 
function, cardiovascular disease (CVD) and rheumatoid arthritis. We find it noteworthy 
that there is enrichment of smoking-associated CpGs for genes associated with 
rheumatoid arthritis because DNA methylation is one of the proposed molecular 
mechanisms underlying this disease 37. It is also interesting that the most significant 
association of smoking with methylation was for the gene HIVEP3 (a.k.a. Schnurri3), the 
mammalian homolog of the Drosophila zinc finger adapter protein Shn38.  This gene 
regulates bone formation, an important determinant to osteoporosis, which was one 
of the enriched GWAS phenotypes. 
When we examined time since smoking cessation, we found that the majority 
of the differentially methylated CpG sites observed in analysis of current versus never 
smokers returned to the level of never-smokers within five years of smoking cessation. 
This is consistent with the fact that risks of many smoking-related diseases revert to 
nonsmoking levels within this period of time. Our results also indicate that cigarette 
smoking induces long-lasting alterations in DNA methylation at some CpGs. While 
speculative, it is possible that persistent methylation changes at some loci might 
contribute to risks of some conditions that remain elevated after smoking cessation. 
In all but two of our 14 cohorts DNA was extracted from the entire circulating 
leukocyte population. Thus there is the possibility of confounding by the effects of 
smoking on differential cell counts. We attempted to adjust for cell type and found that 
results were generally little changed by the adjustment. 
Our significant results are highly enriched for CpG sites associated with the 
expression of nearby genes (i.e., in cis) even though a single measurement of gene 
expression in blood is probably subject to considerably more within-subject variability 
than DNA methylation,39 limiting our ability to find correlations. Differential DNA 
methylation at many of the CpGs we identified in relation to smoking status may have 
a functional impact on nearby gene expression. Our analysis of genomic regions further 
supports the potential functional impact of our findings on gene expression. We 
demonstrated enrichment for sites with greater functional impact such as island 
shores, gene bodies, DNAse1 hypersensitivity sites, and enhancers, whereas we found 
no enrichment for CpG islands. These results reinforce previous findings showing that 
island shores, enhancers, and DHS sites are more dynamic (i.e., susceptible to 
methylation changes) than CpG islands40, which may be more resistant to abrupt 
changes in DNA methylation in response to environmental exposures41. Thus our 
results suggest that many of the smoking-associated CpG sites may have regulatory 
effects. 
While identification of changes in methylation patterns may suggest 
mechanisms by which exposure to tobacco smoke exerts its effects on several disease 
processes, DNA methylation profiles can also serve as biomarkers of exposure to 
tobacco smoke. Cotinine is a biomarker only of recent smoking; DNA methylation 
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signals have the potential to serve as robust biomarkers of past smoking history9,42. 
Indeed, several studies have identified several of such markers5,42,43. The large number 
of persistently modified CpGs may be useful to develop even more robust biomarkers 
to objectively quantify long-term cigarette smoking exposure for prediction of risk for 
health outcomes in settings where smoking history is not available or is incomplete as 
well as to validate self-reported never smoker status.  Further, our analyses of both 
former and current smokers show dose-dependent effects at a number of CpGs 
(Supplementary Tables 3 and 7). Methylation based biomarkers could be informative 
for investigating dose response relationships with disease endpoints. This is useful 
because smokers often underreport the amount of smoking, both current and 
historical. 
It is possible that smoking related conditions or correlated exposures may 
contribute to some of the methylation signatures identified. However, our studies are 
nearly all population based studies composed of predominantly healthy individuals, not 
selected for smoking related disease.  Given the number, strength and robustness to 
replication of findings for smoking across the literature and among our diverse cohorts 
from various countries the likelihood that these are confounded by other exposures or 
conditions related to smoking is greatly reduced. 
There several potential limitations to our study. First, the cross-sectional 
design limits our ability to study the time course of smoking effects. In addition, we 
analyzed methylation in DNA samples from blood, which is readily accessible. Although 
we demonstrated that blood derived DNA reveals a strong and robust signature of 
cigarette smoking exposure, studies in target tissues for smoking-related diseases (e.g., 
heart and lung) would be of additional interest. In addition, our analyses could not 
distinguish smoking’s direct effects from its indirect effects due to smoking-induced 
changes in cell metabolism, organ function, inflammation, or injury that could in turn 
influence methylation. However, this is the largest examination to date of the effects of 
smoking on DNA methylation with 16 studies from different countries contributing. 
In conclusion we identify an order of magnitude more sites differentially 
methylated in relation to smoking across the genome than have been previously seen. 
Many of these signals persist long after smoking cessation providing potential 
biomarkers of past smoking history. These findings may provide new insights into 
molecular mechanisms underlying the protean effects of smoking on human health and 
disease. 
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CHAPTER 9: GENERAL DISCUSSION 
The aim of this thesis was to investigate the effects of key factors from the methyl-
group metabolism on genome-wide DNA methylation in a site-specific manner. In 
addition, we also aimed to investigate the effects of other lifestyle factors such as 
nutrition and cigarette smoking on DNA methylation. We conducted several 
epigenome-wide association studies (EWASs) in blood samples of a population-based 
cohort, the Rotterdam Study (RS) and collaborated with other cohorts with similar data 
in a consortium based effort, to increase power and robustness of our findings. 
MAIN FINDINGS 
Methyl-group Metabolism and B-vitamins 
In Chapter 4, we describe that plasma Hcy was associated with subtle differences in 
DNA methylation of blood DNA, since we identified a small number of differentially 
methylated positions (3 DMPs) associated with Hcy in leukocytes of 2,035 individuals. 
Regional analysis identified 68 differentially methylated regions (DMRs) associated 
with Hcy. In Chapter 5, genetically elevated Hcy levels assessed by the MTHFR 677C>T 
variant and combined weighted genetic risk score (GRS) of 18 previously studied Hcy-
associated variants, did not show widespread changes in DNA methylation; identifying 
a few DMPs in cis (< 1Mb upstream or downstream of the SNP) and one DMP in trans 
(> 1Mb upstream or downstream of the SNP) associated with the MTHFR 677C>T 
variant and five trans-CpGs associated with the GRS. In Chapter 6, we conducted an 
interaction study of Hcy and the MTHFR 677C>T variant to investigate their combined 
effect on genome-wide DNA methylation in leukocytes of 1280 individuals. We 
identified 13 DMPs associated with [Hcy x MTHFR 677C>T]. This included four cis-DMPs 
at the AGTRAP-MTHFR-NPPA/B gene cluster on chromosome 1, which were also 
described in Chapter 5, indicating that this association is more likely driven by MTHFR 
677C>T variant since they are cis-DMPs for the MTHFR 677C>T variant. In Chapter 7, in 
leukocytes of 5,841 individuals, we identified six novel DMPs and 74 DMRs significantly 
associated with dietary folate intake, and 29 DMRs significantly associated with dietary 
vitamin B12 intake. No DMPs were found associated with dietary vitamin B12 intake. 
In conclusion, we investigated several important markers of one-carbon 
metabolism and found only subtle differences in DNA methylation that were of modest 
statistical significance. When we examined overlap between the identified methylation 
markers with the various factors from the methyl-group metabolism, we observed that 
all identified CpGs were specific for the marker under study and no overlap was found.   
Lifestyle factors 
In Chapter 8, we focused on association between cigarette smoking as a lifestyle factor 
and DNA methylation in leukocytes assessed in 15,907 individuals. We identified 
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widespread changes in methylation: 18,760 DMPs when comparing current versus 
never smokers, and 2,623 DMPs when comparing former versus never smokers. This 
indicates a pattern of persistent altered methylation, with attenuation for up to five 
years, after smoking cessation. 
CONSIDERATIONS OF OUR MAIN FINDINGS 
Despite the fact that the methyl-group metabolism is the key metabolism delivering 
methyl-groups for DNA-methylation, we did not find widespread effects of Hcy, Hcy-
associated genetic variants and dietary folate and vitamin B12 on DNA methylation 
across the genome. By comparison, when we studied the relation between cigarette 
smoking and DNA methylation, we identified widespread differences. There could be 
several explanations for the observed minimal effects of methyl-group metabolism on 
methylation pattern, that are listed below: 
Mildly elevated Homocysteine levels 
Hcy concentrations between 15-30 μmol/L are referred to as mild or moderate 
hyperhomocysteinemia (HHcy), whereas concentrations between 30-100 μmol/L and 
>100 μmol/L are referred to as intermediate and severe HHcy, respectively [1-3]. The 
subtle findings in Chapter 4 and Chapter 6 may be explained by the generally low 
median concentrations of Hcy in each cohort, with only about 10.2–32.3% of 
individuals in the mild or moderate range of HHcy above 15 μmol/l. In other words, the 
range of 3.4-35.4 μmol/l of Hcy might be too low, indicating a still balanced methyl-
group metabolism. It might be that more extreme deregulation of the methyl-group 
metabolism, as present in intermediate or severe HHcy, as occurs in severe folate or 
vitamin B12 deficiency, diseased individuals or inborn errors of metabolism, will lead to 
deregulation of DNA-methylation. 
Mildly elevated Hcy concentrations might not have resulted in altered s-
adenosylmethionine (SAM) and s-adenosylhomocysteine (SAH) levels in study 
participants. The ratio of SAM:SAH is frequently used as an indicator of cellular 
methylation potential, where SAM is the substrate and SAH is the product of essential 
methyltransferase reactions. A few human studies have suggested that elevated Hcy 
with corresponding increase in SAH is more strongly associated with global DNA 
hypomethylation, as compared to corresponding alteration in SAM [4, 5]. SAM and SAH 
was measured only in few previous studies, where they reported that individuals with 
mild, moderate or intermediately elevated Hcy levels showed increased SAM or 
increased SAH, with some showing corresponding decrease in SAM:SAH ratio [5-8]. 
We measured Hcy concentrations in plasma. Since methyl-group metabolism 
effectively takes place intracellularly, a double-blind trial by Smith et. al. [9] showed 
that FA supplementation significantly lowered plasma Hcy, but not intracellular Hcy. FA 
supplementation also did not lower intracellular SAM and SAH, which is possibly the 
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reason why global DNA methylation as measured by liquid chromatography-tandem 
mass spectrometry remained unaffected [9, 10]. 
Dietary data 
Dietary intake of folate and vitamin B12 that are major determinants of B-vitamin 
status, was associated with subtle differences in genome-wide methylation profiles. In 
older individuals, vitamin B12 uptake is usually impaired as a consequence of issues 
related to absorption [11], health disorders, medications or lifestyle factors [12]. Given 
the fact that the mean age in the majority of our examined cohorts was over 60 years, 
it is highly likely that dietary vitamin B12 intake might not accurately reflect 
intracellular status and therefore, could result in misclassification of vitamin B12 status 
[13, 14]. Dietary data is also prone to measurement errors, which can compromise our 
ability to detect statistically significant associations. Furthermore, there were 
differences in nutrient intake ranges across cohorts which could be related to the 
number and type of food items used in the FFQs, and the types of food composition 
reference tables used to calculate the nutrient data. Except for those studies for which 
covariates were not present, in the analysis, adjustments were done for age, sex, body 
mass index (BMI), differential white blood cell (WBC) counts, smoking status, physical 
activity, B-vitamin supplement intake, and alcohol (grams per day or drinks per week) 
and coffee (grams per day or servings per day) consumption. All these adjustments 
could have reduced the amount of variability left in nutrient intake, resulting in 
reduced power. Notably, the findings from previous birth cohort studies identified 
much more DNA methylation changes in neonates in relation to maternal folate intake 
or levels, as compared to our study in elderly [15, 16]. It could be that the effect of low 
B-vitamins intake is not seen in the individual itself but that the effects of low B 
vitamins are transmitted to the next generation to show an effect on DNA [17, 18]. 
Moreover, fetuses are very sensitive for disturbances in the methyl-group metabolism 
during development due to increased placental and fetal demand for folate, and 
therefore, any insufficiencies could have major implications [19-21]. Lastly, there could 
be a threshold effect for a possible association, i.e., there is a possibility that regulation 
of methylation is very tight and that mild differences in the metabolism can be 
compensated for, but not so for more extreme deregulation. This could mean that in 
our cohorts the folate and vitamin B12 status were consistently sufficiently optimal to 
prevent changes in DNA methylation patterns. 
Cohort heterogeneity and sample size 
Hcy concentrations are associated with different pathophysiologies and it should be 
noted that in our studies, the study population were either population based, or 
consisted of cases with venous thromboembolism, or have a mildly increased risk to 
develop Type 2 diabetes and/or cardiovascular disease. Individuals with Type 2 
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diabetes have a different metabolism due to insulin resistance and impaired insulin 
secretion [22]. DNA methylation of insulin related and unrelated genes have been 
previously associated with insulin resistance and Type 2 diabetes [22, 23]. In addition, 
SNPs associated with type 2 diabetes [24] and/or cardiovascular diseases [25, 26] might 
affect DNA methylation variability. Therefore, this clinical heterogeneity between 
cohorts could have hindered identifying DMPs that are associated with Hcy. 
A large sample size in EWAS studies is essential to improve statistical power in 
order to detect subtle changes and can possibility compensate for cohort 
heterogeneity. We performed an EWAS in relation to Hcy in 2,035 individuals and in 
relation to folate and B12 in 1,280 individuals and were not able to show large 
difference. In addition, we studied the effect of MTHFR 677C>T and other Hcy-
associated DNA variants on methylation in a sample size of 9,894 individuals, we again 
did not find large differences in methylation. This genetic study strongly suggest that 
there is no large difference in methylation patterns of circulating leukocytes in 
individuals with mildly elevated homocysteine levels. 
RNA or protein methylation 
Hcy is an important intermediate of the methyl-group metabolism that mediates the 
transfer of methyl groups to DNA as well as to RNA and proteins. Recent studies have 
shown that RNA methylation at the 6 methyl position of adenine (m6A) and 5 methyl 
position of cytosine (5-mC) regulates processes such as gene expression, RNA splicing, 
RNA stability, RNA degradation, mRNA translation and development, the aberrant 
methylation of which showing its implications in health and diseases [27-30]. 
Furthermore, protein methylation particularly on the nitrogen side-chains of the 
arginine and lysine residues are also known to be involved in numerous cellular 
processes such as DNA damage repair, RNA metabolism and gene expression [31-33]. It 
could be that the effects of Hcy and other methyl-group metabolism factors are more 
specific on the methylation of RNA or proteins. 
In an animal model, diet-induced HHcy altered global protein arginine 
methylation in a tissue-specific manner [34]. Plasma Hcy elevation is known to 
parallelly increase plasma SAH elevation leading to subsequent DNA hypomethylation 
[5]. When the effect of accumulation of intracellular SAH on both DNA methylation and 
protein arginine methylation was further investigated in cultured human umbilical vein 
endothelial cells, it was found that protein arginine methylation is more sensitive to 
SAH accumulation than DNA methylation, indicating that proteins are more prone to 
be hypomethylated than genomic DNA [35]. Large studies on the relation between 
(factors of the) methyl-group metabolism and methylation of RNA and/or proteins are 
currently missing, and it therefore remains to be discovered whether this relationship 
exists. 
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Tissue specificity 
The most commonly studied tissues in molecular epidemiology are blood and buccal 
epithelial cells as they are easy to obtain and are readily available. We conducted 
EWASs of Hcy level, by MTHFR 677C>T genotype and for folate/vitamin B12 intake, in 
whole blood leukocytes. However these effects could be different across tissues such 
as heart, brain and liver, from which methylation profiles are difficult to obtain. Few 
studies have performed DNA methylome profiling of other human tissues [36-39]. 
Tissue specific methylation differences are also seen in genomic DNA and domain of 
the H19 gene of liver, aorta, kidney and brain in mice with HHcy [40-42]. The tissue-
specific methylation reflects tissue-specific regulation of RNA expression and the 
biological dynamics are explained by the turnover or maintenance of binding sites for 
important transcription factors [43]. Moreover, it has been shown that the methylation 
profile of blood is highly distinct and contains relatively low levels of methylation as 
compared to other somatic tissues such as buccal cells [44-48]. The difference in DNA 
methylation between blood as compared to buccal cells, was more prominent at 
regions of low CpG density than at medium or high CpG density, while buccal cells had 
more variable CpGs as compared to blood tissue [47]. This distinction of blood as 
compared to other tissues was suggested to be due to the fact that blood is not a solid 
tissue and that the components of blood are a part of the inflammatory and immune 
systems, which are functionally related to many diseases [46, 47, 49, 50]. The other 
readily available tissue, buccal cells showed a significantly larger overlap with 
hypomethylated regions in a large number of other tissues in one report [44]. 
Therefore, buccal cells might be better than blood for large-scale epidemiological 
studies. It is clear that using blood as a surrogate tissue necessitates careful 
interpretation of results and correlation with the tissue of interest [51]. Depending on 
the clinical interest, other tissues should be further investigated such as heart, liver, 
kidney and brain. 
Cellular heterogeneity 
DNA methylation measurements from whole blood leukocytes is a mix of different cell 
types with varying proportion of different white blood cell counts (WBCs). There are 
five types of WBCs which include neutrophils (~62%), eosinophils (~2.3%), basophil 
(~0.4%), lymphocytes (~30%) and monocytes (~5.3%). Neutrophils, eosinophils and 
basophils together form the granulocytes. Since DNA methylation can be specific for 
different cell types, its analysis might be confounded due to differences in 
interindividual composition of cell types [52-57]. Therefore, DNA methylation analysis 
requires cautious consideration of cell count adjustments in the model. In order to 
adjust for cellular heterogeneity, RS and most other studies used measured percentage 
of differential cell counts of granulocytes, lymphocytes and monocytes. Other studies 
used percentage of imputed cell counts derived from the houseman method [58], to 
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adjust for cellular heterogeneity. The Houseman method uses methylation profiles to 
statistically estimate relative proportions of cell type components in whole blood that 
includes granulocytes, monocytes and subtypes of lymphocytes that include the B cells, 
natural killer (NK) cells, and T cells. The R2 correlation between measured and 
houseman imputed cell counts is 0.580, 0.645 and 0.259 in granulocytes, lymphocytes 
and monocytes, respectively, in a subset of 700 samples of the Rotterdam Study 
[Figure 1]. It is important to keep in mind that Houseman uses a reference-based 
algorithm that is based on only six reference individuals [52]. Therefore, its estimates 
are not fully optimal, and can introduce biases in association results. 
Even after cell type adjustments, cellular heterogeneity could still be an issue 
due to several reasons. One, if a particular cell type is underrepresented, then a change 
in DNA methylation associated to it may not be detected, and can only be detected if 
DNA methylation in such cell type is measured separately [52, 59]. Two, in important 
cell types of blood, few CpGs in regulatory regions may have opposite methylation 
patterns between the cell types. Considering these interindividual differences between 
cells, cautious interpretation of the overall methylation results is needed [52]. Three, B 
cells show a separate cluster and the largest number of DMPs with its associated genes 
belonging to other pathways, as compared to other lymphocytes [52]. This distinct 
methylation profile of B cells should be considered, and adjusting for the percentage of 
total measured lymphocytes may not reduce this heterogeneity.  
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Cigarette smoking 
We observed a large epigenome-wide impact of smoking on DNA methylation pattern 
with a total of 18,760 significant DMPs annotated to over 7,000 genes. Why is the 
effect of smoking so much larger than Hcy and other methyl-group metabolism 
factors? One, Hcy and other methyl-group metabolism factors such as folate and 
vitamin B12 are associated with smoking [60-62] and with other lifestyle factors such 
as physical activity [63, 64], coffee consumption [65-67] and alcohol consumption [68, 
69]. Therefore, Hcy, folate and vitamin B12 cannot be seen separately from lifestyle 
factors and that these factors might have masked some associations. Moreover, 
despite our inclusion of these known confounders as covariates in the B-vitamin EWAS 
models, the possibility of inter-correlations of these confounders with each other or 
other factors belonging to the causal pathway could nullify the findings. Two, in 
addition to the methyl-group metabolism, smoking could affect DNA methylation via 
few other known mechanisms [70] such as: 
a) Cigarette smoke contains carcinogens such as arsenic, chromium, polycyclic 
aromatic hydrocarbons, formaldehyde, and nitrosamines that causes double-stranded 
breaks to the DNA causing DNA damage [71]. The enzyme DNMT1 is recruited to repair 
the damage in surviving cells which causes methylation of CpGs adjacent to the 
repaired nucleotides [71-73]. 
b) Cigarette smoke can alter DNA methylation through the effect of nicotine 
on DNMT1 expression. Nicotine binds to and activates the nicotinic acetylcholine 
receptors that increases intracellular calcium and activates the key transcription factor 
(cAMP response element-binding protein) of many genes with possible downregulation 
of DNMT1 [74-76]. 
c) Cigarette smoking increases expression of the DNA-binding protein Sp1 
which protects CpG sites from being methylated [77-79]. 
d) Cigarette smoke contains carbon monoxide that competes with oxygen to 
bind to hemoglobin. This causes inadequate oxygenation of tissues in a condition called 
hypoxia [80]. Hypoxia further leads to the HIF-1α-dependent upregulation of 
methionine adenosyltransferase 2A, which is an enzyme that synthesizes the methyl 
donor, SAM [81]. 
e) Cigarette smoking is also associated with a general inflammatory state and 
cell ratios in the body [82-85], which could also alter DNA methylation. 
These large effects of cigarette smoking on genome-wide DNA methylation 
could further influence post-translational modifications possibly Immunoglobulin G 
glycosylation [86]. 
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METHODOLOGICAL CONSIDERATIONS 
Measurement of genome-wide methylation 
The human genome contains more than 28 million CpGs [87], 70-80% of which are 
methylated [88]. However, the Illumina 450K arrays only measures 1.7% of the CpGs in 
the genome. The CpGs are unevenly distributed across the human genome. 
Methylation in promoters and enhancers create the most functional impact. Among 
the gene regions for CpGs included on this array, most (41%) of them are present at 
gene promoters, 31% at gene bodies, 35% at 3’UTR regions and 3% at intergenic 
regions. For the enhancer regions, that are not present for a large part on the Illumina 
450k arrays, but are newly incorporated as 333,265 new CpG sites identified by the 
ENCODE [89, 90] and FANTOM5 [91] projects, in the recent Illumina 850k EPIC array 
[92]. It is possible that Hcy effects on DNA methylation may be specific to other sites 
and regions in the genome that are not measured by the Illumina 450k arrays, for 
example, enhancers. Therefore, future studies in this field can use the recent Illumina 
850k EPIC arrays which has similar advantages as Illumina 450k arrays and not only 
contains >90% of the original content from Illumina 450K arrays but also includes high 
coverage from enhancer regions. Also, when calculating and analyzing genomic DNA 
methylation, i.e., the median of CpGs per sample using this Illumina 450k array data, 
one needs to keep in mind that the results might be biased due to limited genome 
coverage. 
DATA-ANALYSIS 
Normalization 
A divergence between the β-values of the Infinium type I and type II probe assays was 
noticed previously wherein the β-values retrieved from the type II assay were of 
smaller range, less accurate and less stable as compared to the β-values retrieved from 
type I assay [93, 94]. In order to overcome this bias, several correction methods were 
proposed to rescale the type II β-values as per the type I β-values [93, 94] with each 
method having its own pros and cons. In the RS, we investigated the performance of 
these methods and although they all performed in a satisfactory manner, we decided 
to use DASEN [95] or quantile normalization from CPACOR workflow (separately done 
for Type 1 and Type 2 assays) [96] which performs between samples correction. The 
association analysis performs regression across samples per probe, and therefore it is 
important to perform between samples correction per probe instead of across probes 
correction per sample. 
Differentially methylated regions 
In the analysis from this thesis, we used the method Comb-p [97, 98] to estimate 
methylation differences across regions. This software was developed considering the 
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uneven distribution of CpGs on Illumina 450k arrays. It uses nominal p-values as input 
in a sliding window and also takes into account the correlation between CpGs 
associated with these p-values. This method uses only p-values as input, not only from 
single EWASs but also from meta-analyses. In the results described in Chapter 4 and 
Chapter 7, we found 68, 74 and 29 DMRs to be significantly associated with Hcy levels, 
dietary folate and dietary vitamin B12 intakes, respectively. The number of DMRs were 
much more than the observed DMPs. In addition, top DMR findings did not reflect a 
strong association for one or more single CpGs that were part of the identified DMR. 
Therefore, although DMR analysis on array-data is used in an increasing number of 
manuscripts, a standard method is yet to be identified. Since the design of the array is 
not optimal for DMR-analysis (large “gaps” between CpGs), simply “adding-up” results 
from two nearby CpGs seems too simple. A better option might be to include 
predefined regions based on databases with functional annotation of the genome, such 
as ENCODE. However, we still know very little about actual correlation of CpGs in 
different circumstances. All this, makes the “pure statistical” collapsing of different 
CpGs doubtful and results from these analysis should be carefully interpreted. 
IMPLICATIONS AND FUTURE DIRECTIONS 
Smoking-associated methylation changes showed relatively larger differences as 
compared to the factors that are more directly related to methylation-metabolism such 
as Hcy, Hcy-associated variants or B-vitamin intake. First, validation or replication is 
needed for the identified Hcy- , folate intake- and vitamin B12- associated DMPs. If 
true, they can be used as potential biomarkers in methyl-group metabolism related 
pathologies and for identification of new pathways and biological mechanisms 
associated with it. In addition, the smoking-associated DMPs could serve as sensitive 
markers for lifetime exposure to cigarette smoking. Although these DMPs need to have 
good sensitivity and specificity to be used as biomarkers for diagnostics, their use in 
diagnosis could serve many purposes [99, 100]. 
Since SAM is a major methyl donor and SAH is a potent inhibitor of methyl-
transferase reactions, the ratio of SAM/SAH is thought to reflect the cellular 
methylation capacity [5]. Therefore, coming back to the possibilities discussed before 
as to why we found limited findings, measurements of SAM and SAH would be 
interesting to investigate methyl-group metabolism related methylation changes. 
However, SAM is an intrinsically unstable molecule [101], which needs controlled 
preanalytical conditions. Therefore, it is a challenging task to measure SAM or 
SAM:SAH ratio in population-based studies, and very few studies have studied this up 
to now [5-8]. 
Inorder to identify true effects of intermediate or severe HHcy i.e. more 
extreme dysregulated methyl-group metabolism, a population with a broader range of 
Hcy, i.e., individuals with severe HHcy or with folate/vitamin B12 deficiency should be 
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recruited. Furthermore, since dietary data is prone to measurement errors, 
measurements of plasma or cellular levels of vitamin B12 and folate should be 
conducted to confirm the role of these B-vitamins on DNA methylation. Tissues other 
than blood need to be investigated to find specific effects and more homogenous cell 
types should be studied for accuracy. Choosing the right tissue depends on the clinical 
interest. However, tissues such as heart, liver, kidney and brain are not readily 
available and are difficult to obtain in a substantial number of samples. Therefore, use 
of surrogate tissues such as blood or buccal cells can be improved by understanding 
the relationship between surrogate tissues and target tissues in an independent data 
set using more information, such as from correlated CpG sites [102]. Although 
methylation levels are largely conserved across tissues, it should be kept in mind that 
such prediction accuracy could vary across different tissue types, populations, 
phenotypes, diseases, genotypes and environmental exposure [102]. 
Intracellular Hcy, SAM and SAH 
It could be that the effects of Hcy are seen at an intracellular level instead of plasma 
level, since methyl-group metabolism effectively takes place intracellularly. It was 
previously shown that plasma Hcy and intracellular SAH but not intracellular SAM were 
associated with lymphocyte DNA hypomethylation [5]. Moreover, heterozygous 
cystathionine β-synthase (CBS +/−) mice given a methyl-deficient diet for 24 weeks, 
showed that tissue-specific alterations in global DNA methylation levels of liver, kidney, 
brain and testes occurred not due to decreased intracellular SAM concentrations of 
these tissues alone, but due to increased intracellular SAH with or without combination 
with decreased intracellular SAM [103]. Brain and testes showed most sensitivity to 
alterations in SAH and DNA methylation, as compared with liver and kidney which can 
be mainly due to low SAH hydrolase activity and lack of complete transsulfuration 
pathway in these tissues [103]. Since for most methyl-group metabolites, plasma 
concentrations showed poor reflection of intracellular concentrations [9], future 
studies should measure intracellular Hcy, SAM and SAH concentrations and investigate 
their effect on genome-wide DNA methylation. This could be the reason why we did 
not find large differences of plasma homocysteine on genome-wide DNA methylation.  
Hydroxymethylation 
Hydroxymethylation is another kind of chemical modification which occurs from 5-
methylcytosine to form 5-hydroxymethylcytosine (5hmC) catalyzed by ten-eleven 
translocation (TET) enzymes [104]. 5-hmC are known to play roles in gene expression, 
mammalian development, transcriptional regulation and human diseases [105]. It 
could be that the role of Hcy, B vitamin diet intake, other methyl-group metabolism 
factors and smoking is specific to some 5-hydroxycytosines. Like other techniques that 
are based on the bisulfite treatment, the Illumina 450k array is primarily incapable to 
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differentiate 5-methylcytosines from 5-hmC because both are resistant to bisulfite 
treatment [106-108]. Moreover, due to the low abundance of 5hmC as compared to 5-
methylcytosines, it is technically more challenging to measure 5hmC [108]. Essentially, 
5hmC can be measured by digestion- and antibody-based techniques [109] and LC/MS-
MS [110, 111] or by TET-assisted bisulfite treatment followed by 450k arrays or 
sequencing. 
Mendelian randomization 
The relationship of Hcy, vitamin B12 and folate with DNA methylation can be subject to 
substantial bias, given the strong relationship between several lifestyle factors, 
diseases and methyl-group factors. To circumvent this bias, genetic factors determining 
the methyl-group factors as an instrument can be used to study the relationship 
between these factors and methylation by Mendelian Randomization (MR). This would 
eliminate the effects that are possibly caused by measurement errors, confounding and 
reverse causality. However, in Chapter 5 we performed a MR study of MTHFR 677C>T 
or genetic risk score (GRS). If a formal MR-study is conducted, the used SNPs or so 
called instruments need to satisfy 3 basic assumptions [112, 113]. One, the instrument 
should be associated with our exposure, Hcy. Two, the instrument should not associate 
with any confounder of the exposure-outcome association. Three, the instrument 
should not affect our outcome, DNA methylation, except through Hcy. This condition is 
also referred to as pleiotropy. Although all three assumptions are satisfied in the case 
of the MTHFR 677C>T [114], the GRS model might violate assumption three [112, 113]. 
Recent research in MR studies have developed several methods that can be used in the 
future to correct and estimate the correct causal estimates in case of pleiotropy [115-
117]. 
Furthermore, the relationship between Hcy and DNA methylation should be 
known, before MR can be performed [118]. This relationship is only known in studies 
until now where DNA methylation is measured at a global level. Therefore, for the 
MTHFR 677C>T variant, we did not perform a complete MR because in Chapter 4 we 
did not find large effects of Hcy on site-specific DNA methylation, and therefore, we 
could not estimate the causal effect in this case. However, we performed a genetic 
study which focused on the association of genetically defined elevated Hcy levels with 
DNA methylation. The results were in line with the results described in Chapter 4, 
where subtle changes in genome-wide DNA methylation was observed. 
 Furthermore, there could be application of the MR technique for other 
exposures such as cigarette smoking, which has shown a larger effect on genome-wide 
DNA methylation as described in Chapter 8. A recent study of 822 individuals has 
already evaluated the previously found associations of cigarette smoking with 5 DMPs, 
using the MR study [119]. Using the SNPs rs4074134 for current smoking and 
rs9920506 for ever smoking as instruments, they found causal effect on 
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hypomethylation of two of the 5 DMPs of the F2RL3 and GPR15 genes. Future studies 
can conduct similar studies on the much larger list of the cigarette smoking associated 
DMPs that we identified in Chapter 8. 
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CHAPTER 10: SUMMARY 
Homocysteine and DNA methylation 
Homocysteine (Hcy) is a key metabolite of the methyl-group metabolism, elevated 
levels of which in a medical condition called hyperhomocysteinemia (HHcy) are 
associated with several disorders such as cardiovascular diseases and osteoporotic 
fractures. Being a byproduct of the methyltransferase reaction, Hcy’s role in alteration 
of DNA methylation levels is thought as one of the underlying mechanisms of Hcy-
associated disorders. Several studies have investigated the association between Hcy 
and DNA methylation in both animal models and human subjects. We reviewed this 
literature in Chapter 2 and found that in animal models, both diet- and genetically-
induced elevated Hcy showed alteration in DNA methylation indicating Hcy as a 
keyplayer. However in human subjects, elevated Hcy did not show consistent 
alterations in DNA methylation. These contradictory findings in humans might be 
explained by the differences in tissue types, small sample sizes, pathophysiological 
effects of the underlying disease, genetic differences between humans, limited studies 
and the fact that DNA methylation was measured on a global scale. 
To follow up on our understanding of this review, we conducted a 
epigenome-wide association study (EWAS) of Hcy in Chapter 4 to investigate the 
association between plasma Hcy and DNA methylation in leukocytes of 700 individuals 
of the RS. We increased our sample size up to 2,035 individuals by collaborating with 
other cohorts and conducted a meta-analysis of the individual EWAS results per cohort. 
We found that plasma Hcy was associated with subtle changes in DNA methylation, 
wherein we identified some novel epigenetic loci; three differentially methylated sites 
(DMPs) and 68 differentially methylated regions (DMRs) associated with Hcy. 
Given the strong relationship between several lifestyle factors, diseases and 
Hcy, the relationship between Hcy and DNA methylation can be subject to substantial 
bias possibly caused by measurement errors, confounding and reverse causality. 
Therefore we eliminated these effects in Chapter 5 by using genetically defined 
elevated Hcy, i.e. the most consistent MTHFR 677C>T variant and the combined 
weighted genetic risk score (GRS) of 18 previously studied Hcy-associated variants, to 
test whether genetically defined elevated Hcy levels are associated with DNA 
methylation changes in leukocytes of 9,894 individuals from 12 cohorts. Except for the 
cis-DMPs (< 1Mb upstream or downstream of the SNP), we did not observe widespread 
changes in DNA methylation; mainly one trans-DMPs (< 1Mb upstream or downstream 
of the SNP) associated with the MTHFR 677C>T variant and five trans-CpGs associated 
with the GRS. 
Lastly in Chapter 6, we conducted an interaction study of plasma Hcy and 
MTHFR 677C>T variant to investigate their combined effect on genome-wide DNA 
methylation in leukocytes of 1280 individuals from 2 cohorts. We identified 13 DMPs 
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associated with [Hcy x MTHFR 677C>T]. This included four cis-DMPs at the AGTRAP-
MTHFR-NPPA/B gene cluster on chromosome 1, which were also found in Chapter 5, 
indicating that this association was driven by the MTHFR 677C>T variant. We did not 
see overlaps of any other DMPs between our analysis of plasma Hcy, MTHFR 
677C>T/GRS and [Hcy x MTHFR 677C>T] in Chapter 4, 5 and 6, respectively. 
Nutrition, Lifestyle and DNA methylation 
The metabolites and co-enzymes that participate in the methyl-group metabolism are 
methionine, choline, betaine and B-vitamins, namely folate, vitamin B2, B6 and B12. 
Folate and vitamin B12 are widely studied co-enzymes and are essential micronutrients 
involved in the donation of methyl groups in cellular metabolism, deficiencies of which 
could impair the remethylation pathway and lead to elevated Hcy. Therefore, general 
nutrition intake including the status of these vitamins could play a vital role in DNA 
methylation. We conducted a systematic review in Chapter 3 to study the relation 
between micro- and macro- nutrients and DNA methylation in disease-free individuals 
across the life course. Micronutrients included B-vitamins, where in most studies, we 
found that folate but not vitamin B12 was associated with DNA methylation. However, 
the directions of these associations were inconsistent across studies. This was 
attributed to differences across life course and nutrient and methylation tissue type. 
To study the effect of the nutritional folate and vitamin B12 intake on a large 
epigenome-wide scale, we conducted meta-analyses in leukocytes of 5,841 participants 
from EWASs of 10 cohorts in Chapter 7, where we identified some novel epigenetic 
loci; mainly 6 novel DMPs and 74 DMRs significantly associated with dietary folate 
intake, and 29 DMRs significantly associated with dietary vitamin B12 intake. Although 
both dietary intake and cellular levels of folate are important determinants of plasma 
Hcy, we did not see overlaps of the six folate intake-associated DMPs with our analysis 
of plasma Hcy, MTHFR 677C>T/GRS and [Hcy x MTHFR 677C>T] in Chapter 4, 5 and 6, 
respectively. 
In addition to the one carbon metabolism and nutritional factors, smoking is a 
crucial lifestyle factor for disorders such as respiratory diseases, cardiovascular 
diseases, cancer and reproductive outcomes has been previously associated with 
epigenome-wide DNA methylation. However, large-scale meta-analysis studies with 
increased sample sizes have not been conducted yet. In Chapter 8, we focused on 
association between cigarette smoking as a lifestyle factor and DNA methylation in 
leukocytes, assessed in 15,907 individuals (2,433 current, 6,518 former, and 6,956 
never smokers) from EWASs of 16 cohorts. We identified 2,623 DMPs at bonferroni 
threshold P<1×10-7 (18,760 DMPs at false discovery rate (FDR) <0.05) when comparing 
current versus never smokers, and 185 DMPs at bonferroni threshold P<1×10-7 (2,623 
DMPs at FDR <0.05) when comparing former versus never smokers, indicating a 
pattern of persistently altered methylation, with attenuation, after smoking cessation.  
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HOOFDSTUK 10: SAMENVATTING 
Homocysteïne en DNA-methylatie 
Homocysteïne (Hcy) is een belangrijke metaboliet in het metabolisme van 
methylgroepen. Verhoogde concentraties  van homocysteïne in het bloed, in medische 
terminologie hyperhomocysteïnemie (HHcy) genoemd, zijn geassocieerd met 
verschillende stoornissen zoals hart- en vaatziekten en osteoporotische fracturen. 
Omdat Hcy een bijproduct is van de DNA-methyltransferasereactie, wordt een 
verandering in DNA-methylering beschouwd als één van de mogelijke pathologische 
mechanismen bij Hcy-geassocieerde aandoeningen. Verschillende studies hebben de 
associatie tussen Hcy en DNA-methylering bij zowel diermodellen als bij mensen 
onderzocht. Wij hebben deze literatuur in Hoofdstuk 2 samengevat en daarin 
aanwijzingen gevonden dat in diermodellen zowel dieet- als genetisch geïnduceerde  
HHcy veranderingen in DNA-methylering tot gevolg hebben die aan Hcy worden 
toegeschreven. Bij de mens vertoonde verhoogd Hcy echter geen consistente 
veranderingen in DNA-methylering. Deze tegenstrijdige bevindingen kunnen worden 
verklaard door verschillen in onderzochte weefseltypes, steekproefgroottes, 
pathofysiologische effecten van de onderliggende ziekte, genetische verschillen tussen 
mensen, opzet van de studies en het feit dat meestal globale DNA-methylering werd 
gemeten. 
In aansluiting op dit overzicht van de literatuur hebben wij in Hoofdstuk 4 een 
epigenoom-brede associatiestudie (EWAS) van Hcy uitgevoerd om de associatie tussen 
plasma Hcy en DNA-methylering in leukocyten van 700 individuen van de Rotterdam 
Studie (RS) te onderzoeken. Wij hebben onze steekproefomvang verder verhoogd tot 
2.035 personen door samen te werken met andere cohorten en hebben een meta-
analyse uitgevoerd van de individuele EWAS-resultaten per cohort. Wij vonden dat 
plasma-Hcy geassocieerd was met subtiele veranderingen in DNA-methylering, waarbij  
een aantal nieuwe epigenetische loci werd geïdentificeerd: drie differentieel 
gemethyleerde posities (DMPs) en 68 differentieel gemethyleerde regio's (DMRs) 
geassocieerd met Hcy. 
Gezien de sterke relatie tussen verschillende leefstijlfactoren, ziekten en Hcy, 
kan de relatie tussen Hcy en DNA-methylering onderworpen zijn aan substantiële bias, 
veroorzaakt door meetfouten, verstorende factoren of omgekeerde causaliteit. In 
Hoofdstuk 5 hebben wij getracht  deze factoren te elimineren door gebruik te maken  
van genetisch vastgelegde  HHcy, dwz van de meest consistente MTHFR 677C>T variant 
en de gecombineerde gewogen genetische risicoscore (GRS) van 18 eerder 
bestudeerde Hcy-geassocieerde varianten, om te testen of deze genetisch 
gedefinieerde verhoogde Hcy niveaus zijn geassocieerd met DNA-
methyleringsveranderingen in de leukocyten van 9.894 individuen uit 12 cohorten. Met 
uitzondering van  cis-DMP's (<1Mb stroomopwaarts of stroomafwaarts van de SNP), 
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hebben wij geen wijdverspreide veranderingen in DNA-methylering waargenomen;  
wel één trans-DMP's (<1Mb stroomopwaarts of stroomafwaarts van de SNP) 
geassocieerd met de MTHFR 677C>T variant en vijf trans-CpG's geassocieerd met de 
GRS. 
Ten slotte hebben we in Hoofdstuk 6 een interactiestudie uitgevoerd van 
plasma Hcy en de MTHFR 677C>T variant  om hun gecombineerde effect op genoom-
brede DNA-methylering in leukocyten van 1280 individuen uit 2 cohorten te 
onderzoeken. Wij identificeerden 13 DMP's geassocieerd met [Hcy x MTHFR 677C>T]. 
Dit omvatte vier cis-DMP's in het AGTRAP-MTHFR-NPPA/B gencluster op chromosoom 
1, die ook werden gevonden in hoofdstuk 5, en dit geeft aan dat deze associatie wordt 
aangedreven door de MTHFR 677C>T variant. We hebben geen overlappingen van 
andere DMP's gezien tussen onze analyses van plasma Hcy,  MTHFR 677C>T/GRS en 
[Hcy x MTHFR 677C>T] in respectievelijk de hoofdstukken 4, 5 en 6. 
Voeding, levensstijl en DNA-methylatie 
De metabolieten en co-enzymen die deelnemen aan het methyl-groep-metabolisme 
zijn methionine, choline, betaïne en de B-vitamines folaat, vitamine B2, B6 en B12. 
Folaat en vitamine B12 zijn veel bestudeerde micronutriënten die in het 
celmetabolisme als coenzym betrokken zijn bij de overdracht van methylgroepen , en 
waarvan tekorten de remethylatie-route kunnen verstoren en zo leiden tot verhoogd 
Hcy. Daarom zou algemene voedingsinname inclusief de status van deze vitaminen, 
een vitale rol kunnen spelen bij DNA-methylering. Wij hebben in Hoofdstuk 3 een 
systematische review uitgevoerd om de relatie tussen micro- en macronutriënten en 
DNA-methylering in ziektevrije individuen gedurende de levensloop te bestuderen. B-
vitaminen zijn micronutriënten, waarvan we in de meeste onderzoeken vonden dat 
folaat wel maar vitamine B12 niet geassocieerd was met DNA-methylering. De richting 
van deze associaties was in verschillende studies echter niet consistent. Dit werd 
toegeschreven aan verschillen in levensloop, type voeding en het type  weefsel 
onderzocht op methylering. 
Om het effect van de folaat en vitamine B12 inname uit voeding op een grote, 
epigenoom-brede schaal te bestuderen, hebben we in Hoofdstuk 7 een meta-analyses 
uitgevoerd in leukocyten van 5.841 deelnemers van EWASs van 10 cohorten , en daarin 
enkele nieuwe epigenetische loci geïdentificeerd: zes nieuwe DMP's en 74 DMR's die 
significant geassocieerd zijn met foliumzuurinname via het dieet en 29 DMR's die 
significant geassocieerd zijn met de inname van vitamine B12. Hoewel zowel de 
inname via de voeding als de cellulaire niveaus van folaat belangrijke determinanten 
zijn van plasma Hcy, hebben we geen overlappingen gezien van de zes 
foliumzuurinname-geassocieerde DMP's met onze analyses van plasma Hcy, MTHFR 
677C>T/GRS en [Hcy x MTHFR 677C>T] in de hoofdstukken 4, 5 en 6. 
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Naast het methylgroep-metabolisme en voedingsfactoren, is roken een 
cruciale leefstijlfactor die wordt gerelateerd aan aandoeningen van de luchtwegen, 
hart- en vaatziekten, kanker en zwangerschap  én   eerder is geassocieerd met 
veranderingen in epigenoom-brede DNA-methylering. Er zijn echter nog geen 
resultaten van grootschalige meta-analyseonderzoeken met toegenomen 
steekproefgroottes bekend. In Hoofdstuk 8 hebben we ons gericht op de associatie 
tussen het roken van sigaretten als leefstijlfactor en DNA-methylering in leukocyten, 
door middel van  EWASs bij 15.907 personen uit 16 cohorten (2.433 actieve, 6.518 
voormalige en 6.956 nooit-rokers). Wij identificeerden 2.623 DMP's bij Bonferroni-
drempel P <1 × 10-7 (18.760 DMP's bij fout-positieven ratio (FDR) <0,05) bij vergelijking 
van actieve versus nooit-rokers, en 185 DMP's bij Bonferroni-drempelwaarde P <1 x 10-
7 (2.623 DMP's bij FDR <0,05) bij vergelijking van voormalige versus nooit-rokers, 
hetgeen wijst op een patroon van aanhoudend veranderde maar wel verzwakkende 
methylering na stoppen met roken. 
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